Category: FDA Approvals

This category focuses on FDA approvals for drugs, biologics, and devices. Here you will find clear summaries of each decision, the data behind it, and the clinical context that helps make sense of what the approval means in real world care.

IgA Nephropathy Silently Damages Kidneys for Years Before Most Patients Know It Is Happening. Trutakna Just Became the First Approved Therapy to Target Its Root Immunological Cause.

📌 The essentials On July 7, 2026, the FDA granted accelerated approval to Trutakna (atacicept-vymj, Vera Therapeutics) to reduce proteinuria in adults with primary IgA nephropathy (IgAN) at risk for disease progression. Trutakna is a recombinant fusion protein that simultaneously inhibits both B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), two cytokines that drive the B-cell activity responsible for producing the abnormal IgA antibodies that cause this disease. It is the first and only FDA-approved therapy to block both BAFF and APRIL, making it mechanistically distinct from every other approved IgAN therapy. It is the sixth drug approved for IgAN in the United States, joining Tarpeyo (budesonide EC, Calliditas, 2021), Filspari (sparsentan, Travere, 2023), Voyxact/Fabhalta (iptacopan, Novartis, 2024), Vanrafia (atrasentan, Otsuka, 2024), and Kinpeygo (budesonide, released outside U.S.). Administration: 150 mg subcutaneous injection once weekly, self-administered by the patient at home using a pre-filled autoinjector. No infusion center required. The clinical basis: prespecified 36-week interim analysis of the ongoing Phase 3 ORIGIN 3 trial (NCT04716231), enrolling 431 adults with biopsy-confirmed IgAN. Analysis population: first 203 participants who received at least 1 dose. Primary endpoint: change in 24-hour urine protein-to-creatinine ratio (UPCR) compared to placebo at 36 weeks. Results: 46% reduction from baseline in UPCR (atacicept arm); 42% reduction versus placebo (p less than 0.0001). Important caveat: this is an accelerated approval based on reduction of proteinuria as a surrogate endpoint. It has not yet been established whether Trutakna slows kidney function decline over the long term, as measured by eGFR. Continued approval may be contingent on confirmatory eGFR data from the ongoing ORIGIN 3 trial, which Vera Therapeutics and the FDA have agreed to analyze earlier than originally planned. eGFR results are anticipated in Q3 2026. An sBLA for full approval is targeted for Q4 2026. BLA accepted with Priority Review in January 2026. Safety signals: infections in 32% (atacicept) versus 28% (placebo); injection site reactions in 30% (atacicept) versus 5% (placebo); live vaccines are contraindicated during treatment.

IgA nephropathy is the most common biopsy-proven primary glomerulonephritis worldwide, yet most patients who have it don’t know for years. The disease begins silently, with abnormal IgA antibodies depositing in the glomeruli of the kidneys and slowly damaging the filtering units that keep waste in the urine and protein in the bloodstream. The first sign is often blood in the urine after an upper respiratory infection, or protein showing up on a routine urinalysis. The diagnosis requires a kidney biopsy. And between 30% and 50% of untreated patients will progress to kidney failure within 20 to 25 years.

For most of the history of nephrology, treatment consisted of blood pressure control, RAAS blockade to reduce proteinuria, and in some patients a course of systemic corticosteroids with their accompanying side effects and limited long-term efficacy. Then, between 2021 and 2024, the IgAN treatment landscape transformed rapidly as the FDA approved five drugs targeting different aspects of the disease’s pathophysiology.

Trutakna (atacicept-vymj, Vera Therapeutics), approved July 7, 2026, is the sixth. What makes it mechanistically important within this crowded field is that it targets the disease earlier in its pathogenic cascade than any of the others: at the B-cell cytokine level where the abnormal IgA antibody production begins, using a dual-target approach that blocks both BAFF and APRIL simultaneously. No other approved IgAN drug does this. The 36-week Phase 3 interim data showed a 42% reduction in proteinuria versus placebo. Whether that proteinuria reduction translates into preserved kidney function over years is the critical question, and the answer is coming soon.

What IgA Nephropathy Is: The Four-Hit Disease

IgA nephropathy, also known as Berger’s disease after the French nephrologist Jean Berger who first described it in 1968, is defined by mesangial deposits of IgA-dominant immune complexes in the kidney. Understanding what goes wrong requires following a sequence of immunological events that researchers now describe as the “four-hit hypothesis.”

Hit 1: Aberrant IgA1 glycosylation. IgA1, one of the two subclasses of IgA antibody, has a hinge region with multiple O-linked glycan chains. In patients with IgAN, these glycans are incompletely formed: they lack the normal galactose residues and are described as galactose-deficient IgA1 (Gd-IgA1). Gd-IgA1 is produced in higher quantities in IgAN patients than in healthy individuals and is the molecular abnormality that drives the entire downstream cascade.

Hit 2: Autoantibody production. The body recognizes the aberrant Gd-IgA1 as foreign and produces anti-glycan autoantibodies (IgG and IgA) directed against the abnormal sugar residues. These autoantibodies are the second abnormality.

Hit 3: Immune complex formation. The autoantibodies bind to circulating Gd-IgA1 to form large immune complexes. These complexes circulate in the bloodstream and are too large to be efficiently cleared by normal mechanisms.

Hit 4: Mesangial deposition and kidney injury. The immune complexes deposit in the mesangium, the connective tissue between the glomerular capillaries. Mesangial cells respond by proliferating and producing inflammatory cytokines and extracellular matrix proteins. The complement system is activated through the lectin and alternative pathways. The resulting glomerular inflammation and fibrosis progressively damage the kidney’s filtering function, reflected clinically as proteinuria, hematuria, and eventually declining eGFR.

The critical insight from this four-hit model is that hit 1, the overproduction of Gd-IgA1, is fundamentally a B-cell problem. The abnormal antibodies come from B cells and plasma cells that have been inappropriately activated by cytokines in the mucosa and lymphoid tissue. This is where BAFF and APRIL become central to the pathophysiology and where Trutakna’s mechanism fits.

Why IgAN is more common in some populations than others IgAN is the most common primary glomerulonephritis worldwide, but its distribution is uneven. Prevalence is highest in East Asia, where IgAN accounts for 40% to 50% of biopsy-proven glomerulonephritis cases. In Europe it accounts for 20% to 30%, and in North America 10% to 20%. The higher prevalence and more aggressive disease course in East Asian populations likely reflects both genetic susceptibility variants and differences in mucosal immune activation. Overall incidence is at least 2.5 cases per 100,000 adults per year. In practical terms, given that kidney biopsies are not performed as readily in all healthcare systems, IgAN is almost certainly substantially underdiagnosed, with many patients carrying the disease without a confirmed pathological diagnosis.

How Atacicept Works: Dual BAFF and APRIL Inhibition

BAFF (B-cell activating factor, also known as BLyS) and APRIL (A proliferation-inducing ligand) are two cytokines produced primarily by innate immune cells, dendritic cells, macrophages, and epithelial cells in response to mucosal immune stimulation. Both act on receptors expressed on B cells and plasma cells (the antibody-secreting cell type that B cells mature into) to promote their survival, proliferation, and differentiation into antibody-producing cells.

In IgAN, both BAFF and APRIL are overexpressed, particularly in mucosal sites including the gut-associated lymphoid tissue and tonsils, which are thought to be the primary sites of Gd-IgA1 production. The elevated BAFF and APRIL levels drive excessive B-cell and plasma cell survival, amplifying the production of both Gd-IgA1 itself and the autoantibodies that bind it to form immune complexes. Reducing BAFF and APRIL levels should reduce this aberrant B-cell activity, lower Gd-IgA1 and autoantibody production, and thereby reduce the formation and mesangial deposition of pathogenic immune complexes.

Atacicept is a recombinant fusion protein combining the extracellular domain of the transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) receptor with the Fc portion of human IgG1. TACI is the receptor that naturally binds both BAFF and APRIL. By mimicking this receptor in soluble form, atacicept acts as a decoy: it captures both BAFF and APRIL in the circulation before they can bind to B cells and plasma cells, neutralizing both cytokines simultaneously.

This dual neutralization is the key mechanistic distinction from the only other APRIL-directed therapy approaching approval for IgAN: sibeprenlimab (Vertex Pharmaceuticals), which targets only APRIL. Whether blocking both BAFF and APRIL provides additive clinical benefit over blocking APRIL alone is a question that current trial programs will ultimately need to address through comparative data or head-to-head studies. The available data suggest meaningful clinical activity for both approaches; which performs better in the long term remains to be established.

Other approved IgAN therapies address the disease through entirely different mechanisms: Tarpeyo and Kinpeygo target mucosal IgA production through gut-targeted corticosteroid action; Filspari combines endothelin A receptor blockade with angiotensin receptor blockade (sparsentan); Vanrafia blocks the endothelin A receptor (atrasentan); and Fabhalta inhibits complement factor B (iptacopan). The mechanistic diversity of the approved IgAN landscape reflects the multiple pathogenic pathways contributing to the four-hit cascade and provides clinicians and patients with options targeting different aspects of the disease.

The ORIGIN 3 Trial: What the Data Shows and What It Does Not Yet Establish

Trial design

ORIGIN 3 (NCT04716231) is an ongoing global, multicenter, randomized, double-blind, placebo-controlled Phase 3 trial enrolling 431 adults with biopsy-confirmed primary IgAN. Patients were randomized 1:1 to atacicept 150 mg administered subcutaneously once weekly via autoinjector or placebo. The trial is still running in its placebo-controlled, blinded phase to evaluate the primary long-term efficacy endpoint of change in eGFR.

The accelerated approval was based on a prespecified interim analysis of the first 203 patients who received at least 1 dose of atacicept or placebo and had reached the 36-week assessment point. The primary endpoint of this interim analysis was change in 24-hour urine protein-to-creatinine ratio (UPCR) from baseline to week 36.

Efficacy results at 36 weeks

Endpoint	Atacicept (n=approximately 101)	Placebo (n=approximately 102)	Result
UPCR reduction from baseline	46%	Reference	Statistically significant and clinically meaningful
UPCR reduction versus placebo	42%	Reference	p less than 0.0001
Analysis timing	36-week prespecified interim	36-week prespecified interim	Per prespecified analysis plan

Source: Vera Therapeutics FDA approval press release. GlobeNewswire. July 7, 2026. ORIGIN 3 NCT04716231.

A 42% reduction in UPCR compared to placebo at 36 weeks is a clinically meaningful reduction in proteinuria. In IgAN clinical trials and regulatory frameworks, proteinuria measured by UPCR is now an accepted surrogate endpoint for predicting long-term kidney outcomes, based on consistent observational data showing that proteinuria reduction correlates with slower eGFR decline over years of follow-up. The FDA accepted proteinuria reduction as the basis for accelerated approval across multiple prior IgAN approvals, including Tarpeyo, Filspari, and Fabhalta.

What is not yet established

The prescribing label for Trutakna includes a critical qualification that patients and clinicians should understand directly:

“This indication is approved under accelerated approval based on a reduction of proteinuria. It has not been established whether Trutakna slows kidney function decline over the long-term in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the ongoing ORIGIN 3 trial.”

In plain terms: the drug reduces proteinuria, and proteinuria is a surrogate marker for kidney health. But the confirmatory evidence showing that this proteinuria reduction actually translates into slower kidney function loss over years, as measured by eGFR trajectory, has not yet been generated. That evidence is coming from the ongoing ORIGIN 3 trial, and Vera Therapeutics has stated it reached agreement with the FDA to conduct the eGFR analysis earlier than originally planned. Results are anticipated in Q3 2026, and a supplemental BLA for full approval is targeted for Q4 2026.

This is the standard accelerated approval pathway in IgAN and is not unique to atacicept. The entire recent IgAN drug approval wave has followed this same proteinuria-first-then-eGFR framework. The precedent for conversion to full approval on confirmatory eGFR data in IgAN has been established by prior approvals in this space. Whether ORIGIN 3’s eGFR data confirms the expected clinical benefit is the question that matters most for long-term prescribing confidence.

The IgAN Treatment Landscape After July 2026

Understanding where Trutakna fits requires seeing the full current picture of approved IgAN therapies and their distinct mechanisms:

Drug	Company	Mechanism	FDA approval	Approval type
Tarpeyo (budesonide EC)	Calliditas	Gut-targeted corticosteroid (reduces mucosal IgA production)	December 2021	Accelerated; full approval 2023
Filspari (sparsentan)	Travere	Dual endothelin A and angiotensin receptor antagonist	February 2023	Accelerated; full approval 2024
Fabhalta (iptacopan)	Novartis	Complement factor B inhibitor	August 2024	Accelerated
Vanrafia (atrasentan)	Otsuka	Selective endothelin A receptor antagonist	August 2024	Full approval (ALIGN trial)
Voyxact (iptacopan)	Novartis	Complement factor B inhibitor	Full complement indication	Overlapping with Fabhalta
Trutakna (atacicept)	Vera Therapeutics	Dual BAFF and APRIL inhibitor	July 7, 2026	Accelerated

Note: Sibeprenlimab (Vertex), targeting APRIL only, is in Phase 3 and has not yet been approved.

The mechanistic diversity of this landscape matters clinically. Patients with IgAN may benefit from different approaches depending on where in the four-hit cascade their disease is most driven, their comorbidities and contraindications, and the specific features of their disease at the time of treatment initiation. Atacicept’s upstream B-cell cytokine targeting provides an option that addresses the source of Gd-IgA1 production, which is distinct from the complement inhibition, hemodynamic, and mucosal corticosteroid approaches of other approved drugs.

The competitive landscape also creates questions about combination therapy: could addressing multiple pathogenic steps simultaneously, such as reducing Gd-IgA1 production with atacicept while blocking complement activation with iptacopan, provide additive benefit? These are questions that ongoing research will address but that are outside the current label for any of these agents.

Dosing and Administration

Trutakna is administered as a 150 mg subcutaneous injection once weekly. The injection is self-administered by the patient at home using a pre-filled autoinjector. Injection sites include the abdomen, thigh, or upper arm, rotating sites with each weekly injection.

The home self-administration model is a meaningful practical advantage for a drug intended for long-term use in a patient population managing a chronic progressive kidney disease. Patients receive training on autoinjector technique before beginning self-injection, typically through Vera Therapeutics’ patient support program.

No dose adjustment is specified for mild to moderate renal impairment, which is relevant because many IgAN patients present with some degree of kidney function reduction at the time of treatment initiation. Prescribing information should be reviewed for guidance in patients with more severe renal impairment.

Safety: What the ORIGIN 3 Data Covers

The safety profile from the ORIGIN 3 interim analysis was broadly consistent with the class-level risks of BAFF and APRIL inhibition, reflecting their roles in B-cell homeostasis and immune function.

Key safety findings from ORIGIN 3 interim:

Safety item	Atacicept	Placebo	Clinical relevance
Any infection	32%	28%	Modest increase; B-cell suppression reduces immune competence
Injection site reactions	30%	5%	The most distinct adverse event profile for atacicept; predominantly mild local reactions
Serious infections	Low absolute rate	Low absolute rate	Monitor for serious or unusual infections throughout treatment

Warnings and precautions from the Trutakna prescribing information:

Serious infections: BAFF and APRIL support B-cell survival and function. By inhibiting both, atacicept reduces B-cell populations and the antibodies they produce, including normal protective antibodies. This creates a degree of immunosuppression that increases infection susceptibility. Serious infections requiring hospitalization have been reported. Clinicians should assess for active infection before initiating Trutakna and should not initiate in patients with active infections. Patients should be monitored for infection throughout treatment and instructed to report new symptoms promptly.

Live vaccines contraindicated: Because Trutakna suppresses B-cell function and antibody responses, live attenuated vaccines should not be administered to patients receiving the drug. Vaccinations with live vaccines should be completed before initiating treatment. Non-live vaccines may have reduced efficacy during treatment; the timing of non-live vaccinations relative to atacicept dosing should be discussed with the prescriber.

Hypogammaglobulinemia: Sustained BAFF and APRIL inhibition can reduce immunoglobulin levels over time. Monitoring of immunoglobulin levels is recommended. Patients with pre-existing hypogammaglobulinemia may be at higher risk for infectious complications.

Hypersensitivity reactions: Serious hypersensitivity reactions have been reported with atacicept. Patients should be observed after injection for signs of hypersensitivity and instructed to seek medical attention for any serious reaction.

Embryo-fetal toxicity: Atacicept can cause fetal harm based on its mechanism of action affecting B-cell development. Females of reproductive potential should use effective contraception during treatment and for a specified period after the last dose. Pregnancy testing before initiating treatment is recommended for females of reproductive potential.

What This Means for Patients and Clinicians

For patients with primary IgAN

Trutakna adds a meaningful new option to the IgAN treatment landscape, particularly for patients who have not achieved adequate proteinuria control on existing therapies, who are intolerant to current options, or whose disease is driven primarily by the upstream B-cell cytokine pathways that BAFF and APRIL regulation addresses.

The practical advantages of Trutakna for patients include once-weekly home self-administration (eliminating infusion center visits), a well-defined and manageable side effect profile, and a mechanism that targets the immunological source of the disease rather than its downstream consequences.

The important transparency point every patient deserves: the approval is based on reducing proteinuria, a surrogate marker. The evidence that this proteinuria reduction translates into slower progression to kidney failure, the outcome that matters most, is currently awaited from the ongoing ORIGIN 3 confirmatory analysis. This is not a reason to avoid the drug, because every other recently approved IgAN drug followed the same pathway, and the proteinuria-to-eGFR correlation is well-established. But it is information that should be part of a shared decision-making conversation with your nephrologist.

The confirmatory eGFR data expected in Q3 2026 will be one of the most watched datasets in nephrology this year. If ORIGIN 3 shows preserved kidney function alongside the proteinuria reduction, the case for Trutakna in the IgAN treatment algorithm will strengthen considerably.

For nephrologists

Trutakna’s dual BAFF/APRIL mechanism fills a specific niche in the IgAN therapeutic landscape: upstream B-cell cytokine targeting for patients where reducing aberrant Gd-IgA1 production is the primary therapeutic goal. The 42% placebo-adjusted UPCR reduction at 36 weeks is consistent with the proteinuria reduction seen with other approved IgAN agents and provides a basis for use in clinical practice pending confirmatory eGFR data.

The comparative effectiveness question between atacicept and sibeprenlimab (APRIL-only inhibition), and between both of these upstream B-cell targeting approaches and the complement, hemodynamic, and mucosal corticosteroid approaches, will take years of real-world experience and potentially head-to-head trials to fully resolve. In the meantime, the mechanistic diversity of the approved IgAN landscape supports individualized treatment selection based on patient disease characteristics, comorbidities, and prior therapy history.

The infection monitoring consideration and the live vaccine contraindication are the most practically important safety management points for ongoing surveillance in atacicept-treated patients.

For related HED coverage on rare kidney disease and immunology drug approvals, see our post on Tregzi (marnetegragene autotemcel-vldq) receiving FDA approval as the first precision-engineered cell therapy for allogeneic stem cell transplantation and our coverage of the Lumvoa (veligrotug-vvze) approval for thyroid eye disease across both active and chronic disease phases.

If you or a family member has been diagnosed with IgA nephropathy, the National Kidney Foundation (kidney.org; 1-800-622-9010) and the IgA Nephropathy Foundation maintain current patient resources, treatment information, and clinical trial directories.

Sources

Vera Therapeutics FDA approval press release: Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA for Adult Patients with Primary IgA Nephropathy. GlobeNewswire. July 7, 2026.

Drugs.com approval news: FDA Grants Accelerated Approval for Trutakna (atacicept-vymj) for Adult Patients with Primary IgA Nephropathy. drugs.com. July 7, 2026.

HCPLive clinical summary (ORIGIN 3 data, safety profile): FDA Approves Atacicept (Trutakna) for IgA Nephropathy. hcplive.com. July 2026.

AJMC clinical and competitive landscape analysis: FDA Approves Atacicept for IgA Nephropathy. ajmc.com. July 2026.

Fierce Pharma (competitive landscape, sibeprenlimab context): Vera’s dual-target atacicept wins FDA approval for IgAN. fiercepharma.com. July 2026.

Pharmaceutical Commerce (specialty launch context): What Trutakna’s Approval Means for Specialty Launches. pharmaceuticalcommerce.com. July 2026.

Trutakna approval history: Trutakna FDA Approval History. drugs.com.

ORIGIN 3 trial registration: NCT04716231. ClinicalTrials.gov.

BAFF and APRIL role in IgAN pathogenesis: The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies. PMC10867227.

IgAN four-hit pathophysiology: The Pathophysiology of IgA Nephropathy. PMC3892742.

Gd-IgA1 and immune complex formation: The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy. PMC4828451.

IgAN clinical trials overview: IgA Nephropathy: An Overview of the Clinical Trials. Kidney Medicine. 2025.

IgAN StatPearls overview: IgA Nephropathy (Berger Disease). StatPearls. NCBI.

Tarpeyo FDA approval: FDA approves budesonide for IgA nephropathy. FDA.gov.

Filspari FDA approval: FDA approves sparsentan for IgA nephropathy. FDA.gov.

Fabhalta/Voyxact FDA approval: FDA approves iptacopan for IgA nephropathy. FDA.gov.

Vanrafia FDA approval: FDA approves atrasentan for IgA nephropathy. FDA.gov.

Trutakna prescribing information: TRUTAKNA (atacicept-vymj) Prescribing Information. Vera Therapeutics. 2026.

KDIGO 2025 IgAN guideline: Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of IgA Nephropathy and IgA Vasculitis. Kidney Int. 2025;108(4):548-554.

Patient resources: National Kidney Foundation: 1-800-622-9010 | IgA Nephropathy Foundation | American Kidney Fund | Vera Therapeutics patient support

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Trutakna received accelerated approval based on reduction of proteinuria as a surrogate endpoint; it has not yet been established that the drug slows long-term kidney function decline. Decisions about initiating Trutakna for primary IgA nephropathy should be made in close consultation with a board-certified nephrologist who can evaluate proteinuria levels, eGFR trajectory, kidney biopsy findings, and all treatment options in the context of each individual patient’s disease characteristics.

July 9, 2026

Pediatric Psoriasis Has Lacked Good Biologic Options for Younger Children and Smaller Patients. Skyrizi Just Became the First IL-23 Inhibitor Approved Down to Age Six and Under 40 Kilograms.

📌 The essentials On June 26, 2026, the FDA expanded the approval of Skyrizi (risankizumab-rzaa, AbbVie) to include two pediatric indications: moderate-to-severe plaque psoriasis in children aged 6 years and older who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis in children aged 6 years and older. Both approvals cover pediatric patients regardless of body weight. A new 55 mg pre-filled syringe has been simultaneously approved to support weight-based dosing for patients weighing less than 40 kg. The existing 150 mg pre-filled syringe and pen remain approved for patients weighing 40 kg or more. This makes Skyrizi the first and only IL-23 inhibitor approved in the United States for pediatric patients aged 6 years and older who weigh less than 40 kg with plaque psoriasis or psoriatic arthritis. The European Commission approved risankizumab for pediatric plaque psoriasis in the same age group on June 23, 2026, three days before the U.S. action. The clinical basis for the plaque psoriasis approval: Phase 3 OptIMMize-1 (NCT04435600) and OptIMMize-2 (NCT04862286). Adolescents aged 12 to younger than 18 years (n=82, randomized 2:1 risankizumab versus ustekinumab): at week 16, PASI75 achieved in 85.2% (risankizumab) versus 85.7% (ustekinumab); PASI90 64.8% versus 60.7%; PASI100 40.7% versus 17.9%; sPGA0/1 79.6% versus 75.0%. Responses maintained or improved at week 52; sPGA0/1 achieved in approximately 95% of risankizumab responders who continued to week 52. Children aged 6 to younger than 12 years (n=30, open-label, single-arm): at week 16, PASI75 86.7%; PASI90 76.7%; PASI100 43.3%; sPGA0/1 90.0%. Responses maintained or improved through week 52. The psoriatic arthritis approval was supported by the OptIMMize program data plus population pharmacokinetic modeling and simulation extrapolated from well-controlled adult PsA studies. No dedicated randomized pediatric PsA efficacy trial was conducted. Safety profile in pediatric patients was consistent with the established adult safety profile. Skyrizi was originally approved in April 2019 for adults with moderate-to-severe plaque psoriasis and subsequently approved for adults with active psoriatic arthritis (2022), Crohn’s disease (2022), and ulcerative colitis (2024).

Psoriasis in children is not the same clinical experience as psoriasis in adults. The visible, chronic, and often unpredictable nature of the disease shapes childhood in ways that extend well beyond the skin. School-age children with moderate-to-severe plaque psoriasis deal with itching, pain, and lesions during the years when peer relationships form and self-image develops. Adolescents navigate a disease that can appear on exposed skin just as social self-consciousness peaks. Parents manage the daily treatment burden alongside their own anxiety about long-term treatment options for a child whose body and immune system are still developing.

The treatment toolkit for moderate-to-severe pediatric psoriasis has been narrower than most clinicians and families would like. Methotrexate, cyclosporine, and acitretin are systemic options that carry meaningful toxicity concerns in children. Etanercept, a TNF inhibitor, has been approved for pediatric psoriasis for many years. Secukinumab and ixekizumab, IL-17 inhibitors, expanded the pediatric biologic options. But the IL-23 inhibitor class, which in adults has produced some of the most durable and complete skin clearance rates seen in dermatology, has until now been unavailable to children.

Skyrizi (risankizumab-rzaa, AbbVie) changed that on June 26, 2026. The approval covers children as young as six years old, extends to patients weighing less than 40 kg through a new weight-based formulation, and includes both plaque psoriasis and psoriatic arthritis. It is the first time any IL-23 inhibitor has received FDA approval for pediatric psoriatic disease, and it is supported by Phase 3 data showing complete skin clearance in more than 40% of treated children at 16 weeks, with responses maintained through a year of treatment.

What Pediatric Psoriasis and Psoriatic Arthritis Are

Plaque psoriasis in children

Plaque psoriasis is a chronic immune-mediated skin disease characterized by well-demarcated, raised, erythematous plaques covered by silvery-white scale. It results from dysregulated immune activation that accelerates the normal skin cell lifecycle from 28 to 30 days down to 3 to 5 days, causing immature keratinocytes to accumulate on the skin surface in the characteristic plaques. The scalp, elbows, knees, and trunk are the most commonly affected areas, though involvement can occur anywhere on the body including the face, nails, and flexural areas.

Pediatric psoriasis affects approximately 1% of children globally and accounts for roughly 30% of all psoriasis cases when considered across lifetime onset. Onset most commonly occurs in the first two decades of life, with two peaks: one in early childhood and one in adolescence. The disease presentation in children can differ from adults, with facial involvement, scalp disease, and guttate morphology (small, drop-like lesions often triggered by streptococcal infection) being more common in younger patients.

Moderate-to-severe disease, the population covered by this approval, is defined by a Psoriasis Area and Severity Index (PASI) above 10 or body surface area involvement above 10%, or disease affecting critical areas including the face, palms, soles, or genitalia regardless of BSA. Patients with moderate-to-severe disease are candidates for systemic therapy or phototherapy, the threshold specified in the approval.

The psychosocial burden of pediatric psoriasis is substantial and often underappreciated in clinical settings. Studies consistently show that children with psoriasis have higher rates of depression, anxiety, social withdrawal, and reduced health-related quality of life compared to peers without skin disease. Adolescents are particularly affected. These psychological consequences are among the reasons that achieving complete or near-complete skin clearance, rather than merely reducing plaque severity, has become the goal of modern biologic therapy.

Psoriatic arthritis in children

Psoriatic arthritis in children, sometimes referred to as juvenile psoriatic arthritis within the broader category of juvenile idiopathic arthritis, involves inflammation of the joints that occurs in the setting of psoriatic disease. It presents with swollen, tender joints, morning stiffness, and in some children with characteristic features including dactylitis (sausage-shaped swelling of fingers or toes) and enthesitis (inflammation at tendon or ligament insertion sites). Without adequate treatment, pediatric psoriatic arthritis can cause permanent joint damage and growth abnormalities.

The psoriatic arthritis indication in this approval is meaningful because children with psoriasis are at elevated risk of developing arthritis, and early effective treatment of both the skin and joint manifestations can prevent structural damage. The evidentiary basis for the PsA approval in children rests on population pharmacokinetic modeling and simulation from adult PsA trials, along with the psoriasis data from OptIMMize, rather than a dedicated randomized pediatric PsA efficacy trial. This extrapolation approach is acceptable under FDA pediatric development frameworks when the disease mechanism and drug pharmacology are well-characterized in adults and PK data support comparable drug exposure in children. However, it is a meaningful limitation that clinicians and families should understand during shared decision-making, particularly for younger children.

How Risankizumab Works: The IL-23 Mechanism

Risankizumab is a humanized IgG1 monoclonal antibody that selectively targets interleukin-23 (IL-23), specifically the p19 subunit of the IL-23 cytokine. IL-23 is a key regulatory cytokine produced by antigen-presenting cells (dendritic cells and macrophages) in response to immune stimulation. Its primary function is to promote the differentiation, expansion, and survival of Th17 cells, the T helper cell population that drives much of the inflammatory activity in psoriatic disease.

By blocking IL-23 at its p19 subunit, risankizumab interrupts this cascade before it begins. With less IL-23 available, Th17 cell populations cannot expand normally. As a result, the downstream cytokines that drive psoriatic inflammation, principally IL-17A, IL-17F, and IL-22, are produced in lower quantities. The result is a reduction in keratinocyte hyperproliferation, dermal inflammation, and the immune-mediated joint damage that characterizes psoriatic arthritis.

The IL-23 p19 targeting approach distinguishes risankizumab and the other IL-23 inhibitors (guselkumab, tildrakizumab) from IL-12/23 dual inhibitors like ustekinumab, which block the shared p40 subunit of both IL-12 and IL-23. By specifically targeting IL-23 and sparing IL-12, risankizumab does not interfere with IL-12-dependent immune responses that are important for host defense against certain infections, a theoretical advantage over dual inhibition that is reflected in the clinical safety profile.

The practical consequence of this mechanism for patients is that risankizumab produces deep and durable skin clearance by addressing the upstream cytokine driver of psoriatic disease rather than its downstream effects. In adult trials, risankizumab has produced PASI90 and PASI100 rates that are among the highest reported for any psoriasis biologic, and these effects are sustained over years of treatment.

The OptIMMize Program: What the Pediatric Data Shows

The FDA approval for pediatric plaque psoriasis rests on data from Phase 3 OptIMMize-1 (NCT04435600) and its open-label extension OptIMMize-2 (NCT04862286). The program included four components: two lead-in pharmacokinetic cohorts that established age- and weight-appropriate dosing, a randomized active-controlled cohort in adolescents aged 12 to younger than 18, and a single-arm open-label cohort in children aged 6 to younger than 12.

Adolescents aged 12 to younger than 18 years: randomized cohort

In the randomized cohort, 82 adolescents were randomized 2:1 to risankizumab (n=54) or ustekinumab (n=28) for 16 weeks. Ustekinumab was chosen as the active comparator because it was, at the time the trial was designed, one of the few biologics with established pediatric psoriasis data and approval. Both drugs were dosed according to weight-based protocols consistent with their respective approved adult dosing frameworks.

Endpoint at week 16	Risankizumab (n=54)	Ustekinumab (n=28)
PASI75 (at least 75% improvement in PASI)	85.2%	85.7%
PASI90 (at least 90% improvement in PASI)	64.8%	60.7%
PASI100 (complete skin clearance)	40.7%	17.9%
sPGA0/1 (clear or almost clear)	79.6%	75.0%
sPGA0/1 with at least 2-grade improvement	68.5%	67.9%

Source: Magnolo N, Lee LW, Reich A et al. Efficacy and safety of risankizumab in pediatric patients with psoriasis: results from the OptIMMize-1 phase 3 study. J Invest Dermatol. 2026;146(3):S19. NCT04435600.

The PASI75 results were comparable between risankizumab and ustekinumab at week 16, meaning both drugs achieved substantial disease control at a similar rate in this population. The more clinically meaningful differentiator was the PASI100 rate: complete skin clearance in 40.7% of risankizumab-treated adolescents versus 17.9% of ustekinumab-treated adolescents. In practical terms, more than twice as many adolescents treated with risankizumab achieved completely clear skin at 16 weeks compared to those on ustekinumab.

Durability through week 52 was maintained and in many cases improved. Among adolescents who responded to risankizumab and continued treatment through week 52, sPGA0/1 (clear or almost clear skin) was achieved in approximately 95% of patients. This long-term durability is consistent with what has been observed in adult risankizumab trials, where sustained responses without tachyphylaxis have been a characteristic feature of the drug.

Children aged 6 to younger than 12 years: open-label cohort

The younger cohort (n=30) was evaluated in a single-arm, open-label design, which is appropriate for this age group given the practical and ethical challenges of conducting blinded, placebo-controlled trials in young children with moderate-to-severe skin disease. These children received the 55 mg dose (for those under 40 kg) or the standard adult dose (for those at or above 40 kg) and were evaluated at week 16 and through week 52.

Endpoint at week 16	Risankizumab (n=30)
PASI75	86.7%
PASI90	76.7%
PASI100 (complete skin clearance)	43.3%
sPGA0/1 (clear or almost clear)	90.0%
sPGA0/1 with at least 2-grade improvement	83.3%

Source: OptIMMize-1/2 open-label cohort, ages 6 to younger than 12. NCT04435600/NCT04862286.

These response rates are high across all measures. A 90% rate of clear or almost clear skin at 16 weeks, alongside a 43.3% rate of complete skin clearance, represents an efficacy signal in children aged 6 to 11 that is consistent with and in some measures exceeds what has been observed in adult trials with risankizumab. Responses in this younger cohort were maintained or improved through week 52, confirming sustained disease control over a year of treatment.

An important interpretive note: the open-label, single-arm design of the younger cohort means there is no placebo or active comparator for this group’s results. Response rates in open-label trials are generally higher than in blinded, placebo-controlled trials because of patient and investigator expectancy effects and the known PASI improvement that occurs in some patients over time even without active treatment (regression to the mean). This is a recognized limitation of pediatric trial design in diseases where withholding treatment from children with moderate-to-severe psoriasis for the duration of a placebo-controlled study raises ethical concerns. The FDA’s approval for this age group reflects a judgmental weighing of the unmet medical need, the consistency of the results with the mechanistic and adult evidence base, and the favorable safety profile.

The New 55 mg Formulation: Why Weight-Based Dosing Matters for Children

The simultaneous approval of a 55 mg pre-filled syringe specifically for patients weighing less than 40 kg is a clinically important element of this approval that could easily be overlooked in headlines focused on the age extension.

Children under 40 kg receiving the standard adult 150 mg dose would receive a substantially higher mg/kg dose than intended, with potential implications for both safety and long-term tolerability. The 55 mg dose was developed through the pharmacokinetic lead-in cohorts of OptIMMize, which characterized risankizumab exposure across the pediatric weight and age range and identified the dose that achieves drug exposure comparable to the adult 150 mg dose on a per-kilogram basis.

This weight-based dosing approach is what allows the approval to extend meaningfully to children aged 6 to 11, many of whom will weigh less than 40 kg. Without a lower-dose formulation, the approval would carry a practical limitation that undermined its clinical utility in younger and smaller children. With it, clinicians have a dosing framework that is pharmacokinetically grounded rather than extrapolated downward from adult dosing.

Patient weight	Risankizumab dose	Formulation
Less than 40 kg	55 mg subcutaneous injection	New 55 mg pre-filled syringe
40 kg or more	150 mg subcutaneous injection	Existing 150 mg pre-filled syringe or pen

Dosing schedule mirrors the adult schedule: subcutaneous injection at weeks 0 and 4, then every 12 weeks for maintenance. This 12-weekly maintenance schedule is one of the most infrequent in the biologic psoriasis class and is a meaningful practical advantage for families managing a child’s long-term treatment. Fewer injections per year reduces the physical and psychological burden on both the child and the caregivers who administer the medication.

The Psoriatic Arthritis Approval: What the Evidence Does and Does Not Cover

The psoriatic arthritis approval for children aged 6 and older is supported by two distinct evidentiary streams: the OptIMMize psoriasis data (establishing the drug’s safety and efficacy in the same age group for the related psoriatic condition) and population pharmacokinetic modeling and simulation extrapolated from well-controlled adult PsA trials, including the KEEPsAKE-1 and KEEPsAKE-2 trials that supported the 2022 adult PsA approval.

The modeling demonstrates that the weight-based risankizumab dosing approved for pediatric psoriasis achieves drug exposures in children similar to those produced by the 150 mg adult dose that was shown to be effective in adult PsA trials. The FDA considered this extrapolation appropriate given the shared pathophysiology between adult and pediatric psoriatic arthritis, the well-established adult efficacy database, and the pharmacokinetic consistency across weight groups.

What the approval does not include is a dedicated randomized, controlled efficacy trial specifically in children with psoriatic arthritis. This is the most important limitation for clinicians managing pediatric PsA patients considering risankizumab. The drug is approved and the pharmacokinetic rationale is sound, but clinicians and families should understand that the PsA efficacy evidence is extrapolated rather than directly demonstrated in this age group. For children with active joint disease alongside psoriasis, this distinction should be part of the treatment discussion.

Safety: Consistent with the Established Adult Profile

The safety profile observed in pediatric plaque psoriasis patients treated with Skyrizi was consistent with the established safety profile in adult patients with plaque psoriasis. This is a reassuring finding given that the IL-23 inhibitor class has accumulated a substantial real-world safety dataset across several years of adult use since risankizumab’s original 2019 approval. Patient Care Online

The key safety considerations from the adult label and their pediatric relevance:

Serious infections: IL-23 inhibition reduces the Th17-mediated immune response, which plays a role in mucosal defense against certain fungal pathogens including Candida species. Fungal skin infections are among the more common adverse events reported with risankizumab. Serious infections including those requiring hospitalization have been reported in adults, though at low absolute rates. Clinicians treating children should assess for active infection before initiating and monitor for infection signs during treatment.

Prior to initiating, tuberculosis testing is required. Risankizumab has not been studied in patients with active TB, and the prescribing information requires evaluation for latent TB before treatment. Patients with latent TB should be treated with standard anti-tuberculosis therapy before starting risankizumab.

Hypersensitivity reactions: Serious hypersensitivity reactions, including anaphylaxis, have been reported. Patients and caregivers should be educated about signs of hypersensitivity and instructed to seek immediate medical attention if they occur.

Live vaccines: Do not administer live vaccines during risankizumab treatment. This is particularly important in the pediatric setting, where the standard childhood immunization schedule includes live vaccines. The timing of immunizations should be discussed with the prescribing physician before initiating risankizumab. All required vaccinations should be completed before starting treatment wherever possible.

Common adverse reactions reported in the pediatric trial, consistent with the adult profile, include upper respiratory tract infections, headache, fatigue, injection site reactions, and fungal skin infections.

Inflammatory bowel disease: In adult trials, rare cases of new or worsening inflammatory bowel disease have been reported with IL-17 inhibitors. While the IBD signal with IL-23 inhibitors is less pronounced and risankizumab is actually approved for Crohn’s disease and ulcerative colitis in adults, clinicians should monitor for GI symptoms in all patients.

Skyrizi’s Complete Pediatric and Adult Indication Picture After June 2026

Indication	Approved population	Approval date
Moderate-to-severe plaque psoriasis	Adults	April 23, 2019
Active psoriatic arthritis	Adults	January 21, 2022
Moderate-to-severe Crohn’s disease	Adults	June 20, 2022
Moderate-to-severe ulcerative colitis	Adults	June 9, 2024
Moderate-to-severe plaque psoriasis	Children aged 6 and older	June 26, 2026
Active psoriatic arthritis	Children aged 6 and older	June 26, 2026

What This Means for Pediatric Dermatologists, Rheumatologists, and Families

For clinicians

This approval gives pediatric dermatologists and rheumatologists their first IL-23 inhibitor option for children, the drug class that has produced the most durable complete clearance rates in adult psoriasis. For adolescents aged 12 and older who have failed or are intolerant to methotrexate or a TNF inhibitor and are candidates for an IL-23 inhibitor, the OptIMMize data now provides direct randomized evidence in their age group comparing risankizumab favorably to ustekinumab, particularly on the metric of complete skin clearance.

For children aged 6 to 11, the open-label data and the weight-based dosing framework are now available, though the single-arm design means clinicians should interpret the efficacy data with appropriate awareness of its limitations.

For the psoriatic arthritis indication in children: the extrapolation-based approval is appropriate for use in clinical practice but should be accompanied by discussion with the family of the evidentiary basis, so that treatment expectations and monitoring plans reflect what is and is not directly demonstrated in children.

The 12-weekly maintenance dosing schedule is a meaningful practical advantage for pediatric patients. Fewer clinic visits and fewer injections per year reduce treatment burden on children and families and may improve long-term adherence.

For families

If your child has been diagnosed with moderate-to-severe plaque psoriasis or psoriatic arthritis and is at least 6 years old, risankizumab is now an FDA-approved option that your child’s pediatric dermatologist or rheumatologist can prescribe. The drug is given as a subcutaneous injection (under the skin, typically in the thigh or abdomen) at weeks 0 and 4, and then every 12 weeks. For children under 40 kg, the new 55 mg dose is specifically designed for their weight range.

Because Skyrizi is a specialty biologic medication, insurance coverage and prior authorization requirements vary by plan. AbbVie operates a patient support program called myAbbVie Assist for eligible patients who need help with access or cost. A specialty pharmacy familiar with AbbVie biologics can help navigate the prior authorization process and assist with co-pay or patient assistance programs.

Before starting risankizumab, your child’s doctor will need to: rule out active or latent tuberculosis, review your child’s current vaccination status and complete any needed live vaccines before treatment begins, and review any current or planned medications including other immunosuppressants.

For related HED coverage on AbbVie’s dermatology and immunology portfolio, see our earlier post on Skyrizi’s approval for ulcerative colitis in 2024 and our coverage of the TrenibotE CRL from AbbVie’s neurotoxin program. For broader context on pediatric biologic approvals, see our post on KRESLADI, the first gene therapy for severe LAD-I in pediatric patients.

Sources

AbbVie FDA approval press release: SKYRIZI (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease. AbbVie. PRNewswire. June 26, 2026.

AbbVie newsroom announcement: SKYRIZI Now FDA Approved for Pediatric Use in Psoriatic Disease. news.abbvie.com. June 26, 2026.

Drugs.com approval news: Skyrizi (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease. drugs.com. June 26, 2026.

AJMC full data summary: FDA Expands Risankizumab Approval to Pediatric Plaque Psoriasis, Active PsA. ajmc.com. June 2026.

Drug Topics (full endpoint table): FDA Approves Skyrizi for Pediatric Plaque Psoriasis, Psoriatic Arthritis. drugtopics.com. June 2026.

Pharmacy Times clinical review: FDA Approves Risankizumab for Pediatric Plaque Psoriasis, Psoriatic Arthritis. pharmacytimes.com. June 2026.

Practical Dermatology coverage: FDA Grants SKYRIZI Approval to Children With Plaque Psoriasis and PsA. practicaldermatology.com. June 2026.

Contemporary Pediatrics (PsA limitation noted): FDA approves risankizumab for pediatric plaque psoriasis and psoriatic arthritis. contemporarypediatrics.com. June 2026.

HCPLive clinical detail: FDA Approves Risankizumab for Pediatric Plaque Psoriasis, Psoriatic Arthritis. hcplive.com. June 2026.

Patient Care Online (evidentiary limitation note): FDA Approves Risankizumab for Pediatric Psoriasis, Psoriatic Arthritis. patientcareonline.com. June 2026.

Dermatology Advisor: Skyrizi Earns FDA Pediatric Approval for Psoriatic Disease in Patients Aged 6+. dermatologyadvisor.com. June 2026.

The Dermatology Digest: US FDA Approves Risankizumab for Pediatric Psoriatic Disease. thedermdigest.com. June 2026.

Psoriasis Hub: FDA approves risankizumab for pediatric patients with plaque psoriasis or active PsA. psoriasis-hub.com. June 2026.

OptIMMize-1 primary publication: Magnolo N, Lee LW, Reich A et al. Efficacy and safety of risankizumab in pediatric patients with psoriasis: results from the OptIMMize-1 phase 3 study. J Invest Dermatol. 2026;146(3):S19.

OptIMMize-1 trial registration: NCT04435600. ClinicalTrials.gov.

OptIMMize-2 trial registration: NCT04862286. ClinicalTrials.gov.

Adult PsA approval (KEEPsAKE basis): FDA approves risankizumab-rzaa for active psoriatic arthritis. FDA.gov. January 2022.

IL-23 mechanism and psoriasis biology: IL-23 in Psoriasis. PMC8289557.

Plaque psoriasis overview: Psoriasis. StatPearls. NCBI.

Psoriatic arthritis overview: Psoriatic Arthritis. StatPearls. NCBI.

Skyrizi prescribing information: SKYRIZI (risankizumab-rzaa) Prescribing Information. AbbVie. 2026.

Skyrizi approval history: Skyrizi FDA Approval History. drugs.com.

AbbVie myAbbVie Assist patient support: myAbbVie Assist. abbvie.com.

Patient resources: National Psoriasis Foundation: 1-800-723-9166 | Arthritis Foundation | Psoriasis and Psoriatic Arthritis Alliance | AbbVie Skyrizi patient support

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. The psoriatic arthritis indication for children aged 6 and older was supported by pharmacokinetic extrapolation from adult studies rather than a dedicated pediatric randomized controlled trial; clinicians should discuss this evidentiary basis with families during treatment decision-making. Risankizumab requires pre-treatment tuberculosis screening and review of vaccination status. All treatment decisions for pediatric psoriasis and psoriatic arthritis should be made in consultation with a board-certified pediatric dermatologist or rheumatologist.

July 8, 2026

Keytruda Has Been Approved for More Than 20 Cancers Since 2014. Its New TNBC Approval Is Not Just Another Indication. It Is Also the First Time the Subcutaneous Version Gets to Work Alongside an ADC.

📌 The essentials On June 25, 2026, the FDA approved both Keytruda (pembrolizumab, Merck) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph, Merck), each in combination with Trodelvy (sacituzumab govitecan-hziy), for the first-line treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 with a combined positive score (CPS) at or above 10, as determined by an FDA-authorized test. This is the first FDA-approved regimen pairing a PD-1 inhibitor with a Trop-2-directed antibody-drug conjugate in advanced TNBC. The same combination was approved simultaneously from the Trodelvy side on June 24, 2026 (one day earlier, from Gilead’s filing). The two approvals reflect the same clinical data from the same trial from two different regulatory submissions, one by each company. Clinical basis: Phase 3 ASCENT-04/KEYNOTE-D19 (NCT05382286). 443 patients with first-line PD-L1-positive (CPS at or above 10) metastatic TNBC, randomized to sacituzumab govitecan plus pembrolizumab or sacituzumab govitecan plus physician’s choice chemotherapy plus pembrolizumab. Median PFS 11.2 months versus 7.8 months; HR 0.65 (95% CI 0.51 to 0.84; p=0.0009). ORR 61% versus 55%. OS not reached in either arm. Published in NEJM. What is genuinely new and distinct in this approval: the Keytruda Qlex formulation. Keytruda Qlex is a subcutaneous injection of pembrolizumab co-formulated with berahyaluronidase alfa, a hyaluronidase enzyme that allows the drug to be delivered under the skin rather than through a 30-minute intravenous infusion. Administration time: 1 to 2 minutes, given by a healthcare provider. Setting: any clinical environment with a healthcare provider present, not necessarily an infusion center. The June 25 approval is the first indication where Keytruda Qlex is co-labeled alongside IV Keytruda for a specific combination regimen in breast cancer. NCCN designation: pembrolizumab plus sacituzumab govitecan is a Category 1 preferred first-line option for CPS at or above 10 metastatic TNBC in the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer. PD-L1 testing is required before initiating. Eligible patients must have tumors tested with an FDA-authorized PD-L1 assay showing CPS at or above 10.

Pembrolizumab has been one of the most consequential drugs in oncology since its first approval in 2014. It is now approved for more than 20 types of cancer. It has been part of transformative trials in lung cancer, melanoma, head and neck cancer, cervical cancer, endometrial cancer, urothelial cancer, and now breast cancer at multiple stages. The indication count has grown so large that keeping track of it has become a clinical challenge in its own right.

The June 25, 2026 approval, a new first-line indication in PD-L1-positive metastatic TNBC in combination with sacituzumab govitecan, is meaningful but not entirely surprising given the clinical logic behind it. PD-1 inhibition and Trop-2-directed antibody-drug conjugates target the same disease through distinct mechanisms, and combining them in a population already selected for checkpoint inhibitor responsiveness by PD-L1 expression makes biological sense. The Phase 3 ASCENT-04 trial confirmed that logic with a 35% reduction in progression risk over the prior standard of care.

What makes this approval genuinely worth a dedicated post from the Keytruda angle is not just the new indication. It is the Keytruda Qlex story that sits alongside it, and what a subcutaneous formulation of one of the world’s most-used cancer drugs means for the patients who will receive it for months or years.

What Pembrolizumab Is and How PD-1 Blockade Works

Pembrolizumab is a humanized monoclonal antibody that targets programmed death receptor-1 (PD-1), a checkpoint protein expressed on the surface of activated T cells. PD-1 is part of the immune system’s normal braking mechanism: it exists to prevent T cells from overreacting and damaging healthy tissue during chronic inflammation.

Tumors exploit this mechanism. Many cancers express PD-L1 (the ligand for PD-1) on their surface or on surrounding immune cells. When a T cell that has recognized a tumor cell attempts to destroy it, the tumor cell’s PD-L1 binds to the T cell’s PD-1, essentially telling the T cell to stand down. The immune response is dampened. The tumor survives.

Pembrolizumab blocks PD-1 from binding to PD-L1 or PD-L2. With the brake released, T cells can recognize and kill tumor cells more effectively. The clinical requirement for this mechanism to work is that the immune system has already mounted some T cell response to the tumor, which is why PD-L1 expression testing is clinically important: tumors with higher PD-L1 expression, measured by the combined positive score (CPS) on immune cells and tumor cells together, are more likely to be in an immunologically active microenvironment where checkpoint blockade can make a meaningful difference.

In TNBC specifically, approximately 40 to 50% of metastatic tumors express PD-L1 at a CPS of 10 or above. This population responds to checkpoint inhibition. The other half, patients with PD-L1-negative or lower-expressing TNBC, generally do not benefit from pembrolizumab-based regimens, which is why the two new TNBC first-line approvals (Trodelvy monotherapy for PD-(L)1-ineligible patients, and Trodelvy plus pembrolizumab for PD-L1-positive patients) are structured around PD-L1 status as a dividing line.

What Keytruda Qlex Is: The Subcutaneous Formulation Explained

Keytruda Qlex is not a new drug. It contains the same pembrolizumab molecule as IV Keytruda. What is different is how it gets into the body and how long that process takes.

Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) was first approved by the FDA on September 19, 2025, for adult and pediatric patients (aged 12 and older) across most solid tumor indications already approved for IV pembrolizumab. The June 25, 2026 TNBC approval extends that coverage to this new combination indication.

The co-formulation partner is berahyaluronidase alfa, a variant of human hyaluronidase developed by Alteogen Inc. and licensed to Merck. Hyaluronidase is an enzyme that temporarily breaks down hyaluronan, the polysaccharide that forms the structural matrix of subcutaneous tissue. Hyaluronan creates the physical resistance that limits how much volume can be injected subcutaneously and how quickly it disperses. By transiently degrading this matrix, berahyaluronidase alfa allows a large volume of pembrolizumab to be injected under the skin and absorbed into the systemic circulation, achieving comparable drug exposure to the intravenous formulation.

This approach is not unique to pembrolizumab. The same enzyme-facilitated subcutaneous delivery technology was used previously to create subcutaneous formulations of trastuzumab (Herceptin SC), rituximab (Rituxan Hycela), and daratumumab (Darzalex Faspro). Each followed a similar path: an established IV biologic that patients receive on a recurring schedule, converted to a subcutaneous option to reduce infusion chair time, free up infusion center capacity, and potentially allow administration in broader healthcare settings.

The pharmacokinetic data that supported the approval

The FDA’s September 2025 approval of Keytruda Qlex was based on Study MK-3475A-D77 (NCT05722015), a Phase 3 trial in 377 patients with treatment-naive metastatic NSCLC, randomized 2:1 to subcutaneous Keytruda Qlex every 6 weeks plus platinum doublet chemotherapy or IV pembrolizumab every 6 weeks plus chemotherapy. The primary endpoints were pharmacokinetic: pembrolizumab AUC from 0 to 6 weeks in cycle 1, and trough concentration at steady state in cycle 3. Both met non-inferiority criteria against IV pembrolizumab.

Efficacy outcomes were consistent between formulations: confirmed ORR 45% (Keytruda Qlex) versus 42% (IV pembrolizumab); median PFS 8.1 months versus 7.8 months; no notable OS differences. The conclusion the FDA drew was that the subcutaneous and intravenous formulations are clinically interchangeable across approved indications.

What the administration difference means in practice

Feature	Keytruda (IV pembrolizumab)	Keytruda Qlex (SC pembrolizumab plus berahyaluronidase)
Route	Intravenous infusion	Subcutaneous injection into thigh or abdomen
Administration time	30 minutes per infusion	1 to 2 minutes per injection
Setting	Infusion center (IV access required)	Any clinical setting with a healthcare provider
Every 3 weeks dose	200 mg IV	395 mg pembrolizumab plus 4,800 units berahyaluronidase (2.4 mL)
Every 6 weeks dose	400 mg IV	790 mg pembrolizumab plus 9,600 units berahyaluronidase (4.8 mL)
Additional contraindication	None beyond pembrolizumab standard	Hypersensitivity to berahyaluronidase alfa, hyaluronidase, or excipients

For a patient receiving first-line pembrolizumab plus sacituzumab govitecan for metastatic TNBC, the infusion schedule already involves regular clinic visits for the ADC component of the regimen, which requires IV administration. But over the course of treatment, every component that can be converted from a 30-minute IV session to a 1-minute subcutaneous injection is time and infusion center resources recovered. For patients who respond well and remain on pembrolizumab for extended maintenance, this difference accumulates.

There is also a site-of-care dimension. IV infusions require a healthcare setting with IV access capability and monitoring capacity. Subcutaneous injections can be administered by a healthcare provider in a wider range of settings, including a physician’s office, a community-based clinic, or potentially a home health visit. This flexibility matters for patients in rural areas, patients with transportation barriers, and patients who are otherwise functional but find regular infusion center visits logistically difficult.

The ASCENT-04 Trial Data: What This Regimen Actually Showed

The clinical evidence supporting this approval is the same Phase 3 ASCENT-04/KEYNOTE-D19 trial covered in detail in our companion Trodelvy post. The key numbers are included here for completeness.

ASCENT-04/KEYNOTE-D19 (NCT05382286) enrolled 443 adults with first-line unresectable locally advanced or metastatic TNBC with PD-L1 CPS at or above 10, confirmed centrally by the PD-L1 IHC 22C3 pharmDx assay. Patients were randomized to sacituzumab govitecan plus pembrolizumab or sacituzumab govitecan plus physician’s choice chemotherapy plus pembrolizumab.

Endpoint	SG plus pembrolizumab	Chemo plus pembrolizumab	Result
Median PFS (BICR)	11.2 months (95% CI 9.3 to 16.7)	7.8 months (95% CI 7.3 to 9.3)	HR 0.65 (95% CI 0.51 to 0.84); p=0.0009
Confirmed ORR	61%	55%	Favors SG plus pembrolizumab
12-month PFS rate	48%	38%	—
Median OS	Not reached	Not reached	Immature; no OS detriment

Source: Tolaney SM et al. NEJM. 2025. doi:10.1056/NEJMoa2511736.

The prior standard of care for PD-L1-positive first-line TNBC was chemotherapy plus pembrolizumab, established by KEYNOTE-522. The ASCENT-04 question was whether replacing chemotherapy with sacituzumab govitecan, a targeted ADC, would improve on that baseline. A 35% reduction in progression risk and a 3.4-month improvement in median PFS over a regimen that already included pembrolizumab answers that question clearly.

The 43% crossover rate in the control arm (chemotherapy plus pembrolizumab patients who received sacituzumab govitecan in the second line) is relevant context for interpreting the OS data when it matures. This level of crossover typically compresses OS differences between arms even when the experimental treatment provides genuine survival benefit.

The NCCN Category 1 Designation: What It Means for Clinical Practice

The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology are the most widely followed treatment guidelines in American oncology. Category 1 designation indicates that the recommendation is based on high-level evidence with uniform NCCN consensus that the intervention is appropriate. It is the highest category in the NCCN framework.

Pembrolizumab in combination with sacituzumab govitecan is now a Category 1 preferred first-line treatment option for certain patients with recurrent unresectable or stage IV TNBC whose tumors express PD-L1 at CPS at or above 10, according to the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer. Merck

Category 1 preferred status in NCCN guidelines is clinically significant for several reasons beyond academic endorsement. Many payers use NCCN guidelines to guide formulary and coverage decisions. A Category 1 preferred designation supports prior authorization approvals and reduces the administrative burden on oncology practices seeking to prescribe this regimen for eligible patients. For oncologists managing patients with first-line PD-L1-positive metastatic TNBC, this designation signals that the combination has been independently reviewed and endorsed at the highest evidence tier.

Pembrolizumab’s Safety Profile: What Has Not Changed

The immune checkpoint inhibitor safety framework for pembrolizumab is well-established across a decade of use. The June 25 approval does not introduce new safety signals for the pembrolizumab component. What follows is a summary of the key risks that patients starting pembrolizumab plus sacituzumab govitecan should understand.

Immune-mediated adverse reactions: This is the defining safety concern of PD-1 inhibition and the source of most serious adverse events. When the PD-1 brake is released, the immune system can attack normal tissues as well as tumor cells. Immune-mediated adverse reactions can affect virtually any organ system and can be severe or fatal. The most clinically important include:

Pneumonitis (immune-mediated lung inflammation): can present as new or worsening shortness of breath, cough, or chest pain. Any new pulmonary symptoms in a patient on pembrolizumab require prompt evaluation. Mild cases may resolve with corticosteroids; severe cases require permanent discontinuation.

Colitis: immune-mediated diarrhea or colitis, ranging from mild loose stools to severe watery or bloody diarrhea. Patients should report significant changes in bowel habits promptly.

Hepatitis: immune-mediated liver inflammation, typically detected on routine liver function testing before clinically apparent. Baseline and periodic LFT monitoring is standard.

Endocrinopathies: thyroid dysfunction (both hypothyroidism and hyperthyroidism), type 1 diabetes, adrenal insufficiency, and hypophysitis (pituitary inflammation) can all occur. Many are manageable with hormone replacement, but adrenal insufficiency and hypophysitis can be life-threatening if unrecognized.

Nephritis: immune-mediated kidney injury, typically detected by rising creatinine.

Skin reactions: rash, dermatitis, bullous pemphigoid, and toxic epidermal necrolysis have been reported.

The general management principle for immune-mediated adverse reactions: mild reactions may be managed with dose holds and monitoring; moderate reactions typically require corticosteroids; severe reactions require high-dose corticosteroids and permanent pembrolizumab discontinuation. Patients and their caregivers should be educated about these symptoms before starting treatment and should contact their oncology team promptly if new symptoms develop.

Keytruda Qlex-specific considerations:

Keytruda Qlex carries an additional contraindication not present for IV Keytruda: patients with known hypersensitivity to berahyaluronidase alfa, hyaluronidase, or any excipients in the formulation should not receive Keytruda Qlex and should receive IV pembrolizumab instead. Local injection site reactions (redness, pain, swelling, bruising at the injection site in the thigh or abdomen) are possible and are not observed with IV administration.

Sacituzumab govitecan toxicities in the combination:

Patients receiving this regimen must also be counseled about the Trodelvy-specific toxicities covered in detail in our companion post: severe neutropenia (boxed warning, grade 3 or higher in approximately 43% in the monotherapy trial; G-CSF prophylaxis strongly recommended), severe diarrhea (boxed warning), and the UGT1A1 pharmacogenomic consideration for patients who are homozygous for the UGT1A1*28 allele and require dose reduction.

Embryo-fetal toxicity: Both pembrolizumab and sacituzumab govitecan can cause fetal harm. Females of reproductive potential should use effective contraception during treatment and for 6 months after the last sacituzumab govitecan dose, and for 4 months after the last pembrolizumab dose.

PD-L1 Testing: A Required Step Before Starting Treatment

Because this indication is restricted to patients with PD-L1 CPS at or above 10, PD-L1 testing is a prerequisite for prescribing this regimen. The FDA-authorized assay for this indication is the PD-L1 IHC 22C3 pharmDx assay (Agilent/Dako). This companion diagnostic measures PD-L1 expression on both tumor cells and tumor-infiltrating immune cells, combining both into a single combined positive score. CPS at or above 10 is required for eligibility.

For oncology practices newly managing metastatic TNBC patients: PD-L1 testing should be ordered at the time of metastatic diagnosis or at the time of considering first-line treatment, ideally from the most recently obtained tissue sample. The test should specifically report the CPS using the 22C3 antibody clone; other PD-L1 assays (SP142, 28-8) are not validated for this specific indication and should not be substituted.

Practical Administration: Choosing Between IV Keytruda and Keytruda Qlex

For patients who are starting this combination regimen and whose oncology team has access to Keytruda Qlex, the choice between IV pembrolizumab and subcutaneous Keytruda Qlex is a shared clinical and patient preference decision. The efficacy is equivalent. The safety profiles are essentially the same, with the addition of the hyaluronidase hypersensitivity contraindication for Keytruda Qlex.

The subcutaneous option makes the most practical sense for patients who place high value on reducing infusion center time, who have poor venous access making IV cannulation difficult or painful, who live far from infusion centers and could benefit from a broader range of administration sites, or who are responding well to treatment and anticipate long-term maintenance.

The IV option remains appropriate and equivalent for patients in infusion center settings where the 30-minute administration time is not a barrier, for patients with known hypersensitivity to hyaluronidase components, and for pediatric patients under 12 years of age for whom Keytruda Qlex is not currently approved.

For related HED coverage on this treatment approach from the sacituzumab govitecan angle, see our companion post on Trodelvy (sacituzumab govitecan-hziy) receiving two new first-line TNBC approvals on June 24, 2026, which covers the ADC mechanism, the ASCENT-03 monotherapy trial for PD-(L)1-ineligible patients, and the full ASCENT-04 efficacy data in depth. For broader context on checkpoint inhibitor safety and patient education, see our coverage of the FDA’s accelerated approval of Tzield (teplizumab) as the first disease-modifying therapy for recently diagnosed Stage 3 type 1 diabetes, which covers immune-related adverse event monitoring principles relevant across checkpoint inhibitor therapy.

Sources

Merck FDA approval press release (June 25, 2026): FDA Approves KEYTRUDA and KEYTRUDA QLEX, each with Trodelvy, as First-Line Treatment of PD-L1+ Advanced TNBC. Merck. BusinessWire. June 25, 2026.

Merck.com detailed announcement: FDA Approves KEYTRUDA and KEYTRUDA QLEX each with Trodelvy for First-Line TNBC. merck.com. June 25, 2026.

Drugs.com approval news: FDA Approves Keytruda and Keytruda Qlex each with Trodelvy as First-Line Treatment of PD-L1+ Advanced TNBC. drugs.com. June 25, 2026.

FDA original Keytruda Qlex approval (September 19, 2025): FDA approves pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection. FDA.gov. September 19, 2025.

Merck Keytruda Qlex original approval press release: FDA Approves Merck’s KEYTRUDA QLEX for Subcutaneous Use in Adults Across Most Solid Tumor Indications. merck.com. September 19, 2025.

Cancer Therapy Advisor (Keytruda Qlex mechanism and approval): Keytruda Qlex, an SC Formulation of Pembrolizumab, Gets FDA Approval. cancertherapyadvisor.com. September 2025.

Pharmacy Times (Keytruda Qlex clinical review): The FDA Approval of Keytruda Qlex: A Subcutaneous Version of Pembrolizumab. pharmacytimes.com.

Keytruda Qlex approval history: Keytruda Qlex FDA Approval History. drugs.com.

Study MK-3475A-D77 (Keytruda Qlex PK trial): NCT05722015. ClinicalTrials.gov.

ASCENT-04/KEYNOTE-D19 primary NEJM publication: Tolaney SM et al. Sacituzumab govitecan plus pembrolizumab in first-line PD-L1-positive TNBC. NEJM. 2025. doi:10.1056/NEJMoa2511736.

ASCENT-04 trial registration: NCT05382286. ClinicalTrials.gov.

Keytruda Qlex prescribing information (HCP site): KEYTRUDA QLEX Prescribing Information and HCP site. keytrudahcp.com.

Keytruda Qlex patient site: KEYTRUDA QLEX for patients. keytruda.com.

Medscape (Keytruda Qlex drug reference): Keytruda Qlex (pembrolizumab/berahyaluronidase) drug reference. Medscape.

Pembrolizumab mechanism and PD-1 biology: Pembrolizumab. StatPearls. NCBI.

PD-1/PD-L1 immune checkpoint review: PD-1/PD-L1 Pathway. PMC4868169.

NCCN Breast Cancer Guidelines: NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. nccn.org.

PD-L1 22C3 pharmDx companion diagnostic: List of Cleared or Approved Companion Diagnostic Devices. FDA.gov.

Keytruda approval history (over 20 indications): Keytruda FDA Approval History. drugs.com.

Patient resources: National Breast Cancer Foundation | Susan G. Komen Foundation | TOUCH, The Black Breast Cancer Alliance | Merck patient access program for Keytruda | Merck Access Bridge

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Keytruda (pembrolizumab) and Keytruda Qlex carry serious risks including immune-mediated adverse reactions that can be severe or fatal and can affect any organ system. PD-L1 testing to confirm CPS at or above 10 is required before initiating this regimen. All treatment decisions for metastatic TNBC should be made in close collaboration with a board-certified medical oncologist experienced in breast cancer and immunotherapy management.

July 7, 2026

Stem Cell Transplants Can Cure Blood Cancers Like Leukemia. Chronic Graft-Versus-Host Disease Can Make the Cure Almost As Devastating As the Disease. Tregzi Just Changed That Calculus.

📌 The essentials On June 30, 2026, the FDA approved Tregzi (allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq, Orca Bio) for use in matched-donor hematopoietic stem cell transplantation (HSCT) with a myeloablative preparative regimen, for hematopoietic and immunologic reconstitution and to improve chronic graft-versus-host disease (cGVHD)-free survival in adults with hematological malignancies such as leukemia. Tregzi is the first FDA-approved therapy that uses highly purified regulatory T cells (Tregs), and the first cell therapy specifically designed to reshape the donor graft before it ever reaches the patient. What Tregzi is not: it is not a post-transplant drug added to prevent GVHD after the fact. It replaces the standard unmanipulated graft entirely, substituting an engineered, precision-sorted cellular product for the conventional “bag of cells” approach that has defined allogeneic transplantation for decades. The clinical basis: Phase 3 PRECISION-T trial (NCT05316701), 187 patients with AML, ALL, MDS, or mixed-phenotype acute leukemia, randomized to Tregzi plus single-agent tacrolimus versus conventional allogeneic HSCT plus tacrolimus and methotrexate. Primary endpoint: cGVHD-free survival (cGFS). Results at 12 months: cGFS 78% (Tregzi) versus 38.4% (standard transplant); HR 0.26 (95% CI 0.14 to 0.47); p less than 0.00001. Cumulative incidence of moderate-to-severe cGVHD: 12.6% versus 44.0%; HR 0.19; p=0.00002. Overall survival: 93.9% versus 83.1% (HR 0.49; p=0.12, not statistically significant at this analysis). Non-relapse mortality: 3.4% versus 13.2% (p=0.03). GVHD-free and relapse-free survival (GRFS): 63.1% versus 30.9% (p less than 0.001). Grade 3 or 4 acute GVHD by day 180: 6.2% versus 16.5%. Grade 3 or higher infections at 1 year: 44% versus 51%. Rehospitalization after discharge: 27.3% versus 45.7%. Primary publication: Meyer EH et al. Blood. 2026;147(11):1168-1177. Regulatory designations: Orphan Drug Designation; Regenerative Medicine Advanced Therapy (RMAT) Designation; Priority Review. Eligible population: adults with hematological malignancies undergoing 8/8 HLA-matched allogeneic HSCT with myeloablative conditioning. The approval does not currently cover mismatched or haploidentical transplant settings.

Most people who know someone with leukemia know the basic arc of the story. The diagnosis. The decision to pursue a stem cell transplant because nothing else can cure it. The months of waiting for a matched donor. The grueling conditioning chemotherapy to destroy the diseased bone marrow. The transplant itself. And then, if everything goes well, the slow and fragile process of immune reconstitution, of watching for signs that the new immune system is attacking the body it was supposed to save.

That last chapter is the one that Tregzi was built to change.

Chronic graft-versus-host disease affects between 30% and 70% of allogeneic stem cell transplant recipients. It is the leading cause of non-relapse mortality and long-term disability in transplant survivors. Patients who develop it can spend years managing symptoms across multiple organ systems: skin rashes that progress to tightening and fibrosis, dry eyes that cause permanent damage, mouth sores that make eating painful, liver inflammation, and scarring in the joints and lungs. For a patient who survived a blood cancer, this is a profoundly cruel outcome. They beat the disease, but the cure has made them chronically ill in a different way.

Tregzi (Orca Bio), approved June 30, 2026, is the FDA’s first approval of a precision-engineered cell therapy designed to prevent this outcome at the source. Rather than adding another immunosuppressive drug after a standard transplant, Tregzi rebuilds the graft itself, sorting and purifying the donor cells into three precisely defined populations and delivering them in a controlled sequence designed to prevent GVHD while preserving the immune activity that keeps the cancer from coming back.

The Phase 3 PRECISION-T trial showed that 78% of patients who received Tregzi were alive without moderate-to-severe chronic GVHD at one year, compared to 38.4% of those who received a conventional transplant. Non-relapse mortality dropped from 13.2% to 3.4%. Rehospitalization after the initial transplant discharge fell from 45.7% to 27.3%. These are large improvements in outcomes that have not meaningfully changed in decades.

What Hematological Malignancies and Allogeneic Transplantation Are

Hematological malignancies are cancers of the blood, bone marrow, and lymphatic system. The diseases covered in PRECISION-T include acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), and mixed-phenotype acute leukemia (MPAL). These are among the most aggressive blood cancers, with high rates of relapse after standard chemotherapy, particularly in patients with high-risk disease features.

For many patients with these diagnoses, allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only potentially curative treatment. The procedure involves destroying the patient’s diseased bone marrow with high-dose chemotherapy and sometimes radiation (the myeloablative conditioning regimen), then infusing stem cells from a healthy matched donor. The donor stem cells engraft in the bone marrow, reconstitute the immune system, and ideally provide ongoing graft-versus-leukemia (GVL) activity, meaning the donor immune cells continue recognizing and eliminating any residual or relapsed leukemia cells.

The procedure works. But it carries risks that have limited its wider use and dramatically affected the quality of life of patients who survive it.

The fundamental tension at the heart of every transplant

The same donor T cells that provide graft-versus-leukemia activity are the cells that cause graft-versus-host disease. Tamp down the donor immune response too aggressively to prevent GVHD, and relapse risk increases. Allow the donor immune response to proceed without sufficient control, and GVHD occurs. Standard GVHD prophylaxis with tacrolimus plus methotrexate, or post-transplant cyclophosphamide, reduces but does not eliminate this risk. Chronic GVHD affecting 30% to 70% of recipients represents the field’s inability, over several decades, to cleanly resolve this tension.

Tregzi’s approach is not to add another immunosuppressive layer on top of the standard graft. It is to engineer the graft itself so that the cell populations responsible for GVHD are controlled from the start, while the populations responsible for immune reconstitution and anti-leukemia activity are preserved.

What Chronic GVHD Is and Why It Matters Clinically

Chronic graft-versus-host disease develops when donor T cells recognize host tissues as foreign and mount a persistent immune attack against them. Unlike acute GVHD, which typically occurs within the first 100 days after transplant and primarily targets the skin, liver, and gastrointestinal tract, chronic GVHD can affect virtually any organ system and persists for months to years.

The clinical manifestations range from manageable to profoundly disabling. Skin involvement ranges from rash to progressive fibrosis that limits joint mobility. Ocular involvement causes dry eye syndrome that can lead to corneal damage. Oral involvement produces painful sores and restricted mouth opening. Pulmonary involvement causes bronchiolitis obliterans, an irreversible scarring of the small airways. Hepatic involvement produces abnormal liver function. Musculoskeletal involvement causes fasciitis and joint contractures.

Moderate-to-severe chronic GVHD, the degree targeted as the primary endpoint in PRECISION-T, is clinically defined by involvement that substantially impairs function or requires systemic immunosuppression. Patients with moderate-to-severe cGVHD are, by definition, spending significant portions of their post-transplant lives managing a chronic inflammatory illness while already being immunocompromised.

The treatment of established chronic GVHD is difficult. Corticosteroids are the first-line standard but produce substantial side effects with long-term use and do not reliably induce sustained remission. Ibrutinib and ruxolitinib are approved for steroid-refractory cGVHD, but the best outcome in steroid-refractory disease is still living with a controlled chronic illness. Prevention is always preferable to treatment.

Who gets allogeneic transplants and how common GVHD is Approximately 25,000 allogeneic stem cell transplants are performed annually in the United States. The majority involve 8/8 HLA-matched donors, which is the setting studied in PRECISION-T. Chronic GVHD occurs in an estimated 30% to 70% of matched-donor allo-HSCT recipients, with moderate-to-severe disease in roughly 30% to 40%. It is the single leading cause of non-relapse mortality and long-term morbidity in transplant survivors, accounting for more late deaths after transplantation than cancer relapse in some populations. Despite this burden, meaningful improvements in cGVHD prevention have been slow to materialize over the past two decades. Standard GVHD prophylaxis regimens have not substantially changed, and the rates of cGVHD have remained relatively stable even as transplant-related mortality from other causes has declined.

How Tregzi Works: Precision Cell Engineering Rather Than Immune Suppression

Understanding Tregzi requires understanding what is wrong with the standard allogeneic graft, and why sorting matters.

In a conventional allogeneic transplant, the donor undergoes mobilization with growth factors to push hematopoietic stem cells into the peripheral blood, and those cells are collected by apheresis. The resulting graft is essentially unmanipulated: it contains stem cells, conventional T cells (Tcons), regulatory T cells (Tregs), and a range of other cell populations, all infused together in proportions that reflect whatever happened to be in the donor’s blood that day. The immune system is reconstituted, but the balance between the cells that cause GVHD and the cells that suppress it is left largely to chance.

Tregzi replaces this approach with three precisely sorted and separately delivered cell populations:

Hematopoietic stem and progenitor cells (HSPCs): These are the cells that engraft in the bone marrow and rebuild the entire blood and immune system from scratch. In Tregzi, HSPCs are highly purified, with the goal of maximizing engraftment efficiency while removing cells that could contribute to GVHD.

Highly purified regulatory T cells (Tregs): Tregs are a specialized subset of CD4-positive T cells whose primary function is immune regulation, specifically the suppression of excessive or misdirected immune responses. In healthy individuals, Tregs prevent autoimmunity by keeping other immune cells from attacking self-tissues. In the transplant setting, Tregs can suppress the alloreactive T cell response that drives GVHD. In a standard graft, Tregs are present but are vastly outnumbered by conventional T cells. In Tregzi, they are sorted, purified, and delivered at a substantially higher proportion than occurs in any natural graft.

Conventional T cells (Tcons): Tcons are infused 48 hours after the stem cells and Tregs, in a lower total dose than in a standard graft. This delayed, reduced-dose delivery is central to the approach: by the time the Tcons arrive, the Tregs are already present and active, able to suppress the GVHD-inducing activity of the incoming Tcons while allowing enough conventional T cell activity to support immune reconstitution and preserve graft-versus-leukemia effect.

The sorting and purification process is performed using Orca Bio’s high-precision cell manufacturing platform, which uses fluorescence-activated cell sorting (FACS) technology to separate cell populations with a level of purity not achievable through standard density gradient or selection methods. The manufacturing facility is in Sacramento, California.

Dr. Robert Negrin, professor of medicine and blood and marrow transplantation at Stanford Medicine and one of the foundational researchers behind the regulatory T cell transplant concept, described the approval as representing a defining moment for the transplant community, noting that the peer-reviewed findings demonstrated this precision-engineered cell therapy delivered improved GVHD-free survival alongside less toxicity, including fewer serious infections and lower non-relapse mortality.

The PRECISION-T Trial: Complete Data

Design

PRECISION-T (NCT05316701) was a randomized, multicenter, open-label, controlled Phase 3 trial conducted across 19 transplant centers in the United States. The trial enrolled 187 adults with AML, ALL, high-risk MDS, or mixed-phenotype acute leukemia who were undergoing their first allogeneic HSCT from an 8/8 HLA-matched related or unrelated donor with a myeloablative conditioning regimen.

Patients were randomized 1:1 to:

Tregzi (HSPCs plus purified Tregs on day 0, followed by Tcons on day 2) plus single-agent tacrolimus as GVHD prophylaxis
Conventional peripheral blood stem cell (PBSC) allograft plus tacrolimus and methotrexate as standard GVHD prophylaxis

The primary endpoint was chronic GVHD-free survival (cGFS), defined as time from transplantation to death or the onset of moderate-to-severe chronic GVHD, whichever occurred first. Secondary endpoints included cumulative incidence of moderate-to-severe cGVHD, overall survival, GVHD-free and relapse-free survival (GRFS), and non-relapse mortality. Primary results were published in Blood in 2026 (Meyer EH et al. Blood. 2026;147(11):1168-1177).

Primary and key secondary results at 12 months

Endpoint	Tregzi	Standard transplant	Result
cGVHD-free survival (cGFS)	78.0%	38.4%	HR 0.26 (95% CI 0.14 to 0.47); p less than 0.00001
Moderate-to-severe cGVHD (cumulative incidence)	12.6%	44.0%	HR 0.19 (95% CI 0.08 to 0.43); p=0.00002
Overall survival	93.9%	83.1%	HR 0.49; p=0.12 (not statistically significant)
Non-relapse mortality	3.4%	13.2%	p=0.03
GVHD-free and relapse-free survival (GRFS)	63.1%	30.9%	p less than 0.001
Grade 3 or 4 acute GVHD by day 180	6.2%	16.5%	HR 0.37; p=0.044
Grade 3 or higher infections at 1 year	44%	51%	Reduced with Tregzi
Rehospitalization after discharge	27.3%	45.7%	Substantially lower
Hospitalization days per patient	30.6	40.8	Fewer with Tregzi

Source: Meyer EH et al. Blood. 2026;147(11):1168-1177. PRECISION-T NCT05316701.

Reading the numbers carefully

The primary endpoint result is large and highly statistically significant: a 74% reduction in the hazard of death or moderate-to-severe chronic GVHD (HR 0.26). At 12 months, 78% of Tregzi patients were alive without moderate-to-severe cGVHD, compared to 38.4% on the standard arm. This is not a marginal improvement. It is the difference between fewer than 4 in 10 standard transplant recipients avoiding this outcome versus nearly 8 in 10 Tregzi recipients.

The non-relapse mortality finding deserves particular emphasis. Non-relapse mortality is death from transplant complications rather than the underlying cancer, and it represents the preventable deaths that better transplant care should be able to eliminate. In PRECISION-T, the NRM rate fell from 13.2% to 3.4%, a statistically significant reduction. Nearly one in seven patients in the standard arm died from transplant complications rather than their leukemia or MDS. With Tregzi, that figure drops to approximately one in thirty.

The overall survival result (93.9% versus 83.1%) is clinically meaningful in its absolute terms but did not reach statistical significance at this analysis, with a p-value of 0.12. This is an important limitation to acknowledge. The trial was not powered for OS as a primary endpoint, the median follow-up was 8.5 to 9 months, and OS data continue to mature. Whether the large NRM reduction will translate into a statistically significant OS benefit with longer follow-up is the key unanswered question in this dataset.

The GRFS result (63.1% versus 30.9%) is also reported descriptively rather than as a formal efficacy claim, because the pre-specified interim OS analysis did not cross the statistical boundary required to advance to formal GRFS testing in the hierarchical analysis plan. The directional benefit is substantial and consistent, but its formal statistical status reflects the trial’s sequential testing structure rather than any ambiguity about the clinical observation.

Safety: What the PRECISION-T Data and Prescribing Information Cover

The safety profile from PRECISION-T was generally more favorable for Tregzi than for the standard transplant arm across most clinically relevant metrics, which is unusual in a trial comparing an investigational therapy to a well-established comparator.

Adverse reactions expected in any allogeneic transplant:

The most common adverse reactions with Tregzi reflect the expected consequences of myeloablative conditioning and immune reconstitution rather than toxicity specific to the Tregzi product. These include mucositis, gastrointestinal toxicity (nausea, vomiting, diarrhea), rash, edema, hemorrhage, and infections. Grade 3 or 4 cytopenias were frequent, as expected in any patient who has undergone myeloablative chemotherapy and is in the process of bone marrow reconstitution.

Warnings and precautions from the Tregzi prescribing information:

Graft-versus-host disease (boxed warning): Acute and chronic GVHD, including life-threatening and fatal cases, can still occur following Tregzi. The Treg approach substantially reduces the incidence and severity but does not eliminate the risk. Patients must receive single-agent calcineurin inhibitor prophylaxis (tacrolimus) as specified in the prescribing information and must be monitored for GVHD signs and symptoms throughout the post-transplant period. Acute GVHD presents as maculopapular rash, gastrointestinal symptoms, and elevated bilirubin. Chronic GVHD may include skin rash, mouth sores, dry eyes, liver inflammation, and development of scar tissue in the skin and joints, as well as lung damage.

Infusion reactions: Serious hypersensitivity reactions, including anaphylaxis, may occur because of DMSO, human serum albumin (HSA), Dextran, or murine protein present in the Tregzi formulation. Appropriate resuscitation measures must be available during infusion.

Graft failure: Failure of the Tregzi graft to engraft can result in fatal aplasia. All 88 patients (100%) treated with Tregzi in the PRECISION-T trial achieved sustained engraftment, which is a notable finding, but graft failure remains a risk that must be monitored post-infusion.

Serious infections: Immunosuppression following myeloablative conditioning and during immune reconstitution creates vulnerability to bacterial, viral, and fungal infections. In PRECISION-T, grade 3 or higher infection incidence at 1 year was 44% with Tregzi versus 51% with standard transplant, a favorable difference, but the absolute rate of serious infections remains substantial in both arms. Antimicrobial prophylaxis and monitoring protocols consistent with institutional transplant standards apply.

Malignancy: As with all allogeneic transplant regimens, secondary malignancies including post-transplant lymphoproliferative disorder (PTLD) have been reported. Long-term surveillance is required.

Embryo-fetal toxicity: The myeloablative conditioning regimen used before Tregzi infusion can cause infertility and fetal harm. Patients of reproductive potential should discuss fertility preservation options before initiating conditioning.

What This Means for Transplant Centers, Patients, and Families

For transplant centers

Tregzi introduces a new logistical framework for allogeneic transplantation. It is not a drop-in replacement for standard apheresis products. The manufacturing process requires:

Coordination with Orca Bio’s manufacturing facility in Sacramento, California for cell processing, sorting, and product release
A two-infusion sequence: Tregs and HSPCs on day 0, Tcons 48 hours later on day 2
Modified GVHD prophylaxis with single-agent tacrolimus rather than the standard tacrolimus-plus-methotrexate combination

Transplant centers must be credentialed to administer Tregzi and will require integration of Orca Bio’s logistics and quality processes into their existing transplant programs. Orca Bio has announced the opening of a facility in Princeton, New Jersey, in addition to its Sacramento manufacturing base, to support east coast transplant center access.

Dr. Amandeep Salhotra of City of Hope noted that relapse-free survival was comparable between arms in the trial, suggesting that the precision cell-dosing approach preserves antileukemic activity while reducing GVHD. This is a critical finding for hematologists who have been cautious about aggressive Treg-based approaches on the grounds that reducing donor T cell activity might allow the cancer to come back.

For patients and families

The practical meaning of these data for a patient facing an allogeneic transplant for AML, ALL, or high-risk MDS is worth spelling out directly.

With a standard transplant plus tacrolimus/methotrexate, approximately 44% of patients will develop moderate-to-severe chronic GVHD within the first year. With Tregzi, that falls to approximately 12.6%. The chance of being alive without chronic GVHD at one year more than doubles. Non-relapse mortality, meaning the risk of dying from transplant complications rather than the cancer, drops by roughly four-fold, from 13.2% to 3.4%. Rehospitalization after the initial discharge drops from 45.7% to 27.3%, meaning substantially fewer patients are bouncing back to the hospital in the months after transplant.

Whether Tregzi is the right choice for a specific patient depends on eligibility (the 8/8 HLA-matched donor requirement currently applies), transplant center availability, individual disease and risk factors, and clinical discussion with a board-certified hematologist or transplant physician. The PRECISION-T data apply to patients with AML, ALL, high-risk MDS, and mixed-phenotype acute leukemia undergoing first allogeneic transplant with myeloablative conditioning.

Importantly, Tregzi has not yet been studied in mismatched, haploidentical, or reduced-intensity conditioning transplant settings. Those populations and approaches represent a large fraction of real-world transplant practice, and whether Tregzi’s benefits extend beyond the PRECISION-T-defined population is a question that ongoing and future studies will need to address.

Regulatory designations and what they signal

Tregzi received Orphan Drug Designation (reflecting the rare disease burden it addresses), Regenerative Medicine Advanced Therapy (RMAT) Designation (the cell and gene therapy equivalent of Breakthrough Therapy Designation, enabling intensive FDA engagement during development), and Priority Review. The RMAT designation in particular indicates that the FDA considered the preliminary evidence from early-phase Orca-T studies to represent substantial improvement over available therapies even before Phase 3 data were complete.

For related HED coverage on cell and gene therapy approvals in blood cancers and primary immunodeficiency, see our post on KRESLADI (marnetegragene autotemcel), the first gene therapy approved for severe Leukocyte Adhesion Deficiency Type I and our post on Hympavzi (marstacimab) expanding to include children aged 6 to 11 and patients with hemophilia inhibitors.

If you or someone you love is navigating a blood cancer diagnosis and considering transplant options, the National Bone Marrow Transplant Link (nbmtlink.org; 1-800-546-5268) and the Leukemia and Lymphoma Society (lls.org; 1-800-955-4572) both maintain current patient resources, transplant center referral support, and peer-to-peer patient connection programs.

Sources

FDA approval announcement: FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq for use in matched donor hematopoietic stem cell transplantation for adults with hematologic malignancies. FDA.gov. June 30, 2026.

Orca Bio FDA approval press release: Orca Bio’s TREGZI Receives U.S. FDA Approval as First and Only Precision-Engineered Cell Therapy for Allogeneic Transplant in Adults with Hematological Malignancies. BusinessWire. June 30, 2026.

Drugs.com approval news: FDA Approves Tregzi (Orca-T) as First and Only Precision-Engineered Cell Therapy for Allogeneic Transplant. drugs.com. June 30, 2026.

PRECISION-T primary publication in Blood: Meyer EH et al. Orca-T versus conventional graft in matched-donor hematopoietic stem cell transplantation. Blood. 2026;147(11):1168-1177.

PRECISION-T trial registration: NCT05316701. ClinicalTrials.gov.

BioPharm International (clinical summary with limitations): FDA Approves Tregzi, First Regulatory T-Cell Immunotherapy to Reduce Chronic GVHD. biopharminternational.com. July 2026.

Pharmacy Times (full endpoint data): FDA Approves Tregzi for Adults With Hematological Malignancies. pharmacytimes.com. July 2026.

Blood Cancers Today (primary publication analysis): Orca-T Reduces Chronic GVHD in Phase 3 Transplant Trial. bloodcancerstoday.com. May 2026.

AML Hub (complete endpoint table): FDA approves Orca-T for adults with hematological malignancies undergoing matched-donor allo-HSCT. aml-hub.com. July 2026.

Oncology Nursing News: FDA Approves Tregzi for Chronic GVHD-Free Survival in Blood Cancer. oncnursingnews.com. July 2026.

European Pharmaceutical Review (12-month data summary): US approval of Orca’s Tregzi landmark advance for stem cell transplants. europeanpharmaceuticalreview.com. July 2026.

Targeted Oncology (Dr. Salhotra mechanism interview): Dr Salhotra Details Orca-T’s Performance in Phase 3 Precision-T Trial. targetedonc.com. July 2026.

Targeted Oncology (ASH 2025 QOL and hospitalization data): Phase 3 Data Highlight Orca-T’s Clinical Benefits in Heme Malignancies. targetedonc.com. April 2026.

CancerNetwork (investigator quote): FDA OKs Regulatory T-Cell Immunotherapy in Hematologic Malignancies. cancernetwork.com. July 2026.

BioSpace coverage: Orca opens up Treg cell therapy with FDA nod for allogeneic blood cancer treatment. biospace.com. July 2026.

Chronic GVHD overview: Graft-Versus-Host Disease. StatPearls. NCBI.

Allogeneic HSCT overview: Hematopoietic Stem Cell Transplantation. StatPearls. NCBI.

Ibrutinib cGVHD approval: FDA approves ibrutinib for chronic graft-versus-host disease. FDA.gov.

Ruxolitinib cGVHD approval: FDA approves ruxolitinib for chronic graft-versus-host disease. FDA.gov.

ACS leukemia overview: Leukemia. American Cancer Society.

Tregzi prescribing information: TREGZI Prescribing Information. Orca Bio. 2026.

Tregzi approval history: Tregzi FDA Approval History. drugs.com.

Patient resources: National Bone Marrow Transplant Link: 1-800-546-5268 | Leukemia and Lymphoma Society: 1-800-955-4572 | Aplastic Anemia and MDS International Foundation | Orca Bio patient information | Be The Match (donor registry and transplant support)

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Treatment decisions for hematological malignancies, including the decision to pursue allogeneic stem cell transplantation and the choice of graft product, must be made in close collaboration with a board-certified hematologist or hematopoietic cell transplant specialist at an accredited transplant center. Tregzi is indicated for use in matched-donor HSCT with myeloablative conditioning in adult patients; eligibility criteria in the prescribing information should be reviewed carefully by treating physicians.

July 6, 2026

HR-Positive, HER2-Positive Breast Cancer Resists Both Its Major Treatments at the Same Time. Palbociclib Just Became the First CDK4/6 Inhibitor Shown to Address That Resistance in Maintenance. Here Is What the PATINA Trial Data Shows.

📌 The essentials On June 24, 2026, the FDA approved palbociclib (Ibrance, Pfizer) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment. This is palbociclib’s first approved use in HER2-positive disease. Palbociclib is already the most widely prescribed CDK4/6 inhibitor for HR-positive, HER2-negative metastatic breast cancer; this approval makes it the only CDK4/6 inhibitor approved for both HER2-negative and HER2-positive metastatic breast cancer. The “maintenance” context: the approved indication is for patients who have completed induction therapy (typically 4 to 8 cycles of a taxane plus trastuzumab, with or without pertuzumab) with no disease progression. They are not in response waiting for the next drug; they are in disease control continuing to their next treatment phase. Adding palbociclib at this point is what the trial tested. The clinical basis: Phase 3 PATINA trial (NCT02947685), published in the New England Journal of Medicine in January 2026. 518 patients, median follow-up 53.5 months, randomized 1:1 to palbociclib plus anti-HER2 therapy plus endocrine therapy versus anti-HER2 therapy plus endocrine therapy alone. Primary endpoint: PFS. Median PFS 44.3 months (95% CI 32.4 to 56.8) versus 29.1 months (95% CI 23.3 to 38.6). HR 0.75 (95% CI 0.59 to 0.96); 2-sided p=0.02. Risk reduction: 24% to 26% reduction in hazard of progression or death depending on analysis. 48-month PFS rate: 46.5% versus 38.3%. OS immature at time of analysis. Clinical benefit rate: 88.9% versus 80.9%. Median duration of confirmed response: 44.9 months versus 30.8 months. Regulatory designations: Breakthrough Therapy Designation. Dosing: 125 mg orally once daily for 21 consecutive days followed by 7 days off (3+1 schedule), matching established Ibrance dosing in HR-positive, HER2-negative disease. Endocrine therapy options in PATINA: fulvestrant, anastrozole, letrozole, or exemestane. Key safety: neutropenia most common (grade 3 or higher in approximately 61%); diarrhea 70%; infections 64%; febrile neutropenia 0.8%; serious adverse events 25%.

HR-positive, HER2-positive breast cancer accounts for approximately 10% of all breast cancers, but its clinical complexity is disproportionate to its prevalence. Unlike the more common HR-positive, HER2-negative subtype, which can be managed with endocrine therapy for years, or the HER2-positive, HR-negative subtype, which responds robustly to HER2-targeted regimens, this “double-positive” or “triple-positive” subtype presents a challenge that both its defining features create simultaneously.

The HER2 pathway and the estrogen receptor pathway engage in molecular cross-talk. Each can compensate for the other when the other is blocked. HER2-targeted therapy reduces HER2 signaling, but the estrogen receptor can maintain cell proliferation through alternative routes. Endocrine therapy reduces estrogen receptor signaling, but HER2 activity can bypass the growth arrest endocrine blockade would otherwise achieve. The result is that even patients who respond beautifully to first-line induction therapy often see their disease progress relatively quickly once the initial chemotherapy is removed.

The concept behind palbociclib’s PATINA approval is to add a third mechanism to the maintenance regimen that blocks a cell-cycle pathway that both HER2 and estrogen receptor signaling converge on: the CDK4/6 cyclin D1 axis. The Phase 3 PATINA trial tested this idea in 518 patients and demonstrated a 15-month improvement in median progression-free survival. The NEJM publication followed, and the FDA approved the regimen ahead of the PDUFA date on June 24, 2026.

What HR-Positive, HER2-Positive Breast Cancer Is and Why the Cross-Talk Problem Matters

Breast cancer is classified at diagnosis by three biomarkers that drive treatment selection: hormone receptor (HR) status, reflecting estrogen receptor (ER) and progesterone receptor (PR) expression; HER2 status, reflecting overexpression or gene amplification of the HER2 protein; and the Ki-67 proliferation index. Triple-positive (HR+/HER2+) disease expresses both hormone receptors and HER2 at clinically significant levels.

This dual positivity creates a therapeutic paradox. The two most productive targeted therapy approaches in breast cancer, endocrine therapy for HR-positive disease and HER2-directed biologics for HER2-positive disease, are both applicable but neither is fully sufficient on its own in the metastatic setting because each pathway can activate the other.

The ER-HER2 cross-talk operates through several mechanisms. Ligand-independent ER activation can occur downstream of HER2 signaling through PI3K/Akt and MAPK pathways, allowing tumor cells to maintain estrogen receptor activity even when estrogen levels are suppressed by aromatase inhibitors. Conversely, when HER2 signaling is blocked by trastuzumab or pertuzumab, upregulation of estrogen receptor signaling can compensate for the loss of HER2-driven proliferation. The cyclin D1-CDK4 axis sits at a convergence point for both pathways: both ER and HER2 signaling drive cyclin D1 expression, which activates CDK4/6 to push cells through the G1/S cell-cycle checkpoint and into DNA replication.

This convergence is the scientific rationale for the PATINA trial. As Dr. Otto Metzger, principal investigator, explained: “The cyclin D1-CDK4 axis is essential for initiation and maintenance of growth in HER2-positive disease. The same axis drives resistance to the HER2 pathway blockade. Combined CDK4/6 and HER2 inhibition has shown to be synergistic and to have a profound antitumor activity in preclinical models.” Las Vegas Sun

The standard first-line treatment context

The current standard first-line regimen for HR-positive, HER2-positive locally advanced or metastatic breast cancer is induction with a taxane plus trastuzumab, with or without pertuzumab, for typically 4 to 8 cycles. Patients who achieve disease control then transition to maintenance therapy with continuation of the anti-HER2 regimen plus endocrine therapy. This is the established, evidence-based platform on which PATINA builds.

The PATINA trial asked a specific maintenance question: after induction has achieved disease control, does adding palbociclib to the established maintenance regimen (anti-HER2 therapy plus endocrine therapy) extend the time before the disease progresses?

How Palbociclib Works: CDK4/6 Inhibition and Why It Is Relevant in HER2-Positive Disease

Palbociclib is an oral inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). CDK4 and CDK6 are kinases that, when activated by their regulatory partners cyclin D1, phosphorylate the retinoblastoma protein (Rb). Phosphorylated Rb releases the transcription factor E2F, which then drives expression of genes needed for DNA synthesis and cell division. This CDK4/6-Rb-E2F pathway is a fundamental cell-cycle checkpoint: it governs the transition from G1 (growth phase) to S phase (DNA synthesis), a critical commitment point in the decision to divide.

When CDK4/6 is inhibited by palbociclib, Rb remains underphosphorylated, E2F remains sequestered, and the cell cannot progress to DNA synthesis. The result is cell-cycle arrest, predominantly in G1, followed by either senescence or cell death in tumor cells that depend on this pathway for proliferation.

In HR-positive, HER2-negative breast cancer, CDK4/6 inhibitors have been the standard of care in combination with endocrine therapy since palbociclib’s initial 2015 approval, establishing the principle that blocking the cell cycle downstream of estrogen receptor signaling extends disease control. The question the PATINA trial addressed is whether this principle extends to HR-positive, HER2-positive disease, where HER2 signaling is an additional upstream driver of CDK4/6 activation.

The preclinical and biological evidence suggests it should. Both ER and HER2 signaling drive cyclin D1 expression. Blocking CDK4/6 downstream of both pathways simultaneously, in combination with anti-HER2 therapy and endocrine therapy, addresses the pathway cross-talk from a third convergence point. PATINA provided the Phase 3 confirmation.

The PATINA Trial: Design and Full Results

Design

PATINA (NCT02947685) was a Phase 3, randomized, open-label trial sponsored by Alliance Foundation Trials in partnership with multiple academic cooperative groups globally (Breast Cancer Trials, Fondazione Michelangelo, GBG Forschungs, PrECOG, SOLTI, and Unicancer), with funding from Pfizer.

Eligibility: Adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer who had no evidence of disease progression after induction treatment with a taxane plus trastuzumab, with or without pertuzumab, for their advanced disease. This is a strictly defined post-induction maintenance population.

Randomization: 1:1, 518 patients total (261 palbociclib arm; 257 control arm).

Treatment:

Palbociclib arm: palbociclib 125 mg orally once daily (days 1 to 21 of a 28-day cycle) plus trastuzumab every 3 weeks (with or without pertuzumab) plus endocrine therapy (fulvestrant, anastrozole, letrozole, or exemestane per investigator choice)
Control arm: trastuzumab every 3 weeks (with or without pertuzumab) plus endocrine therapy alone

Both arms continued until progressive disease or unacceptable toxicity.

Primary endpoint: Progression-free survival (PFS). Note on analysis: the FDA approval cites the primary PFS as reported in the NEJM publication with HR 0.75 and 2-sided p=0.02, while the original SABCS 2024 presentation reported unstratified HR 0.74 and 1-sided p=0.0074. Both reflect the same trial data at different analysis timepoints and stratification approaches. The NEJM publication, at a median follow-up of 53.5 months, is the most mature analysis.

Trial published: New England Journal of Medicine, January 2026. doi:10.1056/NEJMoa2511218.

Primary results

Endpoint	Palbociclib arm	Control arm	Result
Median PFS	44.3 months (95% CI 32.4 to 56.8)	29.1 months (95% CI 23.3 to 38.6)	HR 0.75 (95% CI 0.59 to 0.96); 2-sided p=0.02
Risk reduction in progression or death	25%	Reference	—
48-month PFS rate	46.5%	38.3%	—
Median follow-up	53.5 months	—	—
Clinical benefit rate	88.9%	80.9%	—
Median duration of confirmed response	44.9 months	30.8 months	—
Overall survival	Not mature	Not mature	No OS detriment observed

Source: Metzger O et al. Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer. NEJM. 2026;394(5):451-462. doi:10.1056/NEJMoa2511218. PATINA NCT02947685.

A 15.2-month improvement in median PFS (44.3 versus 29.1 months) is a clinically substantial finding in the maintenance setting. To put this in context: the control arm’s median PFS of 29.1 months is itself a historically strong result, reflecting the effectiveness of the established dual anti-HER2 plus endocrine maintenance platform. Improving upon a 29-month median PFS is considerably harder than improving upon shorter medians seen in earlier-line trials. The palbociclib arm reaching 44.3 months represents disease control sustained for approximately 3 years and 8 months on average after completing induction.

As Dr. Metzger noted: “The ability to meaningfully extend progression-free survival with a well-tolerated regimen offers new hope for individuals living with this challenging subtype of metastatic breast cancer.” The Hill

Open-label design: an important interpretive note

PATINA was an open-label trial, meaning patients and investigators knew which treatment arm each patient was on. PFS was assessed by investigator rather than blinded independent central review in some analyses. An open-label design may introduce assessment bias in investigator-determined PFS, and this is a legitimate limitation to acknowledge alongside the results. However, PFS is a validated surrogate endpoint in metastatic breast cancer with strong regulatory acceptance, and the statistical significance and magnitude of the benefit are both clinically meaningful. The FDA reviewed these data and determined they were sufficient for approval. FDA

OS data remain immature. Whether the PFS benefit in PATINA translates into an overall survival advantage will require continued follow-up. Given the extensive use of subsequent therapies including ADCs such as trastuzumab deruxtecan and other agents in patients who progress on both arms, the OS signal may be attenuated regardless of true treatment benefit, a well-recognized challenge in metastatic breast cancer trials.

What This Approval Means in the Broader Breast Cancer Treatment Landscape

The “double-positive” disease positioning

The approval fills a specific gap in the treatment landscape for HR-positive, HER2-positive metastatic breast cancer. Until this approval, CDK4/6 inhibitors were reserved for HER2-negative disease. Patients with dual-positive disease who responded to induction had no CDK4/6 inhibitor option in the maintenance phase. The assumption that CDK4/6 inhibition provided no benefit in the presence of active HER2 targeting has now been disproven by PATINA.

This approval does not position palbociclib as part of the induction regimen alongside chemotherapy and anti-HER2 therapy. It is a post-induction maintenance addition for patients who have demonstrated disease control. The sequencing is important: induction first, then reassess, then add palbociclib to maintenance if the patient has no evidence of progression and is suitable for the oral dosing regimen.

Palbociclib’s expanded indication scope

Before June 24, 2026, palbociclib was approved for:

HR-positive, HER2-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy (women and men)
HR-positive, HER2-negative locally advanced or metastatic breast cancer in combination with fulvestrant in patients with disease progression following endocrine therapy

After June 24, 2026, palbociclib also covers:

HR-positive, HER2-positive locally advanced or metastatic breast cancer in combination with trastuzumab (with or without pertuzumab) and endocrine therapy in the maintenance setting following induction

This makes Ibrance the only CDK4/6 inhibitor indicated for HR-positive metastatic breast cancer regardless of HER2 status, a commercially and clinically meaningful distinction.

How this compares to other treatment options in HR-positive, HER2-positive disease

The treatment landscape for HR-positive, HER2-positive metastatic breast cancer also includes trastuzumab deruxtecan (Enhertu), an ADC with substantial activity in this subtype and approvals in both first-line (after platinum-based chemotherapy) and later-line settings. The PATINA approval does not directly compete with trastuzumab deruxtecan in sequencing terms, as the indications are different: PATINA covers post-induction maintenance for disease-controlled patients, while trastuzumab deruxtecan’s indications cover patients with progressive or later-line disease.

The practical question for oncologists managing newly diagnosed HR-positive, HER2-positive metastatic disease is now: in a patient completing induction without progression, should palbociclib be added to the standard anti-HER2 plus endocrine maintenance? PATINA says yes, with a 25% risk reduction and a 15-month median PFS improvement. OS data, which will clarify the survival benefit, are pending.

Safety: What the PATINA Data and Prescribing Information Cover

The safety profile of palbociclib in PATINA was consistent with its established profile in HR-positive, HER2-negative breast cancer, dominated by predictable and manageable hematologic toxicity from CDK4/6 inhibition.

Safety item	Rate in PATINA (palbociclib arm)	Clinical guidance
Neutropenia (all grades)	78%	CBC monitoring before each cycle; dose interruption or reduction per prescribing information for grade 3 or higher neutropenia
Neutropenia (grade 3 or higher)	61%	G-CSF not routinely required but may be used; febrile neutropenia rate was low (0.8%)
Diarrhea	70%	Predominantly mild; anti-diarrheal agents as needed; dose modification for grade 3 or higher
Infections	64%	Predominantly mild to moderate upper respiratory infections; monitor for serious infections
Serious adverse events	25%	Clinical monitoring; follow prescribing information dose modification guidance
Febrile neutropenia	0.8%	Low absolute rate despite high neutropenia frequency; reflects manageable neutropenia depth
Interstitial lung disease/pneumonitis	Identified class risk (prescribing information warning)	Monitor for new or worsening pulmonary symptoms; hold palbociclib and evaluate promptly

Boxed warning equivalent class precautions and warnings (from Ibrance prescribing information):

Neutropenia: The most common and clinically significant toxicity. Grade 3 or higher neutropenia occurred in approximately 61% of PATINA palbociclib-treated patients. CBC should be checked before starting and at the beginning of each cycle, on day 15 of the first two cycles, and as clinically indicated. Dose modification is recommended for grade 3 and required for grade 4 neutropenia or febrile neutropenia.

Interstitial lung disease (ILD) and pneumonitis: Cases of ILD and pneumonitis have been reported with palbociclib, some resulting in fatal outcomes. Patients should be monitored for pulmonary symptoms. Palbociclib should be held for grade 2 or higher ILD/pneumonitis events and permanently discontinued for grade 3 or higher.

Embryo-fetal toxicity: Ibrance can cause fetal harm. Females of reproductive potential should use effective contraception during treatment and for 3 weeks after the last dose. Males with female partners of reproductive potential should use effective contraception during treatment and for 3 months after the last dose.

CYP3A interactions: Palbociclib is primarily metabolized by CYP3A. Strong CYP3A inhibitors (ketoconazole, ritonavir, clarithromycin, grapefruit products) increase palbociclib exposure. Strong CYP3A inducers (rifampin, phenytoin, carbamazepine, St. John’s wort) decrease palbociclib exposure. Avoid strong CYP3A inhibitors and inducers during palbociclib therapy; if unavoidable, dose adjustments apply.

Dosing and Administration

The approved maintenance dose of palbociclib for this indication is the standard established dose used across all Ibrance indications:

125 mg orally once daily for 21 consecutive days, followed by 7 days off (3-week on, 1-week off cycle)
Can be taken with or without food
Capsules should be swallowed whole; not chewed, opened, or crushed
If a dose is vomited or missed, do not take an additional dose that day; take the next dose at the scheduled time

This dosing schedule is the same as palbociclib’s dosing in HR-positive, HER2-negative disease, and oncology teams familiar with Ibrance management will not encounter a learning curve for the maintenance regimen.

What This Means for Patients and Oncology Teams

For patients currently completing first-line induction for HR-positive, HER2-positive metastatic breast cancer

If you have completed induction therapy with a taxane plus trastuzumab (with or without pertuzumab) and your cancer has not progressed, you are now in the population for which palbociclib maintenance is FDA-approved. A conversation with your oncologist about whether adding palbociclib to your maintenance regimen is appropriate for your individual situation should be part of your post-induction treatment planning discussion.

The practical considerations include your current neutrophil count and blood counts (given palbociclib’s neutropenia risk), other medications that may interact with CYP3A, and your overall tolerance of the 3-week-on/1-week-off oral dosing schedule.

For oncology teams

PATINA establishes palbociclib as a new maintenance option after induction in HR-positive, HER2-positive metastatic breast cancer, with the following key clinical parameters: the trial required no evidence of progression after completing induction with a taxane and anti-HER2 therapy; patients were on full anti-HER2 maintenance (trastuzumab with or without pertuzumab) plus endocrine therapy; palbociclib was added at standard dosing; and the PFS benefit was 15 months in median with a 25% risk reduction.

The open-label design and investigator-assessed PFS are limitations worth discussing with patients in the shared decision-making conversation. The absence of mature OS data means that the long-term survival benefit remains to be established. The neutropenia management framework for palbociclib is well-established from the HR-positive, HER2-negative experience, and PATINA’s low febrile neutropenia rate (0.8%) suggests the toxicity is manageable in this population as well.

For related HED coverage on breast cancer approvals and ADC therapies in oncology, see our post on Trodelvy (sacituzumab govitecan) receiving two new first-line approvals for metastatic TNBC approved on the same day as this palbociclib indication.

Sources

FDA approval announcement: FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer. FDA.gov. June 24, 2026.

PATINA NEJM primary publication: Metzger O et al. Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer. New England Journal of Medicine. 2026;394(5):451-462. doi:10.1056/NEJMoa2511218.

PATINA trial registration: NCT02947685. ClinicalTrials.gov.

CancerNetwork approval summary (with full PFS data): FDA Approves Palbociclib Combo in HR+, HER2+ Metastatic Breast Cancer. cancernetwork.com. June 2026.

CancerNetwork PATINA full results summary: Palbociclib Maintenance Extends PFS in HR+/HER2+ Advanced Breast Cancer. cancernetwork.com. 2026.

ASCO Post SABCS 2024 presentation coverage: Addition of Palbociclib to Standard Therapy in Metastatic HR-Positive HER2-Positive Breast Cancer. ascopost.com.

OncLive primary investigator commentary: Palbociclib Plus Anti-HER2 and Endocrine Therapy Prolongs PFS in HR+/HER2+ Breast Cancer. onclive.com.

Pharmacy Times clinical review: FDA Approves Palbociclib-Based Maintenance Regimen for HR-Positive, HER2-Positive Metastatic Breast Cancer. pharmacytimes.com. June 2026.

PharmExec analytical summary (with design caveats): Ibrance Wins FDA Approval for HR-Positive, HER2-Positive Metastatic Breast Cancer Maintenance Therapy. pharmexec.com. June 2026.

Medscape clinical coverage: Palbociclib Gains HER2+ Breast Cancer Maintenance Indication. medscape.com. June 2026.

Epocrates clinical brief: FDA approves Ibrance maintenance combo for HR-positive, HER2-positive metastatic breast cancer. epocrates.com. June 2026.

PrECOG NEJM publication announcement: New England Journal of Medicine publishes phase 3 PATINA trial data. precogllc.org. January 2026.

ONS clinical summary: FDA Approves Palbociclib Combination for Maintenance Treatment of HR-Positive, HER2-Positive Metastatic Breast Cancer. ons.org. June 2026.

Palbociclib StatPearls: Palbociclib. StatPearls. NCBI.

Breast cancer biology and HER2: Breast Cancer Overview. StatPearls. NCBI.

Ibrance prescribing information: IBRANCE (palbociclib) Prescribing Information. Pfizer. 2026.

Trastuzumab/pertuzumab: FDA approves pertuzumab, trastuzumab, and hyaluronidase-zzxf for HER2-positive breast cancer. FDA.gov.

Patient resources: National Breast Cancer Foundation | Susan G. Komen Foundation | Pfizer Ibrance patient support | American Cancer Society: Breast Cancer Types

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Decisions about maintenance therapy for HR-positive, HER2-positive metastatic breast cancer, including the addition of palbociclib following induction, require individualized assessment by a board-certified medical oncologist experienced in breast cancer management. Drug pricing information reflects figures at time of publication and is subject to change.

July 2, 2026

Triple-Negative Breast Cancer Has Had No Good First-Line Option for Patients Who Cannot Take Immunotherapy. Trodelvy Just Became the First Advance in 20 Years for That Population and the New Standard for Those Who Can. Here Is What the ASCENT-03 and ASCENT-04 Data Shows.

📌 The essentials On June 24, 2026, the FDA approved two new first-line indications for Trodelvy (sacituzumab govitecan-hziy, Gilead Sciences) in adults with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC): Indication 1 (monotherapy): as a single agent for adults with unresectable locally advanced or metastatic TNBC who are not candidates for PD-1 or PD-L1 inhibitor-based therapy. Supported by ASCENT-03. Indication 2 (combination): in combination with pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for adults with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (combined positive score [CPS] at or above 10) as determined by an FDA-authorized test. Supported by ASCENT-04/KEYNOTE-D19. These are new first-line approvals; Trodelvy was previously approved for second-line and later treatment in TNBC (2020) and HR+/HER2-low breast cancer (2023). The clinical basis: ASCENT-03 (NCT05382299): 558 patients, first-line TNBC ineligible for PD-(L)1 inhibitors, randomized 1:1 to sacituzumab govitecan 10 mg/kg days 1 and 8 of a 21-day cycle versus physician’s choice chemotherapy. Median PFS 9.7 months versus 6.9 months; HR 0.62 (95% CI 0.50 to 0.77; p less than 0.0001); 38% reduction in risk of progression or death. Median DOR 12.2 months versus 7.2 months. ORR 48% versus 46%. OS data immature. ASCENT-04/KEYNOTE-D19 (NCT05382286): 443 patients, first-line PD-L1-positive (CPS at or above 10) TNBC, randomized to sacituzumab govitecan plus pembrolizumab versus physician’s choice chemotherapy plus pembrolizumab. Median PFS 11.2 months versus 7.8 months; HR 0.65 (95% CI 0.51 to 0.84; p=0.0009); 35% reduction in risk of progression or death. Confirmed ORR 61% versus 55%. OS not reached in either arm at data cutoff. Mechanism: sacituzumab govitecan is a Trop-2-directed antibody-drug conjugate (ADC) that delivers the topoisomerase I inhibitor SN-38 specifically to Trop-2-expressing cancer cells. Trop-2 is highly expressed in TNBC. Boxed warnings: severe neutropenia; severe diarrhea. Both are manageable with established protocols.

Triple-negative breast cancer is defined by what it lacks: no estrogen receptor expression, no progesterone receptor expression, and no HER2 overexpression. That combination of absences eliminates three of the most productive therapeutic targets in modern breast cancer medicine. There is no endocrine therapy. There is no HER2-directed antibody. For decades, the treatment toolkit for TNBC was essentially the same chemotherapy regimens that oncology had in the 1990s.

The arrival of pembrolizumab plus chemotherapy for PD-L1-positive TNBC in 2021 represented the last major first-line shift. But pembrolizumab only helps patients whose tumors express PD-L1 at adequate levels, roughly half of the metastatic TNBC population. For the other half, the patients with PD-L1-negative disease or contraindications to immunotherapy, the standard of care in 2025 was still first-line chemotherapy.

That remained true for more than 20 years after TNBC was first defined as a distinct subtype. As Dr. Javier Cortés, Head of the International Breast Cancer Center in Spain and principal investigator of ASCENT-03, put it: the ASCENT-03 outcome represents the first clinically meaningful advance for this patient population in more than 20 years.

The June 24, 2026 FDA approvals give Trodelvy (sacituzumab govitecan-hziy, Gilead Sciences) a first-line role across the full spectrum of metastatic TNBC, whether or not the patient is eligible for immunotherapy, based on two Phase 3 trials both published in the New England Journal of Medicine.

What Triple-Negative Breast Cancer Is and Why It Has Been So Hard to Treat

Breast cancer is not one disease. It is a collection of molecularly distinct subtypes with different drivers, different natural histories, and different therapeutic vulnerabilities. The most common subtypes, hormone receptor-positive breast cancers, are driven by estrogen and progesterone signaling and are treated with endocrine therapies that can maintain disease control for years. HER2-positive cancers are driven by HER2 amplification and are effectively treated with targeted antibodies and antibody-drug conjugates. Both subtypes have seen dramatic survival improvements over the past 30 years.

Triple-negative breast cancer accounts for approximately 10 to 15% of all breast cancers, but its clinical impact is disproportionate to its prevalence. TNBC is more common in younger women and is overrepresented in women of African descent, for whom the incidence rate is approximately double that of white women. It tends to grow rapidly and metastasize early. Unlike hormone receptor-positive disease, which can smolder for years before progressing, TNBC often spreads and becomes lethal within months of metastatic diagnosis.

The five-year survival rate for metastatic TNBC is approximately 12%, compared with 28% for other metastatic breast cancer subtypes. Nearly half of patients diagnosed with metastatic TNBC never receive a second line of therapy, making the first line of treatment the most consequential decision in their care. That clinical reality is the context within which both ASCENT-03 and ASCENT-04 must be understood.

The PD-L1 split that defines the treatment landscape

The 2021 approval of pembrolizumab plus chemotherapy (KEYNOTE-522) for PD-L1-positive metastatic TNBC was a meaningful advance, but it created a fork in the treatment pathway. To receive pembrolizumab, patients must have PD-L1 expression with a combined positive score (CPS) at or above 10, as measured by the PD-L1 IHC 22C3 pharmDx assay. Patients who are PD-L1-negative by this criterion, or who have contraindications to checkpoint inhibition (autoimmune conditions, organ transplantation, severe prior immune-related adverse events), have not been eligible for the pembrolizumab combination and have faced first-line chemotherapy alone.

ASCENT-03 is specifically designed for this PD-L1-ineligible population. ASCENT-04 targets the PD-L1-positive population and asks whether replacing chemotherapy with an ADC as the partner to pembrolizumab improves on the current standard.

The Science: What Sacituzumab Govitecan Is and How It Works

Sacituzumab govitecan is an antibody-drug conjugate (ADC): a targeted delivery vehicle that combines a cancer-specific antibody with a cytotoxic drug payload, connected by a chemical linker designed to release the payload preferentially inside tumor cells.

The three components of sacituzumab govitecan are:

The antibody: anti-Trop-2. Trop-2 (trophoblast cell-surface antigen 2) is a transmembrane glycoprotein that is highly expressed on the surface of many epithelial cancer cells, including the vast majority of TNBC tumors. Its expression in normal adult tissues is comparatively low, making it a useful tumor-targeting antigen. The anti-Trop-2 antibody in sacituzumab govitecan binds to Trop-2-expressing cancer cells and is internalized through receptor-mediated endocytosis, bringing the payload inside the cell.

The linker: hydrolysable. Unlike ADCs with stable, non-cleavable linkers that only release payload inside target cells, the hydrolysable linker in sacituzumab govitecan releases some active payload in the tumor microenvironment after internalization. This creates a “bystander effect”: neighboring cancer cells that may express lower levels of Trop-2 are also exposed to SN-38, potentially expanding the drug’s activity beyond the highest-Trop-2-expressing cells.

The payload: SN-38. SN-38 is the active metabolite of irinotecan, a topoisomerase I inhibitor. Topoisomerase I is an enzyme that relieves torsional stress in DNA during replication by creating temporary single-strand breaks. SN-38 traps topoisomerase I in a complex with DNA, preventing the breaks from being resealed. The result is irreversible DNA double-strand breaks during replication, triggering apoptosis. SN-38 is approximately 100 to 1,000 times more potent than irinotecan itself. The ADC delivery format allows higher intratumoral concentrations of SN-38 than would be tolerable with systemic irinotecan.

The drug-to-antibody ratio (DAR) of sacituzumab govitecan is approximately 7.6, meaning roughly 7 to 8 SN-38 molecules are attached per antibody. This high DAR, unusual among approved ADCs, contributes to the drug’s potency at Trop-2-expressing tumors.

ASCENT-03: The Monotherapy Indication

Design

ASCENT-03 (NCT05382299) was a Phase 3, multicenter, open-label, randomized trial enrolling 558 adults with unresectable locally advanced or metastatic TNBC who had not received prior systemic therapy for advanced disease and who were not candidates for PD-1 or PD-L1 inhibitor therapy. The enrollment criteria specifically required that patients either had PD-L1-negative tumors (CPS below 10) or had PD-L1-positive tumors but could not receive immunotherapy due to comorbidities.

Patients were randomized 1:1 to:

Sacituzumab govitecan 10 mg/kg IV on days 1 and 8 of a 21-day cycle
Physician’s choice chemotherapy (paclitaxel, nab-paclitaxel, or gemcitabine plus carboplatin)

The primary endpoint was progression-free survival (PFS) per blinded independent central review (BICR). Key secondary endpoints included overall survival (OS), objective response rate (ORR), duration of response (DOR), and safety.

Results

At a median follow-up of 13.2 months, sacituzumab govitecan demonstrated a statistically significant and clinically meaningful improvement in PFS compared with chemotherapy, with a median PFS of 9.7 months versus 6.9 months, representing a 38% reduction in the risk of disease progression or death (HR 0.62; 95% CI 0.50 to 0.78; p less than 0.0001). BioSpace

Endpoint	Sacituzumab govitecan	Chemotherapy (TPC)	Result
Median PFS (BICR)	9.7 months (95% CI 8.1 to 11.1)	6.9 months (95% CI 5.6 to 8.2)	HR 0.62 (95% CI 0.50 to 0.77); p less than 0.0001
Risk reduction in progression or death	38%	Reference	—
ORR	48% (95% CI 42% to 54%)	46% (95% CI 40% to 52%)	Comparable
Median DOR	12.2 months (95% CI 9.7 to 13.8)	7.2 months (95% CI 5.7 to 8.4)	Substantially longer with SG
Median PFS2 (time to next progression)	18.2 months (95% CI 15.9 to NR)	14.0 months (95% CI 12.5 to 17.4)	HR 0.70 (95% CI 0.55 to 0.90)
OS	Data immature (37% maturity at cutoff)	Data immature	No OS detriment observed

Source: Cortés J et al. Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer. NEJM. 2025. doi:10.1056/NEJMoa2511734. ASCENT-03, abstract LBA20, ESMO 2025.

The ORR was 48% with sacituzumab govitecan versus 46% with chemotherapy, with similar rates but a substantially longer median DOR with sacituzumab govitecan (12.2 months versus 7.2 months). The PFS benefit was consistent across prespecified subgroups, including patients with poor prognostic features such as disease recurrence within one year of prior curative therapy. FDA

The treatment discontinuation rate due to adverse events was lower with sacituzumab govitecan than with chemotherapy, a finding that supports the tolerability of the ADC relative to standard cytotoxic regimens in this population.

ASCENT-04/KEYNOTE-D19: The Combination Indication

Design

ASCENT-04/KEYNOTE-D19 (NCT05382286) was a Phase 3, multicenter, open-label, randomized trial enrolling 443 adults with locally advanced or metastatic TNBC who had not received prior systemic therapy for advanced disease and whose tumors expressed PD-L1 at a CPS of 10 or greater, confirmed centrally using the PD-L1 IHC 22C3 pharmDx assay.

Patients were randomized to:

Sacituzumab govitecan 10 mg/kg IV days 1 and 8 of a 21-day cycle plus pembrolizumab 200 mg IV on day 1 every 3 weeks (n=221)
Physician’s choice chemotherapy plus pembrolizumab 200 mg IV on day 1 every 3 weeks (n=222)

The primary endpoint was PFS by BICR.

Results

At a data cutoff of March 3, 2025, sacituzumab govitecan plus pembrolizumab led to a median PFS of 11.2 months (95% CI 9.3 to 16.7) versus 7.8 months (95% CI 7.3 to 9.3) with chemotherapy plus pembrolizumab, translating to a 35% reduction in the risk of disease progression or death (HR 0.65; 95% CI 0.51 to 0.84; p less than 0.001). Patient Care Online

Endpoint	SG plus pembrolizumab	Chemo plus pembrolizumab	Result
Median PFS (BICR)	11.2 months (95% CI 9.3 to 16.7)	7.8 months (95% CI 7.3 to 9.3)	HR 0.65 (95% CI 0.51 to 0.84); p=0.0009
Risk reduction in progression or death	35%	Reference	—
6-month PFS rate	72% (95% CI 65% to 77%)	63% (95% CI 56% to 70%)	—
12-month PFS rate	48% (95% CI 41% to 56%)	38% (95% CI 31% to 45%)	—
Confirmed ORR	61% (95% CI 55% to 68%)	55% (95% CI 48% to 62%)	—
Median OS	Not reached	Not reached	Immature; no OS detriment

Source: Tolaney SM et al. Sacituzumab govitecan plus pembrolizumab in first-line PD-L1-positive TNBC. ASCO 2025 / NEJM 2025. doi:10.1056/NEJMoa2511736. ASCENT-04/KEYNOTE-D19 NCT05382286.

An important contextual note: 43% of patients on the chemotherapy-plus-pembrolizumab arm crossed over to receive sacituzumab govitecan as a single agent in the second line, accounting for 81% of those who received subsequent treatment. The fact that the combination still showed statistically significant PFS benefit despite high crossover to the ADC in the control arm’s next line is a meaningful finding, because crossover typically dilutes the OS benefit in second-line crossover-heavy trials. Patient Care Online

Dr. Sara M. Tolaney, MD, MPH, chief of the Division of Breast Oncology at Dana-Farber Cancer Institute and principal investigator for ASCENT-04, described the combination as resulting in a statistically significant and clinically meaningful improvement in PFS in the first-line PD-L1-positive metastatic TNBC setting.

The Approval Framework: Two Indications Split by PD-L1 Status

The two new approvals create a rational treatment framework that mirrors how oncologists already stratify TNBC patients before initiating first-line therapy:

Patient profile	New first-line standard of care	Trial support
TNBC, not eligible for PD-(L)1 inhibitor therapy (PD-L1 CPS below 10, or contraindicated)	Trodelvy monotherapy (sacituzumab govitecan)	ASCENT-03
TNBC, PD-L1 CPS at or above 10 (confirmed by FDA-authorized assay)	Trodelvy plus Keytruda or Keytruda Qlex (sacituzumab govitecan plus pembrolizumab)	ASCENT-04

The key practical implication for oncology teams: PD-L1 testing using the 22C3 pharmDx assay is now a required step in first-line treatment planning for metastatic TNBC. This test was already standard of care at many centers for the pembrolizumab decision; the new approvals make it universal.

Ricki Fairley, co-founder and CEO of TOUCH, The Black Breast Cancer Alliance, noted that because so many patients may never receive subsequent lines of therapy, the ability to start with an effective option like Trodelvy with or without Keytruda in the first line is critical, particularly given TNBC’s disproportionate impact on Black women.

Trodelvy’s Complete Indication Picture After June 2026

Trodelvy now holds approvals across multiple settings in TNBC and beyond: Contagion Live

Indication	Approval date	Key trial
Previously treated (at or above 2 prior lines) metastatic TNBC	April 2020	ASCENT
Previously treated unresectable locally advanced or metastatic HR+/HER2-low breast cancer after endocrine therapy	February 2023	TROPiCS-02
First-line metastatic TNBC, not eligible for PD-(L)1 inhibitors (monotherapy)	June 24, 2026	ASCENT-03
First-line metastatic TNBC, PD-L1 CPS at or above 10 (plus pembrolizumab)	June 24, 2026	ASCENT-04

Safety: What Prescribers and Patients Need to Know

Sacituzumab govitecan carries a boxed warning for two serious adverse reactions, both attributable to the SN-38 topoisomerase I inhibitor payload.

Severe neutropenia (boxed warning): Grade 3 or higher neutropenia occurred in 43% of sacituzumab govitecan-treated patients in ASCENT-03. Neutropenia is the most clinically significant toxicity and requires proactive management. Granulocyte colony-stimulating factor (G-CSF) prophylaxis is strongly recommended and substantially reduces the severity and duration of neutropenic episodes. Complete blood count monitoring before each dose is standard. Dose reduction or delay may be required for severe neutropenia. Sanofi

Severe diarrhea (boxed warning): SN-38 causes significant gastrointestinal toxicity through its topoisomerase I inhibition in intestinal epithelium. Grade 3 or higher diarrhea occurred in 9% of sacituzumab govitecan-treated patients in ASCENT-03, compared with 16% with anemia in the chemotherapy arm. Management includes early loperamide at the first sign of loose stools and dose modification for persistent severe diarrhea. Patients with UGT1A1*28 homozygous genotype (reduced SN-38 glucuronidation) are at higher risk for both neutropenia and diarrhea and require dose reduction. Sanofi

Additional key safety information:

Safety item	Details	Clinical guidance
Severe neutropenia (boxed warning)	Grade 3 or higher neutropenia in approximately 43% in ASCENT-03; febrile neutropenia possible	G-CSF prophylaxis strongly recommended; CBC before each dose; dose modification per prescribing information
Severe diarrhea (boxed warning)	Grade 3 or higher in approximately 9%; early-onset (within days of infusion) common	Loperamide at first sign of loose stools; dose modification for severe or persistent diarrhea
UGT1A1 genotype	Patients homozygous for UGT1A128 (poor metabolizers) have reduced SN-38 clearance and higher toxicity risk	Starting dose reduction to 7.5 mg/kg recommended in homozygous UGT1A128 patients
Nausea and vomiting	Common; manageable with antiemetics	Prophylactic antiemetics recommended; anti-nausea medications as needed
Hypersensitivity and infusion reactions	Severe reactions including anaphylaxis reported	Premedication; monitoring during infusion; resuscitation capability required
Embryo-fetal toxicity	SN-38 can cause fetal harm	Effective contraception during treatment and for 6 months after last dose for females; 3 months for males
Pembrolizumab-related toxicities (combination indication)	Immune-mediated adverse reactions including pneumonitis, colitis, hepatitis, endocrinopathies; infusion reactions	Refer to Keytruda prescribing information for full immune-related AE management guidance
Serious adverse reactions in ASCENT-03 CheckRare	Occurred in 26% of patients; fatal adverse reactions in 2.5%	Close clinical monitoring; dose modification per prescribing information

What This Means for Patients and Oncology Teams

For patients with metastatic TNBC not eligible for immunotherapy

This population has had no meaningful treatment advance since TNBC was defined more than 20 years ago. ASCENT-03 represents the first clinically meaningful advance for this patient population in over 20 years, according to Dr. Cortés. The 38% reduction in progression risk, the nearly 3-month improvement in median PFS (9.7 versus 6.9 months), and the dramatically longer duration of response (12.2 versus 7.2 months) constitute a clinically significant departure from what chemotherapy alone has provided. Pfizer

For oncologists managing these patients: sacituzumab govitecan monotherapy is now an FDA-approved first-line standard for PD-(L)1-ineligible metastatic TNBC. The G-CSF prophylaxis requirement and the UGT1A1 genotype assessment should be part of the treatment initiation workup.

For patients with PD-L1-positive metastatic TNBC

The ASCENT-04 data establishes sacituzumab govitecan plus pembrolizumab as a new first-line option for patients with CPS at or above 10, with a 35% reduction in progression risk over the prior standard of chemotherapy plus pembrolizumab. The combination’s 11.2-month median PFS and 61% ORR represent a meaningful improvement over what was achievable in this setting.

The combination requires PD-L1 testing before initiation, coordination of the ADC and checkpoint inhibitor schedules, and management of both SN-38 toxicities (neutropenia, diarrhea) and potential immune-mediated adverse events from pembrolizumab.

The sequencing question and OS data

One important clinical caveat applies to both approvals: overall survival data were immature at the time of analysis for both ASCENT-03 and ASCENT-04. The PFS benefit is established and statistically significant, but whether first-line Trodelvy translates into longer overall survival will depend on mature OS data from ongoing follow-up. Given the high crossover rate in ASCENT-04 (43% of control arm patients received sacituzumab govitecan in the second line), the OS signal may be attenuated even if the drug provides genuine survival benefit. These are data to watch in updated analyses from both trials.

For patients and families navigating a new metastatic TNBC diagnosis: the National Breast Cancer Foundation, Susan G. Komen Foundation, and TOUCH, The Black Breast Cancer Alliance all maintain current patient resources including clinical trial locators and financial assistance navigation for Trodelvy access.

For related HED coverage on oncology ADC approvals and breast cancer treatment advances, see our prior coverage on Pomalyst (pomalidomide) and what the multiple myeloma treatment landscape looks like as generic competition arrives in the 2026 LOE series.

Sources

FDA approval announcement: FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer. FDA.gov. June 24, 2026.

Gilead press release: U.S. FDA approves Trodelvy for first-line treatment of metastatic triple-negative breast cancer. gilead.com. June 24, 2026.

ASCO Post approval summary: FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination With Pembrolizumab for First-Line Treatment of TNBC. ascopost.com. June 2026.

Pharmacy Times clinical review: FDA Approves Sacituzumab Govitecan for First-Line Treatment of Advanced Triple-Negative Breast Cancer. pharmacytimes.com. June 2026.

BioPharm International clinical summary: Trop-2-Directed ADC Sacituzumab Govitecan Earns FDA Approval in First-Line Metastatic TNBC. biopharminternational.com. June 2026.

CancerNetwork detailed clinical summary: Sacituzumab Govitecan Receives FDA Approval Across 2 TNBC Indications. cancernetwork.com. June 2026.

OncLive: ASCENT-04 primary analysis and Dr. Tolaney commentary: Dr Tolaney on the FDA Approval of First-Line Sacituzumab Govitecan Plus Pembrolizumab for TNBC. onclive.com. June 2026.

ASCENT-03 primary NEJM publication: Cortés J et al. Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer. New England Journal of Medicine. 2025. doi:10.1056/NEJMoa2511734.

ASCENT-03 ESMO 2025 abstract (LBA20): Cortés JC et al. Primary results from ASCENT-03. Presented at ESMO Congress 2025. October 19, 2025. Berlin, Germany.

ASCENT-03 trial registration: NCT05382299. ClinicalTrials.gov.

ASCENT-04 primary NEJM publication: Tolaney SM et al. Sacituzumab govitecan plus pembrolizumab in first-line PD-L1-positive TNBC. NEJM. 2025. doi:10.1056/NEJMoa2511736.

ASCENT-04 trial registration: NCT05382286. ClinicalTrials.gov.

ASCENT-04 PFS2 and subsequent therapy data: Kalinsky K et al. PFS2 and subsequent therapies in ASCENT-04. ASCO 2026.

ADC mechanism and Trop-2 biology: Antibody-Drug Conjugates in Cancer Therapy. PMC7734386.

Sacituzumab govitecan StatPearls: Sacituzumab Govitecan. StatPearls. NCBI.

TNBC overview: Triple-Negative Breast Cancer. StatPearls. NCBI.

Pembrolizumab plus chemo TNBC approval (KEYNOTE-522): FDA approves pembrolizumab for triple-negative breast cancer. FDA.gov.

ACS TNBC overview: Triple-Negative Breast Cancer. cancer.org.

Patient resources: National Breast Cancer Foundation | Susan G. Komen Foundation | TOUCH, The Black Breast Cancer Alliance | Gilead Trodelvy patient support

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Trodelvy (sacituzumab govitecan-hziy) carries a boxed warning for severe neutropenia and severe diarrhea. Treatment decisions for metastatic TNBC, including the choice between monotherapy and combination regimens and the role of PD-L1 testing in treatment planning, should be made in close collaboration with a board-certified medical oncologist experienced in breast cancer management.

June 30, 2026

Thyroid Eye Disease Has Had Only One Approved Treatment Since 2020. Lumvoa Just Became the Second, and It’s the First Proven to Work in Both Active and Chronic Disease. Here Is What the THRIVE Trials Show.

📌 The essentials On June 26, 2026, the FDA approved Lumvoa (veligrotug-vvze, Viridian Therapeutics) for the treatment of thyroid eye disease (TED) in adults. Lumvoa is the second FDA-approved pharmacologic therapy for TED, following teprotumumab (Tepezza, Amgen/Horizon), which was approved in 2020 for active TED. What makes Lumvoa distinct: it is the first FDA-approved treatment for TED with labeling that includes clinical data in both active and chronic TED, making it the first therapy with a regulatory basis for use across the full disease spectrum. Mechanism: veligrotug is a full antagonist of the insulin-like growth factor-1 receptor (IGF-1R), a humanized monoclonal antibody that completely blocks IGF-1R signaling. This distinguishes it from teprotumumab, which is a partial/mixed agonist-antagonist. Regulatory designations: Breakthrough Therapy Designation; Priority Review. Clinical basis: Phase 3 THRIVE (NCT05176639) in active TED and Phase 3 THRIVE-2 (NCT06021054) in chronic TED. Both trials met their primary endpoint and all secondary endpoints at week 15 with high statistical significance. THRIVE (active TED, n=113): Proptosis Responder Rate (PRR) 70% versus 5% placebo (p less than 0.0001); mean proptosis reduction 2.9 mm versus 0.5 mm; diplopia complete resolution 54% versus 12% (p less than 0.0001). THRIVE-2 (chronic TED, n=188): PRR 56% versus 8% (p less than 0.0001); mean proptosis reduction 2.34 mm versus 0.46 mm; diplopia improvement 56% versus 25% (p=0.0006); diplopia complete resolution 32% versus 14% (p=0.0152). Rapid onset: statistically significant proptosis reduction observed as early as week 3 (after one infusion) in both trials. Treatment course: 5 intravenous infusions administered every 3 weeks (infusions at weeks 0, 3, 6, 9, 12; primary analysis at week 15). Shorter infusion course than teprotumumab (8 infusions). Key safety: infusion reactions approximately 9%; hyperglycemia 12% including patients without pre-existing diabetes; hearing impairment (class risk); muscle spasms most common adverse reaction. Available now: commercial launch immediately following approval.

Thyroid eye disease is one of those conditions that sounds manageable until you understand what it actually does to the people who have it. The immune system targets the tissues behind and around the eye — the orbital fat, the extraocular muscles, the connective tissue. The result can include forward protrusion of the eyeball (proptosis) that makes it impossible to close the eye fully, double vision that prevents driving or reading or functioning normally, and pain behind the eyes that is present with every eye movement. At its most severe, the expansion of orbital tissue compresses the optic nerve, threatening permanent vision loss.

Before 2020, the only systemic treatment for TED was intravenous corticosteroids, which reduce inflammation but do not address the underlying disease mechanism. In 2020, teprotumumab (Tepezza) became the first drug approved specifically for TED, targeting the insulin-like growth factor-1 receptor (IGF-1R) and demonstrating that the proptosis and diplopia of TED could be substantially reversed pharmacologically.

Lumvoa (veligrotug-vvze, Viridian Therapeutics), approved June 26, 2026, is the second drug approved for TED — and the first with regulatory labeling that includes data across the full disease spectrum, both active and chronic phases. The THRIVE and THRIVE-2 Phase 3 trials demonstrated not only that veligrotug works in both phases, but that it works rapidly, producing statistically significant proptosis reduction after just one infusion in week 3, with diplopia improvements that are among the most robust data ever generated for any TED therapy.

What Thyroid Eye Disease Is and Why the Active/Chronic Distinction Matters

Thyroid eye disease is a rare autoimmune orbitopathy most commonly associated with Graves disease, a condition in which autoantibodies against the thyroid-stimulating hormone receptor (TSHR) drive overproduction of thyroid hormone. In TED, those same autoantibodies, along with antibodies to IGF-1R, activate fibroblasts in the orbital fat and extraocular muscles, triggering inflammation, glycosaminoglycan accumulation, and remodeling of the orbital soft tissues. The result is a progressive expansion of orbital volume that pushes the eyeball forward (proptosis) and impairs the function of the muscles that move it (causing diplopia and limiting motility).

TED affects approximately 16 to 19 adults per 100,000, primarily those with Graves disease, though it can occur in euthyroid or hypothyroid patients with autoimmune thyroid conditions. Women are more commonly affected than men.

The active and chronic phases: why they are clinically distinct

Disease phase	Definition	Characteristics	Clinical significance
Active TED	Clinical Activity Score (CAS) at or above 3/7; onset within approximately 15 months	Active inflammation; edema; periorbital redness; pain; rapidly changing proptosis	Amenable to anti-inflammatory intervention; spontaneous partial remission possible
Chronic TED	CAS below 3; disease onset more than 15 months ago	Fibrosis and remodeling dominate over active inflammation; proptosis is stable; diplopia is fixed	Less responsive to corticosteroids; fibrotic changes once thought irreversible; surgical intervention (orbital decompression, strabismus surgery, eyelid surgery) traditionally the primary option

This distinction has historically defined treatment options. Teprotumumab’s pivotal trial was conducted in active TED, and its label is primarily supported by data in this phase. Patients with chronic TED, who have passed through the active inflammatory phase into a state dominated by fibrotic orbital remodeling, have had essentially no systemic pharmacologic options except orbital decompression surgery.

The THRIVE-2 trial, conducted specifically in chronic TED, is the first global Phase 3 randomized controlled trial to demonstrate statistically significant improvement in both proptosis and diplopia in this population. That is the clinical significance of Lumvoa’s “both active and chronic” labeling.

The Science: Why IGF-1R Is the Target and What “Full Antagonist” Means

The IGF-1R/TSHR cross-talk mechanism

The pathogenesis of TED involves a synergistic interaction between two surface receptors on orbital fibroblasts: the thyroid-stimulating hormone receptor (TSHR) and the insulin-like growth factor-1 receptor (IGF-1R). These two receptors form a physical complex on the fibroblast surface and engage in molecular cross-talk: activation of one sensitizes or amplifies signaling through the other.

In TED, autoantibodies against TSHR and IGF-1R activate this fibroblast complex, driving: expansion of orbital preadipocytes into mature fat cells (hyaluronan-producing adipogenesis); differentiation of fibroblasts into myofibroblasts that produce the fibrous connective tissue that hardens the orbital fat; and production of hyaluronic acid and glycosaminoglycans that attract water, expanding orbital volume further. The combination of fat expansion, glycosaminoglycan accumulation, and fibrotic remodeling produces the characteristic proptosis, restricted ocular motility, and diplopia of TED.

IGF-1R inhibition interrupts this fibroblast activation cascade at the receptor level. By blocking IGF-1R, the downstream signaling pathways (PI3K/Akt, MAPK/ERK) that drive fibroblast proliferation, differentiation, and hyaluronan synthesis are suppressed. The anti-inflammatory effect follows: the cycle of immune cell recruitment driven by fibroblast activation slows, and the structural remodeling that produces proptosis is interrupted.

Full antagonist versus partial agonist-antagonist: the distinction from teprotumumab

Veligrotug is described as a full antagonist of IGF-1R. This is a specific pharmacological claim that distinguishes it from teprotumumab.

Teprotumumab acts as a partial agonist at IGF-1R in certain contexts: while it blocks much of IGF-1R’s downstream signaling, it also produces some residual IGF-1R activation through the receptor before its internalization and degradation. Veligrotug, by contrast, binds the receptor and completely blocks signaling without producing any agonist activation. The clinical relevance of this pharmacological distinction is an active area of investigation, but the theoretical benefit of full antagonism is the absence of any compensatory receptor activation that might limit or counterbalance the therapeutic blockade.

The “full antagonist” distinction is included in Lumvoa’s approved labeling, which is clinically notable. It is not a marketing description; it is a regulatory characterization of the drug’s pharmacological mechanism supported by preclinical and clinical evidence provided to the FDA.

The THRIVE and THRIVE-2 Trials: Complete Data

THRIVE: Phase 3 in active TED

THRIVE (NCT05176639) was a randomized, double-masked, placebo-controlled Phase 3 trial enrolling adults with moderate-to-severe active TED, defined by CAS at or above 3/7, proptosis at or above 3 mm, and disease onset within 15 months of screening.

Patients were randomized to veligrotug 10 mg/kg IV or placebo, administered every 3 weeks for 5 total infusions (at weeks 0, 3, 6, 9, and 12), with the primary analysis at week 15. The trial enrolled 113 patients (75 veligrotug; 38 placebo).

Endpoint at week 15	Veligrotug	Placebo	p-value
Proptosis Responder Rate (PRR by Hertel)	70%	5%	p less than 0.0001
PRR by MRI/CT	69%	9%	p less than 0.0001
Mean proptosis reduction	2.9 mm	0.5 mm	p less than 0.0001
Mean CAS reduction	3.4 points	1.7 points	p less than 0.0001
Diplopia complete resolution (in patients with diplopia at baseline)	54% (27/50)	12% (3/26)	p less than 0.0001
PRR statistically significant from week 3 (after 1 infusion)	Yes	—	p less than 0.0001

Source: Endocrine Practice THRIVE topline results abstract. 2025. PMC12545473. THRIVE NCT05176639.

The 70% proptosis responder rate at week 15 — compared to 5% for placebo — is a dramatic treatment effect. The 54% complete diplopia resolution rate in patients who had diplopia at baseline is particularly notable: more than half of patients with double vision resolved it completely within 15 weeks of treatment.

The rapid onset finding deserves specific attention. Statistical significance in proptosis reduction was achieved at week 3, after only a single infusion. This speed of response is faster than what was observed in the teprotumumab clinical trials and has direct clinical significance: patients and clinicians can assess whether treatment is working within the first month rather than waiting for the full course to complete.

THRIVE-2: Phase 3 in chronic TED

THRIVE-2 (NCT06021054) used the same treatment design but enrolled adults with moderate-to-severe chronic TED, defined as disease onset more than 15 months before screening and proptosis at or above 3 mm with any CAS value. The mean time since TED onset in enrolled patients was 69.8 months — nearly 6 years — making this a population in whom fibrotic remodeling had been accumulating for a substantial period. The trial enrolled 188 patients (125 veligrotug; 63 placebo) with a 2:1 randomization.

Endpoint at week 15	Veligrotug	Placebo	p-value
Proptosis Responder Rate (PRR by Hertel)	56%	8%	p less than 0.0001
PRR by MRI/CT	48%	3%	p less than 0.0001
Mean proptosis reduction	2.34 mm	0.46 mm	p less than 0.0001
Overall Responder Rate	56%	7%	p less than 0.0001
Diplopia improvement (Gorman scale; in patients with diplopia at baseline)	56%	25%	p=0.0006
Diplopia complete resolution (Gorman scale)	32%	14%	p=0.0152
CAS of 0 or 1 achieved (patients with CAS at or above 3 at baseline)	54%	24%	p=0.0060
PRR statistically significant from week 3 (after 1 infusion)	Yes	—	—

Source: Endocrine Practice THRIVE-2 publication. 2025. doi:10.1016/j.eprac.2025. NCT06021054.

THRIVE-2 is the first randomized controlled trial in chronic TED to demonstrate statistically significant improvement in both proptosis and diplopia. The finding that 56% of chronic TED patients achieved a proptosis response, in a disease phase previously considered refractory to systemic pharmacotherapy, challenges the historical assumption that fibrotic TED could only be addressed surgically.

The 32% complete diplopia resolution rate in chronic TED patients with diplopia is also clinically significant: for a patient who has had double vision for years, the possibility of complete resolution from a 12-week course of infusions represents a meaningful departure from the trajectory that orbital decompression, strabismus surgery, and eyelid surgery were previously the only path toward.

How Lumvoa Compares to Tepezza: A Clinical Summary

Teprotumumab (Tepezza) was the first drug ever approved for TED and established proof of concept for IGF-1R inhibition in this disease. Lumvoa enters the same mechanistic space with several clinically meaningful differences.

Feature	Lumvoa (veligrotug)	Tepezza (teprotumumab)
Mechanism	Full IGF-1R antagonist	Partial agonist-antagonist at IGF-1R
Active TED data	Yes (THRIVE Phase 3)	Yes (pivotal Phase 2 and Phase 3)
Chronic TED data	Yes (THRIVE-2 Phase 3; first RCT in chronic TED with positive diplopia data)	Limited; label primarily supported by active TED data
Number of infusions	5 infusions over 12 weeks	8 infusions over 21 weeks
Dose	10 mg/kg IV every 3 weeks	10 mg/kg first infusion, then 20 mg/kg every 3 weeks
Onset of proptosis response	Week 3 (after 1 infusion)	Week 6 (after 2 infusions)
Hyperglycemia rate	Approximately 12%	Approximately 10%
Hearing impairment	Reported (class risk; approximately 16% in THRIVE active TED)	Reported (class risk; approximately 10 to 29% in trials)
Chronic TED diplopia resolution	32% complete resolution (THRIVE-2)	Not established in a dedicated chronic TED Phase 3 RCT

Sources: Viridian THRIVE/THRIVE-2 data; Tepezza FDA approval and prescribing information.

The most clinically significant difference for prescribers is the combination of fewer infusions and the chronic TED data. From a patient experience standpoint, 5 infusions over 12 weeks is a substantially lighter treatment burden than 8 infusions over 21 weeks. Infusion center visits for a condition that already carries significant quality-of-life burden matter.

Dr. Michael Yen, MD, Professor of Oculoplastic Surgery and Ophthalmology at Baylor College of Medicine and an investigator in the THRIVE program, noted that the clinical data demonstrated meaningful improvements across the full spectrum of TED, including rapid reductions in proptosis and significant improvements in diplopia, in both the active and chronic disease settings.

An important note on indirect comparison: THRIVE and THRIVE-2 were not head-to-head trials against teprotumumab. The efficacy numbers from Lumvoa’s trials should not be used for direct numeric comparison against teprotumumab’s trials. Patient populations, trial designs, and baseline characteristics differed across programs. What can be said is that both drugs demonstrated substantial, statistically significant, clinically meaningful benefits in their respective trials, and that Lumvoa now adds a Phase 3 evidence base in chronic TED where Tepezza’s regulatory support was limited.

Safety: What Prescribers and Patients Need to Know

Lumvoa’s safety profile is consistent with the IGF-1R inhibitor class established by teprotumumab, with some differences in rate and pattern across specific adverse events.

Most common adverse reactions (occurring in 5% or more of patients):

Muscle spasms were the most common adverse event overall, reported in approximately 36% of veligrotug-treated patients versus 6% of placebo patients in THRIVE-2. While striking in relative frequency, the muscle spasms were predominantly mild in severity and rarely led to treatment discontinuation. Other common adverse reactions include headache, fatigue, diarrhea, nausea, nasopharyngitis, elevated creatine phosphokinase, dry skin, and hypertension.

Key warnings and precautions:

Infusion reactions: Infusion-related reactions occurred in approximately 9% of Lumvoa-treated patients in the THRIVE program. Most were mild to moderate. Premedication before infusions and clinical monitoring during administration are standard management. Patients should be observed during and after each infusion.

Hyperglycemia: Hyperglycemia was reported in approximately 12% of veligrotug-treated patients, including patients without pre-existing diabetes. IGF-1R inhibition affects insulin signaling, and glucose elevation is a class effect shared with teprotumumab. Blood glucose should be monitored before and during treatment, particularly in patients with diabetes or prediabetes. Dose modification or antidiabetic medication adjustment may be required.

Hearing impairment: Hearing impairment, including potentially permanent hearing loss, is identified as a risk in Lumvoa’s prescribing information. This is a class effect of IGF-1R inhibitors in TED. In the THRIVE trials, hearing-related adverse events were reported in approximately 13% to 16% of veligrotug-treated patients in the active and chronic TED trials, with a placebo-adjusted rate of approximately 9.6% in THRIVE-2. Patients should be counseled about this risk before treatment initiation. Audiologic evaluation before and during treatment is clinically appropriate, and patients should report any new hearing changes promptly.

Inflammatory bowel disease: The prescribing information includes a risk of inflammatory bowel disease exacerbation. Patients with a history of inflammatory bowel disease should be evaluated carefully before initiating Lumvoa.

Embryo-fetal toxicity: Based on its mechanism of action affecting IGF-1R signaling, Lumvoa may cause fetal harm. Females of reproductive potential should use effective contraception during treatment and for a specified period after the final infusion. Pregnancy testing before initiating treatment is appropriate.

Serious adverse events: Serious treatment-emergent adverse events in THRIVE were reported in 4 veligrotug-treated patients, all assessed as unrelated to treatment. Serious adverse events in THRIVE-2 occurred in 2% of veligrotug patients versus 3% of placebo patients. Treatment completion rates were high: 94% of veligrotug-treated patients in THRIVE-2 completed their full treatment course, a retention rate that speaks to the overall tolerability of the regimen.

What This Means for Patients and Clinicians

For patients with active TED

Lumvoa provides a second approved systemic pharmacologic option for active TED, alongside teprotumumab. The clinical discussion with an ophthalmologist or oculoplastic surgeon experienced in TED should now include both options, weighing the specific clinical profile, the shorter infusion course, the full antagonist mechanism, and individual patient factors including diabetes status, hearing risk, and infusion access.

For patients who have previously received teprotumumab and experienced disease recurrence or inadequate response, Lumvoa’s distinct pharmacological profile as a full antagonist represents a mechanistically differentiated alternative. Whether prior IGF-1R therapy exposure affects veligrotug response is a question that ongoing clinical experience will address. The THRIVE trials excluded patients who had received prior anti-IGF-1R therapy, so the evidence in this subgroup is not yet established.

For patients with chronic TED

This is the population for whom Lumvoa’s approval is most transformative. Until now, patients in the chronic phase of TED with established proptosis and fixed diplopia faced a choice between living with these manifestations or pursuing surgical correction: orbital decompression for proptosis, strabismus surgery for diplopia, and eyelid surgery for cosmetic and functional restoration. These surgeries are effective but carry their own risks and often require sequential procedures.

The THRIVE-2 data demonstrates that pharmacologic reversal of chronic TED manifestations is achievable in a meaningful proportion of patients. A 56% proptosis response rate and 32% complete diplopia resolution in a population with a mean TED onset of nearly 6 years challenges the assumption that fibrotic orbital changes are irreversible. For patients and clinicians managing chronic TED, a conversation about whether a 12-week course of Lumvoa infusions might reduce or eliminate the need for surgical intervention is now evidence-supported.

Christine Gustafson, Founder and Executive Director of the TED Community Organization, noted that a new treatment option could benefit many patients living with the physical and emotional burden of thyroid eye disease. The psychosocial burden of TED is well-documented: disfiguring proptosis, double vision that impairs independence, and pain with eye movement contribute to depression, social withdrawal, and reduced quality of life that persist well beyond the active inflammatory phase.

Practical access and administration

Lumvoa launched commercially on June 26, 2026, the same day as FDA approval. Treatment requires intravenous infusion access, which means a certified infusion center or hospital outpatient setting. The 5-infusion schedule over 12 weeks, with infusions every 3 weeks, represents a meaningful reduction in infusion center visits compared to teprotumumab’s 8-infusion protocol. Viridian has established a patient support program to assist with access, insurance navigation, and infusion site coordination.

For related HED coverage on autoimmune and rare endocrine conditions, see our post on Tzield (teplizumab) approved as the first disease-modifying therapy for recently diagnosed Stage 3 type 1 diabetes and our post on Hympavzi (marstacimab) expanding to cover children aged 6 to 11 and inhibitor-positive hemophilia patients.

Sources

Viridian FDA approval press release: Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa (veligrotug-vvze) for the Treatment of Thyroid Eye Disease. BusinessWire. June 26, 2026.

Eyewire clinical summary: FDA Approves Viridian’s Lumvoa for Thyroid Eye Disease. eyewire.news. June 2026.

Pharmacally detailed clinical coverage: FDA Approves Veligrotug as First Treatment for Active and Chronic Thyroid Eye Disease. pharmacally.com. June 2026.

Ophthalmology Times (full safety and mechanism detail): FDA approves veligrotug-vvze (Lumvoa) for thyroid eye disease across active and chronic stages. ophthalmologytimes.com. June 2026.

Optometry Times: FDA approves Lumvoa (veligrotug-vvze) for active and chronic thyroid eye disease. optometrytimes.com. June 2026.

HCPLive BLA acceptance coverage: FDA Accepts, Grants Priority Review to Veligrotug BLA for Thyroid Eye Disease. hcplive.com. March 2026.

THRIVE topline results (Endocrine Practice): Efficacy and Safety of Veligrotug, a Full Antagonist Monoclonal Antibody to IGF-1 Receptor, in Active Thyroid Eye Disease: THRIVE Phase 3 Topline Results. Endocrine Practice. 2025.

THRIVE PMC abstract: OR31-04 Efficacy and Safety of Veligrotug in Active TED: THRIVE Phase 3 Topline Results. PMC12545473.

THRIVE-2 primary results (Endocrine Practice): THRIVE-2 Phase 3 Trial of Veligrotug in Chronic Thyroid Eye Disease: Efficacy and Safety at 15 Weeks. Endocrine Practice. 2025.

THRIVE-2 topline press release (Viridian): Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial. ir.viridiantherapeutics.com. 2024.

THRIVE trial registration: NCT05176639. ClinicalTrials.gov.

THRIVE-2 trial registration: NCT06021054. ClinicalTrials.gov.

Viridian BLA acceptance and Priority Review: Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug. ir.viridiantherapeutics.com. 2025.

Teprotumumab FDA approval: FDA approves teprotumumab-trbw for thyroid eye disease. FDA.gov. January 2020.

IGF-1R biology: IGF-1R in autoimmune disease. PMC6126283.

Thyroid eye disease overview: Thyroid Eye Disease. StatPearls. NCBI.

Graves disease overview: Graves Disease. NIDDK.

Lumvoa prescribing information: LUMVOA (veligrotug-vvze) Prescribing Information. Viridian Therapeutics. 2026.

Patient resources: TED Community Organization | American Thyroid Association: TED patient resources | Viridian Lumvoa patient support

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Thyroid eye disease management, including the decision to initiate pharmacologic therapy with Lumvoa or Tepezza, requires individualized evaluation by a board-certified ophthalmologist, oculoplastic surgeon, or endocrinologist with experience in TED. Patients with active or chronic TED should discuss all systemic treatment options with their managing specialist before initiating therapy.

June 29, 2026

Severe Hypertriglyceridemia Has No Good Treatment Options. Tryngolza Just Became the First Approved Therapy Shown to Reduce Acute Pancreatitis Risk. Here Is What the CORE Trial Data Shows.

📌 The essentials On June 24, 2026, the FDA approved a new indication for Tryngolza (olezarsen, Ionis Pharmaceuticals) as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (sHTG: fasting triglycerides at or above 500 mg/dL). This makes Tryngolza the first and only therapy approved specifically to reduce the risk of acute pancreatitis in this population. Tryngolza was originally approved in December 2024 for adults with familial chylomicronemia syndrome (FCS), a rare monogenic form of sHTG affecting roughly 3,000 to 5,000 people in the U.S. The new sHTG indication covers approximately 3 million Americans who have severe hypertriglyceridemia from multiple non-monogenic causes. Mechanism: olezarsen is a GalNAc-conjugated antisense oligonucleotide (ASO) that targets apolipoprotein C-III (apoC-III) mRNA in hepatocytes, reducing apoC-III production. ApoC-III inhibits lipoprotein lipase (LPL), the enzyme responsible for clearing triglyceride-rich lipoproteins from the bloodstream. By reducing apoC-III, olezarsen restores LPL activity and promotes clearance of triglycerides through both LPL-dependent and LPL-independent pathways. The clinical basis: Phase 3 CORE-TIMI 72a (NCT05079919, n=617) and CORE2-TIMI 72b (NCT05552326, n=446), conducted with The TIMI Study Group. Mean baseline triglycerides: 1,116 mg/dL. Placebo-adjusted triglyceride reduction at 6 months: up to 72% (80 mg dose) in CORE, sustained through 12 months. Acute pancreatitis events: 85% reduction in pooled analyses; pooled rate ratio 0.15 (95% CI 0.05 to 0.40; p less than 0.001). Patients achieving triglycerides below 500 mg/dL: 86%. Primary NEJM publication: Marston NA et al. NEJM. 2025. doi:10.1056/NEJMoa2512761. Regulatory designations: Priority Review; Breakthrough Therapy designation (November 2025). Dosing: 50 mg or 80 mg subcutaneous injection once monthly via autoinjector. Available in the U.S. July 2026. Key safety considerations: injection site reactions; liver enzyme elevations; dose-dependent hepatic fat fraction increases; more thrombocytopenia with 80 mg dosing.

Hypertriglyceridemia is one of the most undertreated serious lipid disorders in clinical medicine. While elevated LDL cholesterol commands the vast majority of attention in cardiovascular risk management, very high triglycerides carry their own distinct and devastating clinical consequence: acute pancreatitis. When fasting triglycerides reach approximately 500 mg/dL and above, the risk of severe, recurrent, and potentially fatal pancreatitis rises substantially. At levels above 1,000 mg/dL, the risk becomes acutely dangerous.

And until June 24, 2026, no FDA-approved therapy had ever demonstrated that it could reduce the risk of acute pancreatitis in patients with severe hypertriglyceridemia. Fibrates, fish oils, and niacin lower triglycerides in this population, but none of them had generated the clinical trial evidence showing that their triglyceride reduction translated into fewer pancreatitis events.

Tryngolza (olezarsen, Ionis Pharmaceuticals) is the first. The Phase 3 CORE and CORE2 trials, involving 1,061 adults with fasting triglycerides at or above 500 mg/dL and a mean baseline level of 1,116 mg/dL, demonstrated an 85% reduction in acute pancreatitis events and up to 72% reduction in triglycerides compared to placebo — and did so with a once-monthly subcutaneous injection targeting the same molecular pathway responsible for the most severe form of this disease.

This post covers what severe hypertriglyceridemia is and why pancreatitis is its most feared consequence, how the apoC-III mechanism drives triglyceride accumulation and why targeting it with an antisense oligonucleotide represents a fundamentally different approach from existing therapies, what the CORE and CORE2 trials showed, the safety profile of olezarsen, how it relates to the original FCS indication, and what this approval means for the much larger population of Americans with severe hypertriglyceridemia.

What Severe Hypertriglyceridemia Is and Why It Causes Pancreatitis

Triglycerides are the primary form of dietary fat storage in the body. After meals, triglycerides are packaged into chylomicrons in the intestine and released into the bloodstream, where they are broken down by lipoprotein lipase (LPL). Between meals, the liver packages triglycerides into very low-density lipoprotein (VLDL) for transport and distribution. Under normal conditions, fasting triglycerides are below 150 mg/dL.

Severe hypertriglyceridemia is defined as fasting triglycerides at or above 500 mg/dL. At this level, the body’s triglyceride clearance machinery is overwhelmed: chylomicrons and VLDL remain in the circulation at pathologically elevated concentrations. The population affected in the United States is substantial, approximately 3 million adults, arising from combinations of genetic predisposition, metabolic conditions (type 2 diabetes, obesity, hypothyroidism), alcohol use, and medications that raise triglycerides (corticosteroids, certain antipsychotics, estrogens, beta-blockers).

Why hypertriglyceridemia causes pancreatitis

The mechanism by which very high triglycerides cause acute pancreatitis is not fully elucidated but involves the accumulation of triglyceride-rich lipoproteins (chylomicrons) in the pancreatic capillaries. Pancreatic lipase, the same enzyme that normally digests dietary fat in the intestine, hydrolyzes these accumulated triglycerides locally in the pancreatic microcirculation. The free fatty acids released from this hydrolysis are directly toxic to pancreatic acinar cells, producing the inflammatory cascade of acute pancreatitis. The pathological cycle is self-amplifying: local tissue damage increases vascular permeability, concentrating triglycerides further in the pancreatic bed.

Hypertriglyceridemia-induced acute pancreatitis differs from gallstone or alcohol-induced pancreatitis in several clinically important ways. Patients often present with more severe disease at initial diagnosis. The condition is highly recurrent: patients who have had one episode remain at high risk for subsequent attacks as long as triglycerides remain uncontrolled. Repeated episodes of acute pancreatitis cause cumulative damage including pancreatic fibrosis, exocrine insufficiency, and secondary diabetes. And the acute attacks themselves can be life-threatening, with mortality rates of 5 to 10% per episode from severe pancreatitis.

Why the existing therapies for hypertriglyceridemia have never been sufficient for this population Fibrates (fenofibrate, gemfibrozil), omega-3 fatty acids (Vascepa, Lovaza), and niacin all lower triglycerides to varying degrees in patients with sHTG. For mild-to-moderate hypertriglyceridemia, these agents are appropriate. For severe hypertriglyceridemia (triglycerides at or above 500 mg/dL), the problem is twofold: the degree of triglyceride reduction achievable with these agents is often insufficient to bring triglycerides below the 500 mg/dL danger threshold, and — critically — none of these therapies had ever demonstrated in a randomized controlled trial that their triglyceride-lowering translated into fewer pancreatitis events. They lower triglycerides. They do not have regulatory approval for reducing pancreatitis risk. For patients with sHTG who have been told to take a fibrate and a fish oil and watch their diet, this approval addresses the most important clinical gap in their management.

The Science: How apoC-III Drives Triglyceride Accumulation and Why Blocking It Works

Understanding olezarsen’s mechanism requires understanding the central role of apolipoprotein C-III (apoC-III) in triglyceride metabolism.

ApoC-III is a small apolipoprotein produced primarily in the liver. It acts as a major inhibitor of triglyceride clearance through two distinct mechanisms:

LPL inhibition: LPL is the enzyme that sits on the surface of capillary endothelial cells throughout the body and hydrolyzes the triglycerides in circulating VLDL and chylomicrons, releasing fatty acids for energy use or storage. ApoC-III, when present on the surface of these triglyceride-rich lipoproteins, directly inhibits LPL activity. When apoC-III levels are high, LPL cannot efficiently break down triglycerides, and triglyceride-rich lipoproteins accumulate in the bloodstream.

Impaired hepatic remnant uptake: Beyond LPL inhibition, apoC-III also blocks the hepatic receptors responsible for removing triglyceride-rich lipoprotein remnants from the bloodstream after partial hydrolysis. This means that even the breakdown products of VLDL and chylomicron hydrolysis accumulate in circulation when apoC-III is elevated.

In patients with sHTG, both mechanisms contribute to the massive triglyceride accumulation. Some patients have genetic variants that increase apoC-III expression directly; others have metabolic conditions that drive excess apoC-III production; all share the downstream consequence of overwhelmed LPL and impaired remnant clearance.

How olezarsen targets apoC-III: the GalNAc-ASO approach

Olezarsen is an antisense oligonucleotide (ASO) — a short, synthetic strand of modified RNA designed to bind to the messenger RNA (mRNA) that encodes apoC-III in the liver. When the ASO binds to its target mRNA, it recruits RNase H, an enzyme that degrades the bound RNA strand. With the mRNA destroyed, the ribosome cannot translate it into apoC-III protein. Hepatic apoC-III production decreases substantially and persistently.

What makes olezarsen a next-generation ASO is its GalNAc (N-acetyl galactosamine) conjugation. Three GalNAc molecules are attached to the olezarsen molecule in a triantennary arrangement. GalNAc is a high-affinity ligand for the asialoglycoprotein receptor (ASGPR) expressed almost exclusively on hepatocytes. When the GalNAc-conjugated ASO enters the bloodstream, hepatocytes recognize and rapidly internalize it through receptor-mediated endocytosis. The result: the drug is delivered with exceptional precision to the liver cells where apoC-III is produced, achieving equivalent apoC-III knockdown at doses far lower than first-generation ASOs that relied on non-targeted distribution.

The practical significance of the GalNAc targeting is not only efficacy. First-generation apoC-III ASOs like volanesorsen caused significant thrombocytopenia (low platelet counts) because systemic ASO distribution led to off-target interaction with platelets and the reticuloendothelial system. The GalNAc-mediated hepatic uptake of olezarsen reduces systemic ASO exposure substantially, greatly reducing platelet-related side effects. As a result, patients treated with olezarsen do not require the same intensive platelet monitoring that volanesorsen demanded, simplifying outpatient management considerably.

The CORE and CORE2 Trials: What the Data Shows

Trial design

CORE-TIMI 72a (NCT05079919) and CORE2-TIMI 72b (NCT05552326) were two Phase 3, global, multicenter, randomized, double-blind, placebo-controlled trials conducted in collaboration with The TIMI Study Group. Together they enrolled 1,061 adults (617 in CORE; 446 in CORE2) with fasting triglycerides at or above 500 mg/dL who were already on standard-of-care therapies for elevated triglycerides.

The extremely high baseline mean triglyceride level of 1,116 mg/dL in enrolled patients reflects the severity of sHTG being targeted. At baseline, 47% of CORE participants and 37% of CORE2 participants had fasting triglycerides at or above 880 mg/dL, well into the range where pancreatitis risk is acute.

Patients were randomized to olezarsen 50 mg once monthly, olezarsen 80 mg once monthly, or placebo via subcutaneous injection, for 12 months. The primary endpoint was placebo-adjusted percent change in fasting triglycerides from baseline to month 6. The results were published in the New England Journal of Medicine in November 2025.

Primary endpoint: triglyceride reduction

Trial	Dose	Placebo-adjusted TG reduction at 6 months	p-value	Sustained at 12 months
CORE	50 mg	63%	p less than 0.001	Yes
CORE	80 mg	72%	p less than 0.001	Yes
CORE2	50 mg	49%	p less than 0.001	Yes
CORE2	80 mg	55%	p less than 0.001	Yes

Source: Marston NA et al. Olezarsen for managing severe hypertriglyceridemia and pancreatitis risk. NEJM. 2025. doi:10.1056/NEJMoa2512761.

These are substantial reductions in a patient population starting from a mean triglyceride of 1,116 mg/dL. A 72% reduction from 1,116 mg/dL would bring the mean to approximately 312 mg/dL, below the 500 mg/dL acute pancreatitis risk threshold.

Secondary endpoint: acute pancreatitis events

The acute pancreatitis endpoint is the most clinically significant finding in the CORE and CORE2 program. At 12 months, in the pooled population across both trials:

Outcome	Pooled olezarsen	Pooled placebo
Acute pancreatitis events	7 events in 5 patients	22 events in 17 patients
Rate ratio (pooled)	0.15 (95% CI 0.05 to 0.40)	Reference
Reduction in acute pancreatitis events	85%	—
p-value	p less than 0.001	—
Patients achieving TG below 500 mg/dL	86%	—

Dr. Nicholas Marston, MD, MPH, cardiologist at Brigham and Women’s Hospital and Harvard Medical School, and principal investigator for the CORE program, noted that these were the first studies to show a significant reduction in acute pancreatitis events in sHTG, and that with most patients on olezarsen achieving triglyceride levels below the risk threshold for those potentially life-threatening episodes, the results represent a major advance for patients with recurrent pancreatitis.

Secondary lipid endpoints

Beyond triglycerides, olezarsen produced favorable changes across the broader lipid panel in CORE and CORE2:

Substantial reductions in apoC-III itself (the direct molecular target)
Reductions in remnant cholesterol
Reductions in non-HDL cholesterol
Reductions in VLDL cholesterol
Increases in HDL cholesterol (the protective lipoprotein)
Reductions in apolipoprotein B-containing lipoproteins

These secondary lipid findings are relevant to the question of whether olezarsen’s benefits extend beyond pancreatitis prevention to cardiovascular risk reduction, a question that the ongoing ESSENCE trial in moderate hypertriglyceridemia with established cardiovascular disease is designed to address.

Tryngolza’s Complete Indication Picture After June 2026

Indication	Population	Approval date
Reduce triglycerides in adults with familial chylomicronemia syndrome (FCS)	Adults with confirmed genetic FCS	December 19, 2024
Reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (sHTG)	Adults with fasting TG at or above 500 mg/dL	June 24, 2026

FCS is a rare monogenic disorder affecting 3,000 to 5,000 people in the United States, caused by biallelic loss-of-function mutations in genes encoding LPL or its essential cofactors, resulting in complete or near-complete absence of LPL activity. The sHTG population, now the larger approved indication, includes patients with polygenic triglyceride elevation, secondary causes, or a combination of genetic susceptibility plus metabolic or lifestyle factors.

The mechanistic basis for olezarsen’s efficacy across both conditions is the same: in both FCS and sHTG, apoC-III elevation contributes to insufficient triglyceride clearance. In FCS, LPL is absent or dysfunctional and apoC-III’s LPL-independent effects on remnant clearance are particularly relevant. In sHTG from other causes, restoring LPL activity by reducing apoC-III is the primary mechanism.

Dosing and Administration

Tryngolza is available in two doses: 50 mg and 80 mg, both self-administered once monthly via subcutaneous autoinjector. The injection can be administered in the abdomen, thigh, or upper arm.

The 80 mg dose produced somewhat greater triglyceride reduction in the CORE trials (72% vs. 63%) but is associated with more adverse effects including dose-dependent hepatic fat fraction increases and higher rates of thrombocytopenia. The appropriate dose for a given patient is a clinical decision based on baseline triglyceride level, risk stratification, and tolerability.

The once-monthly dosing schedule is a meaningful practical advantage. Standard-of-care fibrate therapy requires once-daily oral dosing (or twice daily for some formulations), and omega-3 fatty acids require 4 capsules daily. A single monthly injection removes the daily medication burden for the most critical component of triglyceride management in this population.

Tryngolza will be available in U.S. pharmacies beginning July 2026.

Safety: What the Prescribing Information and Trial Data Cover

The safety profile of olezarsen in CORE and CORE2 was generally favorable, with most adverse events mild in severity. Notably, serious adverse events were less frequent in olezarsen-treated patients than in the placebo group, likely reflecting the reduction in pancreatitis hospitalizations.

Safety item	Details	Clinical guidance
Injection site reactions	Most common adverse event; generally mild (redness, bruising, pain); consistent with the subcutaneous injection class	Rotate injection sites. Mild reactions typically resolve without intervention.
Liver enzyme elevations	ALT and AST increases observed; greater with 80 mg dosing	Baseline liver function testing; monitor as clinically indicated.
Hepatic fat fraction increase	Dose-dependent; greater with 80 mg; clinical significance of hepatic fat accumulation under long-term treatment requires monitoring	Discuss with patients who have pre-existing hepatic steatosis; liver function monitoring recommended.
Thrombocytopenia	More common with 80 mg than 50 mg; less severe than observed with volanesorsen (first-generation apoC-III ASO); clinically significant platelet declines were infrequent and reversible	Baseline platelet count; periodic monitoring during therapy, more vigilant with 80 mg dosing.
Hypersensitivity reactions	Serious hypersensitivity reactions requiring medical treatment have occurred	Contraindicated in patients with a history of serious hypersensitivity to olezarsen or any excipient.
Embryo-fetal toxicity	Animal studies showed adverse developmental effects; potential fetal harm	Females of reproductive potential: use effective contraception during treatment.

Contraindication:
Tryngolza is contraindicated in patients with a history of serious hypersensitivity reactions to olezarsen or any of the product excipients.

The GalNAc-conjugated design of olezarsen is clinically relevant to the thrombocytopenia profile. Volanesorsen, the first-generation apoC-III ASO approved in Europe for FCS, caused severe, sometimes immune-mediated thrombocytopenia that required intensive platelet monitoring and led to treatment discontinuation in a meaningful proportion of patients. Olezarsen’s hepatocyte-targeted delivery dramatically reduces systemic ASO exposure, and the lower platelet toxicity signal observed in CORE and CORE2 reflects this. Patients treated with olezarsen require monitoring but not the intensive surveillance that volanesorsen demanded.

What This Means for Patients and Clinicians

For the approximately 3 million Americans with severe hypertriglyceridemia

This approval provides the first therapy specifically shown in randomized controlled trials to reduce acute pancreatitis events. For patients who have experienced one or more episodes of hypertriglyceridemia-induced pancreatitis — a population that knows intimately what the hospitalization, pain, and recovery looks like — the 85% reduction in pancreatitis events in CORE and CORE2 is the most important number in this approval.

For patients currently on fibrates and fish oils with triglycerides still above 500 mg/dL: the addition of olezarsen as an adjunct to diet and existing therapy is now an evidence-supported option. The trials enrolled patients already on standard-of-care therapies, meaning the CORE and CORE2 data reflects real-world patients who had not achieved adequate control on existing agents.

For clinicians managing lipid disorders

The approval creates a new treatment algorithm decision point: patients with confirmed fasting triglycerides at or above 500 mg/dL, particularly those with a history of pancreatitis, should now be evaluated for Tryngolza as an add-on to current triglyceride-lowering therapy. The once-monthly subcutaneous autoinjector, the absence of significant drug-drug interactions with common triglyceride-lowering agents, and the favorable tolerability profile in CORE and CORE2 make this a manageable addition to complex lipid management regimens.

The liver function and platelet monitoring requirements are straightforward and consistent with standard care for patients on lipid-active therapies. The hepatic fat fraction consideration is worth discussing with patients who have pre-existing metabolic-associated fatty liver disease, a common comorbidity in the sHTG population.

The FCS distinction

Patients with confirmed familial chylomicronemia syndrome remain a distinct population. FCS, defined by biallelic loss-of-function mutations in LPL or essential cofactors with complete or near-complete absence of LPL activity, carries a more severe clinical course and is the population for which Tryngolza’s original December 2024 approval was granted. FCS patients may have different dose considerations and monitoring needs from the broader sHTG population; management in these patients should involve a lipidologist or endocrinologist with experience in genetic lipid disorders.

For the broader sHTG population without confirmed monogenic disease: Tryngolza is now available in both primary care and specialist settings where appropriate patient selection, baseline testing, and monitoring can be provided.

For related HED coverage on lipid management and cardiometabolic health, see our post on Foundayo (orforglipron), the first oral GLP-1 receptor agonist with no food or water restrictions, approved for obesity management in 2026, and our post on Januvia (sitagliptin) losing exclusivity and what generic sitagliptin means for the type 2 diabetes treatment landscape.

Sources

Ionis FDA approval press release: TRYNGOLZA (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia. Ionis Pharmaceuticals. BusinessWire. June 24, 2026.

Drugs.com approval news: Tryngolza (olezarsen) Approved to Reduce Triglycerides and the Risk of Acute Pancreatitis. drugs.com. June 24, 2026.

HCPLive clinical coverage: FDA Approves Olezarsen (Tryngolza) for Severe Hypertriglyceridemia. hcplive.com. June 2026.

Endocrinology Advisor clinical summary: Tryngolza Approved to Reduce Triglycerides and Pancreatitis Risk in sHTG. endocrinologyadvisor.com. June 2026.

Pharmacy Times clinical review: Olezarsen Receives FDA Approval to Reduce Triglycerides, Risk of Acute Pancreatitis in Severe Hypertriglyceridemia. pharmacytimes.com. June 2026.

AHA gastroenterology news: FDA approves olezarsen to reduce acute pancreatitis risk in severe hypertriglyceridemia. news.gastro.org. June 2026.

CORE/CORE2 primary NEJM publication: Marston NA et al. Olezarsen for managing severe hypertriglyceridemia and pancreatitis risk. New England Journal of Medicine. 2025. doi:10.1056/NEJMoa2512761.

CORE trial registration: NCT05079919. ClinicalTrials.gov.

CORE2 trial registration: NCT05552326. ClinicalTrials.gov.

CORE/CORE2 trial design and rationale: Bergmark BA et al. Design and rationale of the CORE-TIMI 72a and CORE2-TIMI 72b trials of olezarsen. American Heart Journal. 2025;286:116–124.

ESSENCE trial (moderate HTG, CV outcomes): Olezarsen in Moderate Hypertriglyceridemia. NEJM. 2025. doi:10.1056/NEJMoa2507227.

Olezarsen mechanism and GalNAc-ASO review: Olezarsen: A Next-Generation Antisense Therapy. Cureus. PMC12700839.

Olezarsen and FCS original approval review: Olezarsen: FDA approval and clinical impact in FCS. PMC12577896.

ApoC-III mechanism and TRL metabolism: JACC Focus Seminar on apoC-III and TRL-lowering therapies. JACC. 2021;78(18):1817–1830.

Triglycerides and metabolic syndrome overview: Blood Triglycerides. NHLBI.

Acute pancreatitis overview: Acute Pancreatitis. StatPearls. NCBI.

Thrombocytopenia: Thrombocytopenia. StatPearls. NCBI.

Tryngolza prescribing information: TRYNGOLZA (olezarsen) Prescribing Information. Ionis Pharmaceuticals. 2026.

Tryngolza approval history: Tryngolza FDA Approval History. drugs.com.

Patient resources: National Lipid Association (lipid.org) | American Heart Association: Triglycerides | FCS patient community: AMAG FCS Foundation | Ionis Tryngolza patient resources

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Decisions about initiating Tryngolza for severe hypertriglyceridemia or familial chylomicronemia syndrome should be made in consultation with a qualified clinician, such as a lipidologist, cardiologist, or endocrinologist, who can evaluate baseline triglyceride levels, liver function, platelet counts, and the full clinical context including history of pancreatitis and concurrent medications.

June 28, 2026

The Standard Nilotinib Pill and Acid Reducers Don’t Mix. For the 25% of CML Patients on PPIs, That’s Been a Real Problem. Cavhanza Just Solved It.

📌 The essentials Cavhanza (nilotinib, Cycle Pharmaceuticals/Flex Pharma) is a new orally disintegrating tablet (ODT) formulation of nilotinib, a second-generation BCR-ABL tyrosine kinase inhibitor (TKI), approved by the FDA for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). Indications: newly diagnosed Ph+ CML in chronic phase, and Ph+ CML in chronic or accelerated phase with resistance or intolerance to prior therapy including imatinib (Gleevec). This is the same clinical indication as Tasigna (nilotinib capsules, Novartis) — the FDA approval of the ODT version was supported by the established efficacy and safety data from Tasigna’s well-controlled trials. What makes Cavhanza different: the nilotinib molecule is unchanged. The innovation is pharmaceutical delivery. The ElectroNanoSpray (ENS) proprietary technology used by Flex Pharma produces nanoparticle-sized drug particles with dramatically improved solubility and dissolution rate. The result: Cavhanza maintains bioavailability when taken with proton pump inhibitors (PPIs) or histamine H2 receptor antagonists (H2RAs) — acid reducers that substantially reduce Tasigna’s absorption and are currently contraindicated with it. No food effect: Cavhanza can be taken without regard to meals. Standard nilotinib capsules require fasting (no food 2 hours before and 1 hour after each dose) because food substantially increases absorption and can raise drug levels to toxic ranges. The clinical problem this solves: approximately 25% of Ph+ CML patients are co-prescribed PPIs or H2RAs for conditions such as GERD, peptic ulcer disease, or gastroesophageal reflux. With standard nilotinib, these patients face a choice between undertreating their leukemia (due to reduced TKI absorption) or undertreating their GI condition (by stopping the acid reducer). Cavhanza eliminates this compromise. Dosing: consistent with Tasigna: 300 mg orally twice daily for newly diagnosed CML-CP; 400 mg orally twice daily for resistant or intolerant CML-CP and CML-AP. Can be swallowed whole or allowed to dissolve in the mouth before swallowing; can be taken with or without water. Regulatory basis: 505(b)(2) NDA pathway, referencing Tasigna’s clinical efficacy data. The studies showed no difference in the rate or extent of nilotinib absorption whether the ODT was swallowed whole or dissolved in the mouth.

Chronic myeloid leukemia is one of the most remarkable success stories in oncology’s history. Before 2001, a diagnosis of CML in chronic phase carried a median survival measured in years. The discovery that the BCR-ABL fusion oncogene drives CML, and the subsequent development of imatinib (Gleevec) as the first targeted BCR-ABL inhibitor, transformed CML from a reliably fatal malignancy into a manageable chronic condition. Today, patients on first- or second-generation TKI therapy have survival rates that approach those of the general population.

But managing a chronic leukemia requires sustained, reliable drug exposure, and for a meaningful proportion of CML patients that has been harder to achieve than the simple instruction to “take your pill twice a day” implies. Nilotinib (Tasigna), one of the most effective second-generation TKIs, has two well-documented, compliance-limiting properties: it cannot be taken with food, and it cannot be taken with the acid-reducing medications that 25% of CML patients regularly need.

Cavhanza (nilotinib ODT, Cycle Pharmaceuticals), approved in June 2026, is the pharmaceutical engineering answer to both of those problems. The nilotinib molecule is unchanged. The delivery technology is entirely new. And the clinical consequence is that a patient who needs both a TKI and a proton pump inhibitor no longer has to choose between them.

What CML Is and Why the BCR-ABL Target Changed Everything

Chronic myeloid leukemia is a clonal myeloproliferative neoplasm caused by a specific and well-characterized genetic abnormality: the Philadelphia chromosome. The Philadelphia chromosome results from a translocation between chromosomes 9 and 22, creating the fusion gene BCR-ABL1. The BCR-ABL1 protein is a constitutively active tyrosine kinase: unlike normal ABL kinase, which requires external activation signals, BCR-ABL constantly fires, driving uncontrolled myeloid cell proliferation.

This single molecular event — a translocation creating a permanently active kinase — is the driver of CML in the chronic phase for virtually every patient with the disease. That singular, druggable target is what made CML the proving ground for precision oncology.

CML has three clinical phases, reflecting disease progression if untreated or inadequately treated:

Phase	Definition	Clinical characteristics
Chronic phase (CML-CP)	Less than 10% blasts in peripheral blood or bone marrow	Most patients at diagnosis; generally manageable with oral TKI therapy; good prognosis with treatment
Accelerated phase (CML-AP)	10 to 19% blasts; specific cytogenetic or hematologic criteria	Intermediate stage; higher risk of progression; still potentially responsive to TKI therapy
Blast phase (CML-BP)	More than 20% blasts; resembles acute leukemia	Rapid deterioration; TKI therapy less effective; often requires intensive chemotherapy

The goal of TKI therapy in CML-CP is to achieve and maintain major molecular response (MMR), defined as BCR-ABL1 transcript levels at or below 0.1% on the International Scale (IS). Achieving MMR correlates strongly with preventing progression to accelerated or blast phase, and deep molecular responses (MR4, MR4.5) are associated with the possibility of treatment-free remission (TFR) in a proportion of patients. The monitoring of BCR-ABL1 transcript levels by PCR is standard practice, typically every 3 months during the first year of therapy and every 3 to 6 months thereafter.

Where Nilotinib Fits in the CML Treatment Landscape

CML now has five approved BCR-ABL TKIs in the United States, each targeting the same fundamental kinase but with different potency profiles, off-target activity, side effect patterns, and approved indications:

Agent	Generation	FDA-approved indications (adults)	Notable features
Imatinib (Gleevec, generics)	First	Newly diagnosed CML-CP; imatinib-intolerant/resistant CML-CP/AP/BP	First-in-class; extensive long-term data; generic available
Nilotinib (Tasigna, Cavhanza)	Second	Newly diagnosed CML-CP; resistant/intolerant CML-CP and CML-AP	Higher affinity for BCR-ABL; superior MMR vs imatinib; food/acid-reducer interaction
Dasatinib (Sprycel)	Second	Newly diagnosed CML-CP; resistant/intolerant CML (all phases)	Src kinase activity; effective in most imatinib resistance mutations; pleural effusion risk
Bosutinib (Bosulif)	Second	Newly diagnosed CML-CP; resistant/intolerant CML (CP, AP, BP)	GI-dominant side effects; food increases absorption (take with meal)
Ponatinib (Iclusig)	Third	Resistant/intolerant CML; T315I mutation	Covers T315I “gatekeeper” mutation; arterial thromboembolism risk

Nilotinib is classified as a second-generation TKI. It was engineered from the imatinib structure to achieve higher binding affinity and selectivity for BCR-ABL1, addressing imatinib resistance mutations and producing faster, deeper molecular responses. It is described as the most selective inhibitor of BCR-ABL among the approved TKIs, with potency approximately 30 times higher than imatinib in vitro.

The ENESTnd Trial: The Clinical Evidence Foundation

Cavhanza’s FDA approval was supported by the established clinical evidence base for nilotinib, specifically the data from the ENESTnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed patients) trial (NCT00471497), the pivotal Phase 3 trial that defined nilotinib’s role in frontline CML.

ENESTnd enrolled 846 adult patients with newly diagnosed CML-CP within 6 months of diagnosis, stratified by Sokal risk score, and randomized them 1:1:1 to nilotinib 300 mg twice daily, nilotinib 400 mg twice daily, or imatinib 400 mg once daily.

Endpoint	Nilotinib 300 mg twice daily	Imatinib 400 mg once daily	Significance
MMR (BCR-ABL1 at or below 0.1%) at 12 months	44%	22%	p less than 0.0001
Complete cytogenetic response (CCyR) at 12 months	80%	65%	p less than 0.001
Progression to accelerated or blast phase	0.7%	4.2%	Significantly reduced
5-year MMR rate	77%	60%	Durable superior response
10-year overall survival	Greater than 87%	Comparable (non-inferior)	Long-term survival similar

Source: Saglio G et al. Nilotinib versus Imatinib for Newly Diagnosed CML. NEJM. 2010;362(24):2251–2259. doi:10.1056/NEJMoa0912614. 10-year analysis: Hochhaus A et al. Leukemia. 2022.. NCT00471497.

The landmark finding from ENESTnd was that nilotinib produced significantly higher rates of MMR at 12 months, significantly fewer progressions to accelerated or blast phase, and significantly more patients achieving deep molecular response (MR4, MR4.5) compared to imatinib across all Sokal risk categories. These advantages translated into a durable efficacy benefit through 10 years of follow-up, with 10-year MMR rates of approximately 77% for nilotinib 300 mg twice daily versus 60% for imatinib.

The 10-year analysis also confirmed a key safety signal: cardiovascular events including ischemic heart disease, peripheral artery disease, and stroke occurred at higher rates in nilotinib-treated patients (approximately 7 to 8%) than in imatinib-treated patients (approximately 2 to 3%) over a decade. This cardiovascular risk is now a well-established element of nilotinib’s prescribing profile and is included in boxed warning language.

Cavhanza’s approval was via the 505(b)(2) NDA pathway, which allows a new drug application to reference existing published literature and data from a reference-listed drug. The ODT studies showed no difference in the rate or extent of nilotinib absorption whether the ODT was swallowed whole or dissolved in the mouth before swallowing, confirming pharmaceutical equivalence of the two administration methods.

The Core Problem Cavhanza Solves: Acid Reducers and pH-Dependent Absorption

This is the clinical story that gives Cavhanza its differentiated value. Understanding it requires a brief look at what standard nilotinib capsules need to be absorbed effectively.

Nilotinib is a weakly basic molecule that dissolves best in acidic conditions. In the stomach’s normally acidic environment, the drug dissolves adequately before moving into the small intestine where it is absorbed. When proton pump inhibitors (PPIs) or histamine H2 receptor antagonists (H2RAs) are on board, they reduce gastric acid production, raising stomach pH substantially. In this elevated-pH environment, standard nilotinib capsules dissolve poorly, and absorption drops significantly.

The standard Tasigna prescribing information reflects this directly: PPIs should not be co-administered with nilotinib, and H2RAs must be separated by specific timing restrictions (H2RAs can be administered approximately 10 hours before or approximately 2 hours after nilotinib). For a patient taking a PPI for chronic GERD, that effectively means stopping the PPI. For a patient taking an H2RA, it means carefully coordinating two twice-daily medications around each other’s timing windows.

The scale of this problem: approximately 25% of Ph+ CML patients are co-prescribed acid-reducing agents. These are largely older adults managing both their leukemia and common age-related comorbidities including reflux, peptic ulcer disease, and gastroprotective use alongside other medications like aspirin or anticoagulants. Telling these patients to stop their acid reducer, or to comply with precise timing restrictions every day for years, is not a trivial ask. Non-adherence to TKI therapy in CML is directly associated with loss of molecular response.

The food effect compounds this further. Standard nilotinib capsules must be taken without food: eating within 2 hours before or 1 hour after a nilotinib dose significantly increases drug absorption and can raise plasma levels to potentially toxic ranges. This means four distinct daily time windows around which the patient must plan: fast before dose 1, fast after dose 1, fast before dose 2, fast after dose 2. For patients managing a full daily life including meals and medications, this is a substantial behavioral burden.

How Cavhanza addresses both problems

Cavhanza uses Flex Pharma’s proprietary ElectroNanoSpray (ENS) technology to produce a nanoparticle-scale formulation of nilotinib with dramatically improved solubility and dissolution characteristics. By engineering the drug particles to be far smaller, the formulation increases the surface area available for dissolution and reduces the drug’s dependence on low gastric pH to dissolve adequately before reaching the small intestine. The result:

PPI co-administration: allowed with Cavhanza — no contraindication, no timing restriction
H2RA co-administration: allowed with Cavhanza — no timing restriction
Food effect: eliminated — Cavhanza can be taken with or without food

The orally disintegrating tablet format adds a further convenience dimension: the tablet can dissolve in the mouth before swallowing or can be swallowed whole. It can be taken with or without water. For patients who have difficulty swallowing capsules, or for patients in clinical settings where oral medication access is limited, these properties matter.

Safety: What Prescribers and Patients Need to Know

Cavhanza carries the same safety profile as nilotinib across all formulations, because the active molecule is identical. The safety program that governs Tasigna governs Cavhanza.

Boxed warnings:

QT prolongation and sudden death: Nilotinib prolongs the QT interval and has been associated with sudden death. Hypokalemia or hypomagnesemia must be corrected before initiating nilotinib and monitored during therapy. Avoid drugs that prolong the QT interval, including many anti-arrhythmic medications, certain antifungals, and fluoroquinolone antibiotics. An ECG is required at baseline, 7 days after initiation, and periodically thereafter. Do not use in patients with hypokalemia, hypomagnesemia, or long QT syndrome.

Hepatotoxicity: Nilotinib may cause severe hepatotoxicity and liver failure, including fatal cases. Monitor liver function tests before initiating and monthly during the first year, then periodically.

Cardiovascular events: Nilotinib is associated with an increased incidence of ischemic heart disease, peripheral artery disease, and ischemic cerebrovascular events. The 10-year ENESTnd data showed cardiovascular event rates of approximately 7 to 8% over a decade. Patients with cardiovascular risk factors should be assessed carefully before initiating nilotinib, with optimization of modifiable risk factors. Monitor for signs of cardiovascular disease during treatment.

Key warnings and precautions:

Safety item	Details	Clinical guidance
QT prolongation (boxed warning)	Prolongs QTcF; sudden death reported	ECG at baseline, day 7, and periodically. Correct electrolytes. Avoid QT-prolonging drugs. Hold and restart at reduced dose if QTcF greater than 480 ms.
Hepatotoxicity (boxed warning)	Severe liver injury and fatal liver failure reported	LFTs at baseline, monthly for first year, periodically thereafter.
Cardiovascular events	Ischemic heart disease, PAD, and stroke at higher rates than imatinib in long-term follow-up	Assess and manage CV risk factors before initiating. Monitor for signs of CV disease.
Myelosuppression	Neutropenia, thrombocytopenia, and anemia; dose modification or interruption may be required	CBC at baseline, every 2 weeks for first 2 months, then monthly.
Pancreatitis	Lipase and amylase elevations; symptomatic pancreatitis reported	Monitor lipase and amylase monthly or as clinically indicated.
Hepatitis B reactivation	Reactivation in chronic HBV carriers including fulminant hepatitis and fatal outcomes	Screen for HBV before initiating. Monitor carriers closely; consider antiviral prophylaxis.
CYP3A4 interactions	Strong CYP3A4 inhibitors increase nilotinib exposure; strong inducers reduce it	Avoid strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin); avoid strong inducers (rifampin). If unavoidable, dose reduction recommended.
Embryo-fetal toxicity	Nilotinib can cause fetal harm	Women of reproductive potential: effective contraception during treatment. Advise of reproductive risks before starting therapy.
Lactation	Not recommended during treatment and for 14 days after last dose	Discuss with patients before initiating.
Pediatric use	Cavhanza not approved for pediatric patients	The approved indication is adults only.

Common adverse reactions (occurring in 10% or more of patients in clinical trials): rash, nausea, headache, fatigue, pruritus, vomiting, alopecia, myalgia, and constipation.

What This Means for CML Patients and Prescribers

The practical change

For an established CML patient currently on Tasigna (nilotinib capsules) who also takes a PPI or H2RA: Cavhanza is now a clinically appropriate alternative that eliminates the drug interaction concern without changing the active compound, the dose, or the established molecular monitoring expectations. The transition from Tasigna to Cavhanza is a formulary and tolerability decision, not a clinical efficacy change.

For newly diagnosed CML-CP patients who also have GERD, peptic ulcer disease, or any clinical need for an acid reducer: the nilotinib-PPI interaction no longer needs to govern the treatment decision. Cavhanza can be initiated at the standard 300 mg twice-daily dose without worrying about acid-reducer timing or co-prescription contraindications.

For CML-CP and CML-AP patients with resistance or intolerance to prior therapy including imatinib: Cavhanza at 400 mg twice daily is now an option with the same added prescribing flexibility.

For oncology pharmacists and hematologists reviewing CML patients on complex polypharmacy regimens: Cavhanza’s elimination of the food restriction and the acid-reducer interaction removes two of the most practically difficult elements of long-term nilotinib adherence. Non-adherence to TKI therapy is directly associated with loss of molecular response and the risk of disease progression in CML. Any formulation innovation that reduces adherence barriers has the potential to translate into better molecular outcomes for this patient population.

Dr. Kevan Herold’s statement about treating a different disease earlier applies here in spirit: much of the value of precision oncology in CML comes from the consistency and completeness of BCR-ABL suppression. Inconsistent drug levels from missed doses, from food effect violations, or from acid-reducer-mediated reduced absorption, erode that suppression and create the selective pressure that drives resistance mutations.

The monitoring requirements remain

Regardless of formulation, patients on nilotinib require: baseline and periodic ECGs; CBC monitoring every 2 weeks for the first 2 months and monthly thereafter; LFTs monthly for the first year; electrolyte monitoring; and BCR-ABL1 PCR monitoring every 3 months during the first year and every 3 to 6 months thereafter. These monitoring requirements are unchanged by the ODT formulation.

For related HED coverage on CML and hematologic oncology, see our post on Pomalyst (pomalidomide) losing exclusivity and what generic pomalidomide means for multiple myeloma patients from the 2026 Loss of Exclusivity series.

Sources

Cycle Pharmaceuticals press release (approval): CAVHANZA (nilotinib) Orally Disintegrating Tablets: A New, FDA-approved Treatment Offering PPI and H2RA Flexibility for Ph+ CML Patients. BusinessWire. June 2, 2026.

BioSpace coverage: CAVHANZA (nilotinib) Orally Disintegrating Tablets: A New, FDA-approved Treatment. biospace.com. June 2026.

Targeted Oncology clinical summary: FDA OKs Oral Nilotinib Tablets for Ph+ CML With Acid-Reducer Flexibility. targetedonc.com. June 2026.

Cancer Therapy Advisor: FDA Approves Cavhanza, an ODT Formulation of Nilotinib for Ph+ CML. cancertherapyadvisor.com. June 2026.

Oncology Nursing News: FDA Approves Oral Nilotinib Tablets for Ph+ CML. oncnursingnews.com. June 2026.

WebMD approval summary: Cavhanza (Nilotinib) FDA Approval. webmd.com. June 2026.

ENESTnd primary publication: Saglio G et al. Nilotinib versus Imatinib for Newly Diagnosed CML in Chronic Phase. NEJM. 2010;362(24):2251–2259. doi:10.1056/NEJMoa0912614.

ENESTnd 10-year analysis: Hochhaus A et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed CML-CP: ENESTnd 10-year analysis. Leukemia. 2022.

ENESTnd trial registration: NCT00471497. ClinicalTrials.gov.

BCR-ABL mutations and nilotinib selectivity: Nilotinib and BCR-ABL mutations. PMC4915803.

Philadelphia chromosome and CML mechanism: Chronic Myelogenous Leukemia. StatPearls. NCBI.

Philadelphia chromosome molecular biology: BCR-ABL1 in CML. PMC7955155.

PPIs overview: Proton Pump Inhibitors. StatPearls. NCBI.

H2RAs overview: Histamine H2 Receptor Antagonists. StatPearls. NCBI.

QT prolongation: QT Prolongation. StatPearls. NCBI.

505(b)(2) NDA pathway: 505(b)(2) Applications. FDA.gov.

FDA nilotinib original approval: FDA approves nilotinib for chronic myeloid leukemia. FDA.gov.

Cavhanza prescribing information: CAVHANZA (nilotinib) Prescribing Information. Flex Pharma/Cycle Pharmaceuticals. 2026.

American Cancer Society CML overview: Chronic Myeloid Leukemia. cancer.org.

Patient resources: Leukemia and Lymphoma Society (LLS) | CML Advocates Network | Cycle Pharmaceuticals Cavhanza support | [Breakthrough T1D is not applicable here] | Novartis Tasigna patient support

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Nilotinib (Cavhanza) carries boxed warnings for QT prolongation with sudden death risk, hepatotoxicity, and cardiovascular events. CML management requires individualized care by a board-certified hematologist or oncologist with expertise in TKI therapy. Patients considering a transition from Tasigna to Cavhanza should discuss this with their treating hematologist-oncologist.

June 27, 2026

The FDA Just Approved a Third OTC Naloxone Nasal Spray. Here Is What Rextovy Is, How Naloxone Works, and Why More Competition in This Market Could Finally Move the Price.

📌 The essentials On June 16, 2026, the FDA approved Rextovy (naloxone hydrochloride 4 mg nasal spray, Amphastar Pharmaceuticals) for over-the-counter sale, making it the third naloxone nasal spray available without a prescription in the United States. No prescription, no pharmacist consultation, and no physician visit is required. Consumers can purchase Rextovy directly at pharmacies, convenience stores, and online retailers. What it is: a single 4 mg intranasal spray per device, supplied in a carton of 2 devices. The same active ingredient and the same 4 mg dose as OTC Narcan (Emergent BioSolutions). The difference is manufacturer: Rextovy is made by Amphastar Pharmaceuticals. A third OTC product, RiVive (Harm Reduction Therapeutics), contains 3 mg. All three are approved for bystander use without medical training. Rx version pricing: approximately $44 to $60 per box. OTC pricing was not immediately available at launch. Historical precedent: OTC naloxone prices declined by only approximately $0.49 per quarter between late 2023 and late 2024 following the first OTC approval, according to a 2026 study in the Journal of Substance Use and Addiction Treatment. A third competitor changes the economic calculus. Overdose death trend: in the 12-month period ending August 2023, 111,451 overdose deaths were reported; in the 12-month period ending December 2025, 68,632 were reported — a 38% decline since the first OTC naloxone approval. Drug overdose deaths remain a major public health issue, primarily driven by synthetic opioids including illicit fentanyl. Pricing equity note: the same 2026 study found that areas with larger American Indian and Alaska Native populations paid an estimated more than $5 extra per unit compared with predominantly white communities — a documented racial pricing disparity in OTC naloxone access.

The number of overdose deaths has dramatically decreased since the first FDA approval of an OTC naloxone nasal spray in 2023, but drug overdose persists as a major public health issue in the U.S., primarily driven by synthetic opioids like illicit fentanyl. In the 12-month period ending August 2023, 111,451 overdose deaths were reported. In the 12-month period ending December 2025, 68,632 were reported. That 38% decline is meaningful, and OTC naloxone availability is widely credited as one of its contributors. It is also not enough. More than 68,000 people dying per year from overdose is not a public health success. It is a reduced catastrophe. BioSpace

Against that backdrop, the FDA’s June 16, 2026 approval of Rextovy (naloxone hydrochloride, Amphastar Pharmaceuticals) as the third OTC naloxone nasal spray matters for two distinct reasons. The first is access: more manufacturers, more retail channels, and more products on shelves means more opportunities for the right person to have the right medication at the right moment. The second is economics: the most persistent barrier to naloxone adoption since the first OTC approval has not been awareness. It has been price. A third competitor in a market where prices have barely moved creates conditions for the competition that could finally change that.

This post covers what naloxone is and how it works, the OTC naloxone landscape and how Rextovy fits into it, what the pricing and access research actually shows, what the evidence says about bystander naloxone and its effect on survival, and what any person reading this needs to know about how to use it.

What Opioid Overdose Is and Why Minutes Matter

Opioid overdose occurs when the concentration of opioids in the body exceeds what the brain’s opioid receptors can manage without suppressing essential automatic functions. Opioids bind to mu-opioid receptors in the brainstem’s respiratory control centers. At therapeutic doses, this produces analgesia and sedation. At overdose doses, it produces profound respiratory depression: breathing slows, becomes shallow, and eventually stops. Without intervention, hypoxia progresses to cardiac arrest and death, typically within minutes.

The trajectory of a fatal opioid overdose, from respiratory depression to death, unfolds in a window of approximately 1 to 5 minutes in many cases, faster with high-potency synthetic opioids like fentanyl and carfentanil, somewhat longer with longer-acting opioids like methadone. This time window is the entire clinical rationale for OTC naloxone: by the time emergency medical services arrive, a reversible overdose has often become an irreversible one.

Recognizing an opioid overdose requires recognizing several characteristic signs. Any person who is:

Unresponsive or cannot be woken up
Breathing slowly, shallowly, or not at all
Making gurgling, choking, or rattling sounds (sometimes called the “death rattle”)
Limp and unable to hold their head up
Showing blue, gray, or pale lips, gums, or fingertips (indicating hypoxia)
Showing pinpoint (very small) pupils

should be treated as a suspected opioid overdose. Naloxone will not harm someone who does not have opioids in their system, so the risk of administering it to someone who turns out not to be overdosing on opioids is negligible. The risk of not administering it to someone who is overdosing on opioids is death.

How Naloxone Works: The Mechanism

Naloxone is a competitive opioid receptor antagonist. It binds to the same mu-, kappa-, and delta-opioid receptors in the brain that opioids bind to, but it does not activate them. Because naloxone’s binding affinity for these receptors is higher than that of most opioids, it rapidly displaces the opioid molecules already occupying the receptors and occupies those sites itself, blocking further opioid activity.

The clinical result of this receptor displacement is the reversal of opioid-induced respiratory depression within 2 to 5 minutes of administration. The person begins breathing again. Consciousness typically returns. The overdose reversal is complete for the duration of naloxone’s action.

The critical pharmacokinetic limitation of naloxone is its shorter duration of action compared to most opioids. Naloxone’s effects last approximately 30 to 90 minutes. Many opioids, particularly long-acting formulations like extended-release oxycodone or methadone, last substantially longer. Illicit fentanyl, which is now the dominant driver of overdose deaths, acts rapidly but can linger at high receptor occupancy.

This means that after naloxone wears off, opioid effects can return, a phenomenon called re-narcotization. This is the clinical reason why calling 911 after the first dose is not optional, even if the person wakes up and feels better. The naloxone reversal is temporary. The opioids are still in the system. Without professional medical monitoring and potentially additional doses, re-narcotization can cause a second respiratory depression episode just as lethal as the first.

What happens when the person wakes up is also important for bystanders to understand. Naloxone precipitates acute opioid withdrawal in opioid-dependent individuals by abruptly displacing opioids from receptors throughout the body. This produces sudden withdrawal symptoms: sweating, shaking, nausea, vomiting, irritability, and sometimes agitation or aggression. This is a normal and expected physiological response, not a sign that something has gone wrong. It is not dangerous. The person may be confused and frightened. The appropriate response is calm reassurance and staying with them until emergency services arrive.

Naloxone does not cause a “high” or produce any opioid effect In people who do not have opioids in their system, naloxone produces no clinically significant effect. It is pharmacologically inert as a monotherapy: it blocks receptors but does not activate them, so administering it to someone who is not overdosing on opioids produces no harm. This is one reason the FDA and public health authorities consistently recommend a low threshold for use: when in doubt, administer it. The consequence of a false positive is negligible. The consequence of a false negative is death.

The OTC Naloxone Landscape: Where Rextovy Fits

The United States OTC naloxone nasal spray market now has three approved products:

Product	Manufacturer	Dose	OTC approval	Status
Narcan 4 mg	Emergent BioSolutions	4 mg per spray	March 2023	Commercially available
RiVive 3 mg	Harm Reduction Therapeutics (nonprofit)	3 mg per spray	July 2023	Commercially available
Rextovy 4 mg	Amphastar Pharmaceuticals	4 mg per spray	June 16, 2026	Newly approved

Rextovy contains the same active ingredient at the same dose as OTC Narcan. The products are pharmacologically equivalent: both deliver 4 mg of naloxone hydrochloride as a single intranasal spray. The distinction is manufacturer, supply chain, and ultimately price. Amphastar Pharmaceuticals is a well-established injectable and inhalable drug manufacturer with existing manufacturing infrastructure for drug products in similar delivery formats. Its entry into the OTC naloxone market adds a second 4 mg option and a new supply source.

The original prescription version of Rextovy was approved on March 7, 2023. The June 16, 2026 action is a labeling revision converting that product to OTC status, the same regulatory pathway used for OTC Narcan in 2023.

How to Use Rextovy: Step-by-Step

Rextovy’s packaging includes pictorial step-by-step instructions designed for use without medical training. The FDA-approved dosing protocol:

Step 1: Call 911 immediately after (or simultaneously with) giving the first dose. Do not wait to see if the dose works before calling. Emergency services need to be on the way regardless of how quickly the person responds.

Step 2: Lay the person on their back. Tilt their head back slightly to open the airway.

Step 3: Insert the tip of the nasal spray device gently into one nostril. Press the plunger firmly to deliver the full 4 mg dose as a single spray.

Step 4: Wait 2 minutes and watch for a response: spontaneous breathing, return of consciousness, movement.

Step 5: If there is no response after 2 minutes, administer the second device into the opposite nostril. The carton contains 2 devices for this reason.

After administration: Stay with the person until emergency services arrive. If the person regains consciousness, keep them calm and prevent them from taking more opioids. Explain that medical help is coming. If they become agitated (from naloxone-precipitated withdrawal), do not leave. If they lose consciousness again after initial recovery, administer the second dose if not already used and continue rescue breathing if trained to do so.

Rescue breathing: If you know rescue breathing or CPR, administer it while waiting for naloxone to take effect and after doses are given. Rescue breathing can maintain oxygenation during the reversal window.

The fentanyl consideration: Illicit fentanyl and its analogues are significantly more potent than heroin or prescription opioids and may require higher or repeat naloxone doses to achieve reversal. A single 4 mg dose may not be sufficient in a high-potency fentanyl overdose. This is why the 2-device carton is important, and why calling 911 is critical: emergency responders carry additional naloxone doses.

The Pricing Problem and Why a Third Competitor Matters

The clinical and public health value of OTC naloxone is not theoretical. Bystander administration of naloxone before emergency services arrive is associated with substantially higher survival rates in observed overdose events. Multiple studies across community overdose prevention programs consistently show that having naloxone present at the scene and having someone willing and able to use it is one of the most effective single interventions for preventing overdose death.

The problem is access, and access in this context is inseparable from price.

A 2026 study published in the Journal of Substance Use and Addiction Treatment found that OTC Narcan prices declined by only approximately $0.49 per quarter between late 2023 and late 2024, a period during which total sales actually fell slightly. The study also identified a documented racial pricing disparity: areas with larger American Indian and Alaska Native populations paid an estimated more than $5 extra per unit compared with predominantly white communities.

The prescription version of Rextovy currently sells at approximately $44 to $60 per two-dose carton, which is the same general price range as prescription Narcan. OTC pricing was not immediately disclosed at Rextovy’s launch. The meaningful question is not the launch price but the trajectory: with three manufacturers in the OTC naloxone market rather than two, and with Amphastar’s manufacturing cost structure potentially different from Emergent BioSolutions, there is now a realistic competitive mechanism that did not previously exist.

The FDA has stated explicitly that the availability of multiple approved formulations expands access and market availability, encourages competition that may reduce cost, and offers alternative sourcing options. That is a policy statement, not a guarantee. But the mechanism is sound: competition-driven price reduction in generic and OTC pharmaceutical markets follows predictable patterns, and the OTC naloxone market has been waiting for it.

For the communities with the highest overdose burden — uninsured populations, communities with high rates of opioid use disorder, and the communities of color documented to face pricing disparities — even a meaningful reduction from the current $44 to $60 per box baseline could translate directly into lives saved.

Naloxone Is Safe to Give — and There Are No Situations Where Hesitation Is the Right Choice

This point is worth stating plainly because hesitation at the scene of a suspected overdose remains one of the most documented barriers to naloxone use.

Naloxone will not harm someone who does not have opioids in their system. It is not possible to give a fatal dose of naloxone to an overdose victim. The drug has no significant pharmacological activity in the absence of opioid receptor occupancy. Bystanders who are uncertain whether someone is overdosing on opioids should administer naloxone anyway: if opioids are not present, the spray produces no effect. If opioids are present, it may save their life.

The withdrawal symptoms that naloxone can precipitate — agitation, sweating, nausea, vomiting — are distressing but not medically dangerous. They are significantly preferable to continued opioid-induced respiratory depression. A person who is angry and nauseous after naloxone administration is alive. That is the outcome.

SAMHSA’s opioid overdose prevention guidance is clear: treat first, call for help, stay present. There is no scenario in which waiting to see whether a suspected overdose resolves on its own is the appropriate response.

What This Means Practically

If you live with or care for someone using prescription opioids: Ask your pharmacist about keeping naloxone at home. Prescription opioid use, including opioids prescribed legitimately for chronic pain, carries overdose risk — particularly in higher doses, in combination with other sedating medications, or in patients with sleep apnea. Having naloxone in the home is increasingly recommended as a standard safety precaution alongside prescription opioid therapy.

If you use opioids yourself: Carry naloxone. Tell a trusted person where it is and how to use it. The person most likely to administer naloxone in an opioid-related emergency is someone in the immediate vicinity, not a first responder.

If you work in any setting where opioid use may occur: Workplaces, schools, community organizations, faith communities, and public venues are all settings where overdoses occur and where having naloxone present changes outcomes. Rextovy joining the OTC market means one more product on more shelves at potentially lower cost. Stock it.

If you are a pharmacist or healthcare provider: SAMHSA and the CDC recommend co-prescribing naloxone with opioid prescriptions, particularly at higher doses. The OTC availability of Rextovy, Narcan, and RiVive means that the conversation about naloxone access can now happen in any setting — a pharmacy counter, a community health worker visit, a school nurse office — without requiring a prescription. Patient education about signs of overdose, how to use the spray, and why calling 911 is non-negotiable after the first dose saves lives.

For related HED coverage on the opioid crisis treatment landscape, see our post on the FDA’s approval of Sublocade (buprenorphine extended-release injection) for opioid use disorder and our coverage of how the Great American Recovery Initiative has shaped FDA drug approvals and substance use disorder policy in 2026.

If you or someone you know is struggling with opioid use disorder, contact the SAMHSA National Helpline at 1-800-662-4357 (free, confidential, 24/7) or visit findtreatment.gov.

Sources

FDA approval announcement: FDA broadens access to over-the-counter naloxone nasal spray for opioid overdose. FDA.gov. June 16, 2026. BioSpace

Drugs.com approval news: FDA Approves Rextovy (naloxone hydrochloride) Nasal Spray for Over-the-Counter Use. drugs.com. June 16, 2026.

Dermatology Advisor clinical summary (with dosing and packaging): Over-the-Counter Rextovy Cleared for Opioid Overdose Treatment. dermatologyadvisor.com. June 2026.

Drug Topics coverage (with pricing research and pharmacist comment): The FDA Approves Rextovy, an OTC Naloxone for Opioid Overdose. drugtopics.com. June 2026.

TechTimes (OTC market analysis with pricing study detail): Naloxone Nasal Spray Gets Third OTC Brand as FDA Approves Rextovy by Amphastar. techtimes.com. June 2026.

The Hill news coverage: FDA approves third over-the-counter opioid overdose nasal spray. thehill.com. June 2026.

Psychiatry Advisor clinical summary: Over-the-Counter Rextovy Cleared for Opioid Overdose Treatment. psychiatryadvisor.com. June 2026.

Rextovy original Rx approval (March 2023): Rextovy FDA Approval History. drugs.com.

Narcan OTC approval (March 2023): FDA approves first nonprescription naloxone nasal spray. FDA.gov.

Rextovy prescribing information: Rextovy (naloxone hydrochloride) Package Insert. Amphastar Pharmaceuticals. 2026.

Naloxone mechanism and overdose StatPearls: Opioid Toxicity. StatPearls. NCBI.

Mu-opioid receptor pharmacology: Opioid Receptors. StatPearls. NCBI.

Bystander naloxone and survival outcomes: Bystander Naloxone Administration and Opioid Overdose Outcomes. PMC9388745.

CDC naloxone consumer guidance: Naloxone for Opioid Overdose. CDC.

SAMHSA opioid overdose guidance: Opioid Overdose Prevention. SAMHSA.

SAMHSA National Helpline: SAMHSA National Helpline. 1-800-662-4357.

Find treatment: findtreatment.gov. SAMHSA.

Patient resources: National Alliance for Eating Disorders Helpline: 1-866-662-1235 (removed — not relevant to this post) | 988 Suicide and Crisis Lifeline: call or text 988 | SAMHSA National Helpline: 1-800-662-4357 | Harm Reduction Coalition | Next Distro (mail-based naloxone access)

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Rextovy is an over-the-counter emergency medication for suspected opioid overdose. Administering naloxone does not replace calling 911: emergency medical services must be contacted immediately after any suspected overdose. Naloxone is a temporary reversal agent; professional medical evaluation and monitoring are required after administration. If you or someone you know is struggling with opioid use disorder, call the SAMHSA National Helpline at 1-800-662-4357.

June 26, 2026